1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists

By developing TLR7 agonist compounds with 1H-pyrazolo[4,3d]pyrimidine aromatic system, the problem of limited effects of existing TLR7 agonists in applications has been solved, and efficient TLR7 agonism and targeted delivery have been achieved, significantly Improve the treatment effect of cancer and other diseases.

CN115279765BActive Publication Date: 2024-11-12BRISTOL MYERS SQUIBB CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180020862.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-07-29
Filing Date
2021-01-26
Publication Date
2024-11-12
Estimated Expiration
2041-01-26

AI Technical Summary

Technical Problem

Existing TLR7 agonists have limited effects in some applications and are difficult to effectively target specific tissues or organs, affecting their therapeutic effects.

Method used

Developed compounds with 1H-pyrazolo[4,3d]pyrimidine aromatic systems that have TLR7 agonist activity and can be conjugated to antibodies for targeted delivery to target tissues or organs of the intended effect, while also being able to Pegylation regulates its drug properties.

Benefits of technology

The efficient activity of TLR7 agonists is achieved, and it can effectively treat a variety of diseases, especially in cancer immunotherapy, which significantly improves the therapeutic effect and improves the targeted and therapeutic effect of the drug through targeted delivery technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115279765B_ABST
    Figure CN115279765B_ABST
Patent Text Reader

Abstract

The compounds according to formula I or II can be used as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with anti-cancer immunotherapeutic agents, or as vaccine adjuvants. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Application Serial No. 63 / 058,144, filed on July 29, 2020, and U.S. Provisional Application Serial No. 62 / 966,137, filed on January 27, 2020; the disclosures of which are incorporated herein by reference. Background Art

[0003] The present disclosure relates to Toll-like receptor 7 ("TLR7") agonists and conjugates thereof, and methods of making and using such agonists and conjugates thereof.

[0004] Toll-like receptors ("TLRs") are receptors that recognize pathogen-associated molecular patterns ("PAMPs"), which are small molecule motifs that are conserved in certain types of pathogens. TLRs can be located on the cell surface or inside the cell. Activation of TLRs by binding to their cognate PAMPs signals the presence of the relevant pathogen (i.e., infection) in the host and stimulates the host's immune system to resist infection. Humans have 10 TLRs, called TLR1, TLR2, TLR3, etc.

[0005] Activation of TLRs by agonists (of which TLR7 is the most studied) can have a positive effect on the role of vaccines and immunotherapeutics in treating a variety of conditions beyond actual pathogen infection by stimulating the overall immune response. Therefore, there is great interest in the use of TLR7 agonists as vaccine adjuvants or as enhancers in cancer immunotherapy. See, for example, Vasilakos and Tomai 2013, Sato-Kaneko et al. 2017, Smits et al. 2008, and Ota et al. 2019.

[0006] TLR7 (an intracellular receptor located on the endosomal membrane) recognizes PAMPs associated with single-stranded RNA viruses. Its activation induces the secretion of type I interferons (such as IFNα and IFNβ) (Lund et al. 2004). TLR7 has two binding sites, one for single-stranded RNA ligands ( et al. 2007), and one for small molecules such as guanosine (Zhang et al. 2016).

[0007] TLR7 can bind to and be activated by guanosine-like synthetic agonists based on the 1H-imidazo[4,5-c]quinoline skeleton, such as imiquimod, resiquimod, and gardiquimod. For a review of small molecule TLR7 agonists, see Cortez and Va 2018.

[0008]

[0009] Synthetic TLR7 agonists based on the pteridinone molecular scaffold are also known, as exemplified by vesatolimod (Desai et al. 2015).

[0010]

[0011] Other synthetic TLR7 agonists based on a purine-like skeleton, often according to the general formula (A), have been disclosed:

[0012]

[0013] wherein R, R' and R" are structural variables, wherein R" typically contains an unsubstituted or substituted aromatic or heteroaromatic ring.

[0014] Publications of bioactive molecules with a purine-like backbone and their use in treating conditions such as fibrosis, inflammatory disorders, cancer, or pathogenic infections include: Akinbobuyi et al. 2015 and 2016; Barberis et al. 2012; Carson et al. 2014; Ding et al. 2016, 2017a and 2017b; Graupe et al. 2015; Hashimoto et al. 2009; He et al. 2019a and 2019b; Holldack et al. 2012; Isobe et al. 2009a and 2012; Poudel et al. 2019a and 2019b; Pryde 2010; and Young et al. 2019.

[0015] The group R" can be a pyridyl group: Bonfanti et al. 2015a and 2015b; Halcomb et al. 2015; Hirota et al. 2000; Isobe et al. 2002, 2004, 2006, 2009a, 2009b, 2011 and 2012; Kasibhatla et al. 2007; Koga-Yamakawa et al. 2013; Musmuca et al. 2009; Nakamura 2012; Ogita et al. 2007; and Yu et al. 2013.

[0016] There are published texts of related molecules in which the 6,5-fused ring system of formula (A) (i.e., a pyrimidine six-membered ring fused to an imidazole five-membered ring) is modified. (a) Dellaria et al. 2007, Jones et al. 2010 and 2012, and Pilatte et al. 2017 disclose compounds in which the pyrimidine ring is replaced by a pyridine ring. (b) Chen et al. 2011, Coe et al. 2017, Poudel et al. 2020a and 2020b, and Zhang et al. 2018 disclose compounds in which the imidazole ring is replaced by a pyrazole ring. (c) Cortez et al. 2017 and 2018; Li et al. 2018; and McGowan et al. 2016a, 2016b and 2017 disclose compounds in which the imidazole ring is replaced by a pyrrole ring.

[0017] Bonfanti et al. 2015b and 2016 and Purandare et al. 2019 disclosed TLR7 modulators with macrocycles spanning two rings of the purine moiety:

[0018] TLR7 agonists can be conjugated to a partner molecule, which can be, for example, a phospholipid, poly(ethylene glycol) ("PEG"), an antibody, or another TLR (typically TLR2). Exemplary publications include: Carson et al. 2013, 2015, and 2016, Chan et al. 2009 and 2011, Cortez et al. 2017, Gadd et al. 2015, Lioux et al. 2016, Maj et al. 2015, Vernejoul et al. 2014, and Zurawski et al. 2012. A frequent conjugation site is at the R" group of formula (A).

[0019] Jensen et al. 2015 disclosed the use of cationic lipid vehicles for the delivery of TLR7 agonists.

[0020] Some TLR7 agonists (including resiquimod) are dual TLR7 / TLR8 agonists. See, e.g., Beesu et al. 2017, Embrechts et al. 2018, Lioux et al. 2016, and Vernejoul et al. 2014.

[0021] Full citations for documents cited herein by first author or inventor and year are listed at the end of this specification. Summary of the invention

[0022] The present description relates to compounds having a 1H-pyrazolo[4,3d]pyrimidine aromatic system, which have activity as TLR7 agonists.

[0023]

[0024] In one aspect, a compound having a structure according to formula (I) or (II) is provided.

[0025]

[0026] in

[0027] Each X is independently N or CR 2 ;

[0028] R 1 It is H.

[0029] (C1-C5 alkyl),

[0030] (C2-C5 alkenyl),

[0031] (C1-C8 Alkanediyl) 0-1 (C3-C6 cycloalkyl),

[0032] (C1-C8 Alkanediyl) 0-1 (C5-C 10 Spiroalkyl),

[0033] (C2-C8 alkanediyl)OH,

[0034] (C2-C8 alkanediyl)O(C1-C3 alkyl),

[0035] (C1-C4 Alkanediyl) 0-1 (5-6 membered heteroaryl),

[0036] (C1-C4 alkanediyl) 0-1 Phenyl,

[0037] (C1-C4 alkanediyl)CF3,

[0038] (C2-C8 alkanediyl)N[C(=O)](C1-C3 alkyl),

[0039] or

[0040] (C2-C8 Alkanediyl)NR x R y ;

[0041] Each R 2 are independently H, O(C1-C3 alkyl), S(C1-C3 alkyl), SO2(C1-C3 alkyl), C1-C3 alkyl,

[0042] O(C3-C4 cycloalkyl), S(C3-C4 cycloalkyl), SO2(C3-C4 cycloalkyl), C3-C4 cycloalkyl, Cl, F, CN or [C(=O)] 0-1 NR x R y;

[0043] R 3 is [C(=O)] 0-1 H.

[0044] [C(=O)] 0-1 (C1-C5 alkyl),

[0045] [C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 (C3-C8 cycloalkyl),

[0046] [C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 (C4-C 10 Bicycloalkyl),

[0047] [C(=O)]0-1(C1-C4alkanediyl)0-1(C5-C 10 Spiroalkyl),

[0048] [C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 O(C1-C3 alkyl),

[0049] [C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 OH,

[0050] [C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 NR x R y ,

[0051]

[0052] (C1-C4 alkanediyl)(C=O)NR x R y ,

[0053] (SO2)(C1-C5 alkyl),

[0054] (SO2)(C1-C4 alkanediyl) 0-1 (C3-C8 cycloalkyl),

[0055] (SO2)(C1-C4 alkanediyl) 0-1 (C4-C 10 Bicycloalkyl),

[0056] (SO2)(C1-C4 alkanediyl) 0-1 (C5-C 10 Spiroalkyl),

[0057] 6-membered aromatic or heteroaromatic moiety, or

[0058] a 5-membered heteroaromatic moiety;

[0059] R 5 is H, C1-C5 alkyl, C2-C5 alkenyl, C3-C6 cycloalkyl, halo, O(C1-C5 alkyl),

[0060] (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl), phenyl, NH(C1-C5 alkyl), 5- or 6-membered heteroaryl,

[0061]

[0062] and

[0063] R x and R y are independently H or C1-C3 alkyl or R x and R y Combined with the nitrogen to which they are bonded to form a 3- to 7-membered ring in which R 1 , R 2 , R 3 and R 5 middle

[0064] Alkyl, cycloalkyl, alkanediyl, bicycloalkyl, spiroalkyl, cyclic amine, 6-membered aromatic or heteroaromatic moiety, 5-membered heteroaromatic moiety or a moiety of the formula

[0065]

[0066] Optionally substituted with one or more substituents selected from the group consisting of OH, halo, CN, (C1-C3 alkyl), O(C1-C3 alkyl), C(═O)(C1-C3 alkyl), SO2(C1-C3 alkyl), NR x R y ,

[0067] (C1-C4 alkanediyl)OH, (C1-C4 alkanediyl)O(C1-C3 alkyl);

[0068] and

[0069] Alkyl, alkanediyl, cycloalkyl, bicycloalkyl, spiroalkyl or a portion of the formula

[0070]

[0071] Can have CH2 groups replaced by: O, SO2, CF2, C(=O), NH,

[0072] N[C(=O)] 0-1(C1-C3 alkyl),

[0073] N[C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 CF3,

[0074] or

[0075] N[C(=O)] 0-1 (C1-C4 alkanediyl) 0-1 (C3-C5 cycloalkyl).

[0076] The compounds disclosed herein have activity as TLR7 agonists, and some compounds can be conjugated with antibodies for targeted delivery to target tissues or organs of intended action. They can also be pegylated to adjust their pharmaceutical properties.

[0077] The compounds disclosed herein, or their conjugates, or their PEGylated derivatives, can be used to treat subjects suffering from a condition amenable to treatment by activation of the immune system by administering to such subjects a therapeutically effective amount of such compounds, or their conjugates, or their PEGylated derivatives, especially in combination with vaccines or cancer immunotherapeutics. DETAILED DESCRIPTION

[0078] Compound

[0079] In another aspect, the present disclosure provides compounds having a structure according to Formula (I') or (II'), wherein R 1 , R 5 , R 3 and X is as defined for formula (I):

[0080]

[0081] In another aspect, the present disclosure provides compounds having a structure according to Formula (I") or (II"), wherein R 1 , R 5 , R 3 and X is as defined for formula (I):

[0082]

[0083] In the compounds of formula (I), (I') or (I"), the following embodiments

[0084]

[0085] include

[0086]

[0087] where the asterisk * indicates the position of bonding to the pyrazolopyrimidine moiety and the curve represents the position of bonding to the group W, wherein the first embodiment is the preferred embodiment.

[0088] In the compounds of formula (II), (II') and (II"), part

[0089] The preferred embodiment is

[0090] where the asterisk * indicates the position of bonding to the pyrazolopyrimidine moiety and the curve represents the position where the group W is bonded.

[0091] Group R 5 Embodiments of include H (preferred), cyclopropyl, Cl and Me.

[0092] Group R 1 The implementation scheme includes

[0093]

[0094] Group R 1 Additional embodiments include:

[0095]

[0096] Embodiments of the following groups

[0097]

[0098] include:

[0099]

[0100] Embodiments of the following groups

[0101]

[0102] yes

[0103]

[0104] Embodiments of the following groups

[0105]

[0106] yes

[0107]

[0108] Group R 3 The implementation scheme includes:

[0109]

[0110]

[0111] In one aspect, the compounds of the present disclosure are according to formula (Ia), wherein R 1 , R 3 and R 5 is as defined with respect to formula (I):

[0112]

[0113] In another aspect, there is provided a compound according to formula (Ia), wherein

[0114] R 1 yes

[0115]

[0116] R 3 It is H, Me,

[0117]

[0118] and

[0119] R 5 is H, Me, cyclopropyl or Cl.

[0120] In another aspect, the present disclosure provides a compound according to formula (Ib)

[0121]

[0122] in

[0123] R 1 yes

[0124]

[0125] and

[0126] R 3 It is H.

[0127]

[0128] In one aspect, the present disclosure provides compounds having a structure according to Formula (I'a)

[0129]

[0130] Where R 1 and R 3 is as defined for formula (I). Preferably, in the compound of formula (I'a), R 1 yes

[0131]

[0132] and more preferably

[0133]

[0134] Examples of compounds according to formula (I'a) are those wherein

[0135] R 1 yes

[0136]

[0137] And R 3 It is H.

[0138]

[0139] In one aspect, the present disclosure provides compounds having a structure according to Formula (I"a)

[0140]

[0141] Where R 1 and R 3 is as defined for formula (I).

[0142] Examples of compounds according to formula (I"a) are those wherein

[0143] R 1 yes

[0144]

[0145] and

[0146] R 3 yes

[0147]

[0148] In one aspect, the present disclosure provides compounds having a structure according to formula (IIa)

[0149]

[0150] Where R 1 and R 3 is as defined for formula (II).

[0151] Preferably, R 1 yes

[0152]

[0153] R 2 Preferred is OMe, O(cyclopropyl) or OCHF2, more preferred is OMe.

[0154] In one aspect, R 5 It's H.

[0155] In one embodiment of the compound according to formula (Ia):

[0156] R 1 yes

[0157] R 3 is a C3-C8 cycloalkyl moiety wherein one CH2 group in the cycloalkyl moiety is optionally replaced by O, SO2, NH or N(C1-C3 alkyl), as in e.g.

[0158] and

[0159] R 5 is H or Cl (preferably H).

[0160] Specific examples of compounds disclosed herein are shown in Table A below. The table also provides data related to the following biological activities determined according to the procedures provided below: human TLR7 agonism reporter assay and / or induction of CD69 gene in human whole blood. The rightmost column contains analytical data (mass spectrometry, HPLC retention time and NMR). In one embodiment, the compounds of the present disclosure have (a) a human TLR7 (hTLR7) reporter assay EC less than 1,000 nM. 50 values ​​and (b) human whole blood (hWB) CD69 induced EC less than 1,000 nM 50 (When the measurement was performed multiple times, the reported value is the average value.)

[0161]

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199] Pharmaceutical compositions and administration

[0200] In another aspect, a pharmaceutical composition is provided, comprising a compound as disclosed herein or a conjugate thereof formulated with a pharmaceutically acceptable carrier or excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as biologics or small molecule drugs. The pharmaceutical composition may be administered together with another therapeutic agent (especially an anticancer agent) in a combination therapy.

[0201] The pharmaceutical composition may include one or more excipients. Available excipients include carriers, surfactants, thickeners or emulsifiers, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings, disintegrants, lubricants, sweeteners, preservatives, isotonic agents and combinations thereof. Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th edition (Lippincott Williams & Wilkins 2003) teaches the selection and use of suitable excipients.

[0202] Preferably, the pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (for example, by injection or infusion). According to the route of administration, the active compound can be coated in the material to protect the compound from the effects of acid and other natural conditions that may inactivate it. The phrase "parenteral administration" means the mode of administration except enteral administration and topical administration, usually by injection, and includes but is not limited to intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition can be administered via non-parenteral routes, such as external, epidermal or mucosal administration routes, for example, intranasal, oral, vaginal, rectal, sublingual or topical.

[0203] The pharmaceutical composition may be in the form of a sterile aqueous solution or dispersion. They may also be formulated as microemulsions, liposomes, or other ordered structures suitable for achieving high drug concentrations. The composition may also be provided in the form of a lyophilisate (for reconstitution in water prior to administration).

[0204] The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the subject being treated and the particular mode of administration and will generally be that amount of the composition that produces a therapeutic effect. Typically, in terms of percentage, this amount will range from about 0.01% to about 99% of the active ingredient, preferably from about 0.1% to about 70%, most preferably from about 1% to about 30% of the active ingredient, combined with a pharmaceutically acceptable carrier.

[0205] The dosage regimen is adjusted to provide the therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" refers to physically discrete units suitable as unit dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.

[0206] The range of the dosage is from about 0.0001 to 100 mg / kg host body weight and more generally 0.01 to 5 mg / kg host body weight. For example, the dosage can be 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight or 10 mg / kg body weight or in the range of 1-10 mg / kg or alternatively 0.1 to 5 mg / kg. An exemplary treatment regimen is once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months or once every 3 to 6 months. A preferred dosage regimen includes using one of the following dosing schedules via intravenous administration of 1 mg / kg body weight or 3 mg / kg body weight: (i) every four weeks, for six doses, then every three months; (ii) every three weeks; (iii) once 3 mg / kg body weight, then 1 mg / kg body weight every three weeks. In some methods, the dosage is adjusted to reach a plasma antibody concentration of about 1-1000 μg / mL and about 25-300 μg / mL in some methods.

[0207] A "therapeutically effective dose" of a compound of the invention preferably results in a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or the prevention of injury or disability caused by disease distress. For example, for the treatment of tumor-bearing subjects, a "therapeutically effective dose" preferably inhibits tumor growth by at least about 20%, more preferably at least about 40%, even more preferably at least about 60%, still more preferably at least about 80%, relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can reduce tumor size or otherwise improve symptoms in a subject, who is typically a human, but can be another mammal. In the case of two or more therapeutic agents administered in a combination therapy, a "therapeutically effective amount" refers to the efficacy of the combination as a whole, rather than the efficacy of each agent individually.

[0208] The pharmaceutical composition can be a controlled release or sustained release formulation, including implants, transdermal patches and microencapsulated delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid can be used. See, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0209] The therapeutic composition can be administered via a medical device such as (1) a needle-free subcutaneous injection device; (2) a microinfusion pump; (3) a transdermal device; (4) an infusion device; and (5) an osmotic device.

[0210] In certain embodiments, the pharmaceutical composition can be formulated to ensure proper distribution in vivo. For example, to ensure that the therapeutic compounds of the invention cross the blood-brain barrier, they can be formulated in liposomes, which can additionally contain targeting moieties to enhance selective transport to specific cells or organs.

[0211] Industrial applicability and use

[0212] The TLR7 agonist compounds disclosed herein can be used to treat diseases or conditions that can be ameliorated by activating TLR7.

[0213] In one embodiment, TLR7 agonists are used in combination with anti-cancer immunotherapeutics (also referred to as immuno-oncology agents). Anti-cancer immunotherapeutics work by stimulating the body's immune system to attack and destroy cancer cells, especially by activating T cells. The immune system has many checkpoint (regulatory) molecules to help maintain the balance between its attack on legitimate target cells and normal cells that prevent it from attacking health. Some molecules are stimulants (up-regulators), which means that their participation promotes T cell activation and enhances immune response. Other molecules are inhibitors (down-regulators or inhibitors), which means that their participation inhibits T cell activation and alleviates immune response. The combination of agonistic immunotherapeutics with stimulatory checkpoint molecules can lead to the latter's activation and immune response enhancement for cancer cells. On the contrary, the combination of antagonistic immunotherapeutics with inhibitory checkpoint molecules can prevent the immune system from being down-regulated by the latter and help maintain a strong response for cancer cells. Examples of stimulatory checkpoint molecules are B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H. Examples of inhibitory checkpoint molecules are CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, galectin 9, CEACAM-1, BTLA, CD69, galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, CD96, and TIM-4.

[0214] Regardless of the mode of action of the anti-cancer immunotherapeutic agent, its effectiveness can be improved by generally regulating the immune system (such as by activating TLR7). Therefore, in one embodiment, this specification provides a method for treating cancer, comprising administering an anti-cancer immunotherapeutic agent and a therapeutically effective combination of a TLR7 agonist as disclosed herein to a patient suffering from such cancer. The administration time may be simultaneous, sequential or alternating. The administration mode may be systemic or local. The TLR7 agonist may be delivered in a targeted manner via a conjugate.

[0215] Cancers that may be treated by combination therapy as described above include acute myeloid leukemia, adrenocortical carcinoma, Kaposi's sarcoma, lymphoma, anal cancer, appendix cancer, teratoid / rhabdoid tumors, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumors, carcinoid tumors, heart tumors, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasms, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, nasal glioma, Ewing's sarcoma, Eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, germ cell tumors, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypopharyngeal cancer, pancreatic cancer, kidney cancer, laryngeal cancer, chronic myeloid leukemia, lip and oral cavity cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penis cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, laryngeal cancer, thyroid cancer, urethra cancer, uterus cancer, vaginal cancer, and vulvar cancer.

[0216] Anti-cancer immunotherapeutic agents that can be used in the combination therapy as disclosed herein include: AMG 557, AMP-224, atezolizumab, avelumab, BMS 936559, cemiplimab, CP-870893, dacetuzumab, durvalumab, enoblituzumab, galiximab, IMP321, ipilimumab, lucatumumab, MEDI-570, MEDI-6383, MEDI-6469, muromonab-CD3, nivolumab, pembrolizumab, pidilizumab, spartalizumab, tremelimumab, urelumab, utomilumab, varlilumab, vonlerolizumab. Table B below lists one or more of their alternative names (trade names, former names, research codes or synonyms) and their respective target checkpoint molecules.

[0217]

[0218]

[0219] In one embodiment of the combination therapy with a TLR7 agonist, the anti-cancer immunotherapeutic agent is an antagonist anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody. The cancer can be lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial carcinoma (including bladder cancer), gastric cancer, hepatocellular carcinoma or colorectal cancer.

[0220] In another embodiment of combination therapy with a TLR7 agonist, the anti-cancer immunotherapeutic agent is an antagonist anti-CTLA-4 antibody, preferably ipilimumab.

[0221] In another embodiment of the combination therapy with a TLR7 agonist, the anti-cancer immunotherapeutic agent is an antagonist anti-PD-1 antibody, preferably nivolumab or pembrolizumab.

[0222] The TLR7 agonists disclosed herein may also be used as vaccine adjuvants.

[0223] The practice of the present invention may be further understood by reference to the following examples, which are provided by way of illustration and not limitation.

[0224] Analytical procedures

[0225] NMR

[0226] The following conditions were used to obtain proton nuclear magnetic resonance (NMR) spectra: NMR spectra were collected in a 400Mz or 500Mhz Bruker instrument using DMSO-d6 or CDCl3 as solvent and internal standard. Raw NMR data were analyzed by using ACD Spectrus version 2015-01 or MestReNova software from ADC Labs.

[0227] Chemical shifts are reported as low-field parts per million (ppm) relative to internal tetramethylsilane (TMS) or relative to the TMS position inferred by deuterated NMR solvents. Apparent multiplicities are reported as: singlet-s, doublet-d, triplet-t, quartet-q, or multiplet-m. Peaks showing broadening are further denoted as br. Integration is approximate. It should be noted that integral intensity, peak shape, chemical shift, and coupling constants may depend on solvent, concentration, temperature, pH, and other factors. In addition, peaks that overlap or exchange with water or solvent peaks in the NMR spectrum may not provide reliable integral intensity. In some cases, NMR spectra can be obtained using water peak suppression, which may cause overlapping peaks to be invisible or have a changed shape and / or integration.

[0228] Liquid chromatography

[0229] The following preparative and analytical (LC / MS) liquid chromatography procedures were used, as shown in Table A:

[0230] LC / MS Procedure A: Analytical LC / MS was used to determine the final purity and retention time. Injection conditions: Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile: water (containing 0.1% TFA); Mobile phase B: 95:5 acetonitrile: water (containing 0.1% TFA); Temperature: 50°C; Gradient: 0% B to 100% B over 3 min, then hold at 100% B for 0.50 min; Flow rate: 1 mL / min; Detection: MS and UV (220 nm).

[0231] LCMS method B: column: Xbridge BEH C18 XP (50x2.1 mm), 2.5 μm; mobile phase A: 5:95 CH3CN:H2O (containing 0.1% CF3CO2H); mobile phase B: 95:5 CH3CN:H2O (containing 0.1% CF3CO2H); temperature: 50°C; gradient: 0-100% B over 3 minutes; flow rate: 1.1 mL / min.

[0232] LCMS method C: Column: Kinetex XB-C18 (75x3 mm), 2.6 μm; Mobile phase A: 10 mM HCO2NH4 in water (pH 3.3); Mobile phase B: CH3CN; Temperature: 50°C; Gradient: 0-100% B over 3 minutes; Flow rate: 1.1 mL / min.

[0233] LCMS method D: Column: Xbridge BEH C18 XP (50x2.1 mm), 2.5 μm; Mobile phase A: 5:95 CH3CN:H2O (containing 10 mM NH4OAc); Mobile phase B: 95:5 CH3CN:H2O (containing 10 mM NH4OAc); Temperature: 50°C; Gradient: 0-100% B over 3 minutes; Flow rate: 1.1 mL / min.

[0234] Synthesis - General Procedure

[0235] In general, the procedures disclosed herein produce a mixture of regioisomers alkylated at the 1H or 2H position of the pyrazolopyrimidine ring system (which are also referred to as N1 and N2 regioisomers, respectively, implying the alkylated nitrogen). For brevity, the N2 regioisomers are not shown for convenience, but it is understood that they are present in the initial product mixture and are separated later, for example, by preparative HPLC.

[0236]

[0237] The mixture of regioisomers may be separated early in the synthesis and the remaining synthetic steps carried out with the 1H regioisomer, or alternatively, the synthesis may be carried forward with the mixture of regioisomers and separated later as desired.

[0238] The compounds of the present disclosure can be prepared by a variety of methods well known to those skilled in the art of synthetic organic chemistry. These methods include those described below or variations thereof. Preferred methods include, but are not limited to, those described below in the following schemes.

[0239] Solution 1

[0240]

[0241]

[0242] Compound K can be prepared by the synthetic sequence outlined in Scheme 1 above. Nitropyrazole A is reduced to provide compound B, which is then cyclized with 1,3-bis(methoxycarbonyl)-2-methyl-2-thioisourea to give hydroxypyrazolopyrimidine C. Amine RaNH2 is introduced using BOP / DBU coupling conditions, and subsequent bromination using NBS (step 4) gives bromopyrazolopyrimidine E. Alkylation using benzyl halide F gives a mixture of N1 and N2 products, which are separated to give N1 intermediate G. Deprotection of methyl carbamate (step 6) followed by deprotection of tert-butyl carbamate gives intermediate I. Catalytic hydrogenation gives target molecule J. Alkylation or reductive amination of molecule J gives target molecule K (step 9). Coupling of amine J with acid using BOP (or HATU) conditions gives target compound L.

[0243] Solution 2

[0244]

[0245] Alternatively, intermediate G can be obtained using the route described above in Scheme 2. Intermediate C is brominated using NBS and then alkylated to give intermediate N. Amination then takes place using BOP coupling conditions to give intermediate G.

[0246] Solution 3

[0247]

[0248] Another alternative route to compound J is shown in Scheme 3 above. Intermediate D is alkylated with benzyl halide F to give intermediate O. However, in this approach, the ratio of N1 isomer to N2 isomer is generally less favorable. Deprotection of tert-butyl carbamate followed by catalytic hydrogenation gives target molecule J. Sulfonylation of amine J gives target molecule P.

[0249] Solution 4

[0250]

[0251] Compound R can be prepared by the synthetic sequence outlined above in Scheme 4. Suzuki coupling of bromide G with boronic acid (or borane) affords intermediate Q. Deprotection of tert-butyl carbamate followed by catalytic hydrogenation affords the target molecule R.

[0252] Synthesis - Specific Examples

[0253] To further illustrate the foregoing, the following non-limiting, exemplary synthetic schemes are included. Variations of these embodiments within the scope of the claims are within the capabilities of those skilled in the art and are considered to fall within the scope of this disclosure. The reader should recognize that a skilled artisan provided with this disclosure and who is a person skilled in the relevant art will be able to prepare and use the compounds disclosed herein without exhaustive examples.

[0254] Analytical data for compounds numbered 100 and above can be found in Table A.

[0255] Example 1-Compound 124

[0256]

[0257] Preparation of (1): N2 stream was bubbled through a mixture of 5-bromo-3-methoxypyridinecarboxaldehyde (1.85 g, 8.56 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (3.44 g, 11.13 mmol) and K2CO3 (4.14 g, 30.0 mmol) in DMF (25 mL) for 3 min. PdCl2(dppf)-CH2Cl2 adduct (0.699 g, 0.856 mmol) was added. N2 stream was bubbled through for another 2 min. The reaction mixture was stirred at 80 ° C for 5 h and diluted with EtOAc (20 mL). The solid was removed by filtration through a CELITE pad. The filtrate was concentrated. The residue was purified using a silica column (80 g) eluted with EtOAc:hexanes, 0-100% gradient. The desired fractions were concentrated to yield tert-butyl 6-formyl-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 1 (2.7 g, 8.48 mmol, 99% yield).

[0258] LCMS ESI: for C 17 H 23 Calculated value of N2O4 = 319.2 (M+H+), found 319.1 (M+H+ ).

[0259] 1 H NMR (400MHz, DMSO-d6) δ10.14(s,1H),8.48(d,J=1.5Hz,1H),7.65(d,J=1.3Hz,1H),6.55(br s,1H),4.08(br d,J=2.4Hz,2H),3.97(s,3H),3.58(br t,J=5.7Hz,3H),2.57(br d,J=1.8Hz,2H),1.44(s,9H).

[0260] Preparation of (2), part 1: NaBH4 (0.321 g, 8.48 mmol) was added to a mixture of 6-formyl-5-methoxy-3', 6'-dihydro-[3,4'-bipyridine]-1'(2'H)-tert-butyl carboxylate 1 (2.7 g, 8.48 mmol) in MeOH (50 mL). After stirring at room temperature for 5 min, the reaction was quenched with water (10 ml) and extracted with 10% MeOH (6x20 ml) in DCM. The combined organic extracts were dried over Na2SO4, filtered and concentrated. The crude product was purified by silica column (80 g) (eluted with EtOAc: hexane, 0-100% gradient). The desired fractions were concentrated to give tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-l'(2'H)-carboxylate (1.72 g, 5.37 mmol, 63.3% yield).

[0261] LCMS ESI: for C 17 H 25 Calculated value for N2O4 = 321.2 (M+H+), found 321.2 (M+H+).

[0262] 1 H NMR (400MHz, DMSO-d6) δ8.18(d,J=1.5Hz,1H),7.40(d,J=1.5Hz,1H),6.29(br s,1H),4.80(t,J=5.7Hz,1H),4.52(d,J=5.7Hz,2H),4.03(br d,J=2.4Hz,2H),3.86(s,3H),3.56(t,J=5.6Hz,2H),2.56-2.51(m,2H),1.44(s,9H)

[0263] Preparation of (2), part 2. A solution of tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (2.2 g, 6.87 mmol) in DCM (25 mL) was treated with Hunig's base (1.439 mL, 8.24 mmol) and Ms-Cl (0.589 mL, 7.55 mmol) was added dropwise at room temperature. The resulting reaction mixture was stirred at room temperature for 16 h. After quenching with water, the two layers were separated. The aqueous layer was back extracted with EtOAc (2x10 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The crude product was purified by silica column chromatography (80 g) (EtOAc / hexane 0-70% gradient). The desired fractions were concentrated to give tert-butyl 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-l'(2'H)-carboxylate (1.75 g, 5.16 mmol, 75% yield) as a white solid.

[0264] LCMS ESI: for C 17 H 25 Calculated value for ClN2O4 = 339.1 (M+H+), found 339.2 (M+H+).

[0265] 1 H NMR (400MHz, chloroform-d) δ8.21(d,J=1.5Hz,1H),7.15(d,J=1.5Hz,1H),6.11(brs,1H),4.74(s,2H),4.11(br d,J=3.3Hz,2H),3.92(s,3H),3.66(t,J=5.6Hz,2H),2.52(br d,J=1.5Hz,2H),1.50(s,9H).

[0266] Preparation of (3): CsCO (3.85 g, 11.81 mmol) was added to a stirred mixture of methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.700 g, 5.90 mmol) in DMF (60 mL), followed by the addition of tert-butyl 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 2 (2.0 g, 5.90 mmol). The resulting reaction mixture was stirred at room temperature for 16 h. After quenching with saturated NH4Cl solution and stirring for 1 h, the resulting solid was collected by filtration, suspended in MeOH (10 mL), stirred for 1 h, collected by filtration, and air-dried. The filtrate was concentrated, and the residue was purified by silica column chromatography (80 g) (eluted with EtOAc:hexane=0-100% gradient). The desired fractions were concentrated and the resulting materials combined to give tert-butyl 6-((3-bromo-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 3 (2 g, 3.39 mmol, 57.4% yield) as an off-white solid.

[0267] LCMS ESI: for C 24 H 29 Calculated value of BrN7O6 = 590.1 (M+H+), found 590.1, 592.0 (M+H+).

[0268] 1 H NMR (400 MHz, DMSO-d6) δ 11.52-11.18 (m, 1H), 8.04 (br s, 1H), 7.47 (br s, 1H), 6.28 (br d, J = 1.8 Hz, 1H), 5.78 (br s, 2H), 4.01 (br s, 2H), 3.91 (br s, 3H), 3.76 (s, 3H), 3.54 (br s, 2H), 2.50-2.40 (m, 2H), 1.43 (s, 9H). One exchangeable proton is not visible.

[0269] Methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate can be prepared as follows: 1-bromopyrrolidine-2,5-dione (N-bromosuccinimide (NBS), 2.059 g, 11.57 mmol) is added to a solution of methyl (7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.2 g, 10.52 mmol) in DMF (20 mL). The reaction mixture is stirred at room temperature for 1 h. The reaction mixture is post-treated with EtOAc, water and brine. The organic phases are combined, concentrated and dried under high vacuum for 1 h to produce methyl (3-bromo-7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.85 g, 9.89 mmol).

[0270] LC-MS m / z 288.0; 290.0 [M+H] +

[0271] Preparation of (4): DBU (1.225 mL, 8.13 mmol) was added to a suspension of tert-butyl 6-((3-bromo-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 3 (960 mg, 1.626 mmol) and (S)-3-aminohexan-1-ol hydrochloride (625 mg, 4.06 mmol) in DMSO (8 mL) and then stirred for 10 min to produce a clear solution. BOP (1.8 g, 4.06 mmol) was added. The reaction mixture was stirred at 70° C. for 1 h, cooled, poured into saturated NH4Cl solution and stirred for 30 min. The resulting solid was collected by filtration, washed with water, and dried in air to yield (S)-tert-butyl 6-((3-bromo-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 4 (1.2 g, 1.740 mmol, 107% yield) as a brown solid, which was directly carried into the next step without purification.

[0272] LCMS ESI: for C 31 H 41 Calculated value for BrN8O6 = 689.2 (M+H+), found 689.3, 691.3 (M+H+).

[0273] 1H NMR(400MHz,DMSO-d6)δ9.91(s,1H),8.09(d,J=1.5Hz,1H),7.72(d,J=8.4Hz,1H),7.54 (d,J=1.5Hz,1H),6.39-6.22(m,1H),5.89-5.65(m,2H),4.37(t,J=5.6Hz,1H),4.01(br s,2H),3.97-3.92(m,3H),3.63(s,3H),3.58-3.52(m,2H),3.48(br t,J=6.1Hz,1H),3.42(br d,J=5.9Hz,2H),2.55(d,J=1.3Hz,2H),1.82-1.70(m,2H),1.61-1.55(m,2H),1.42(s,9H),1.31-1.15(m,2H),0.82(t,J=7.3Hz,3H).

[0274] Preparation of (5): A mixture of (S)-tert-butyl 6-((3-bromo-7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 4 (1.2 g, 1.740 mmol) in dioxane (5 mL) was treated with NaOH (5.0 M in water, 3.40 mL, 17.40 mmol). The reaction mixture was stirred at 70 °C for 16 h, cooled, quenched with saturated NH4Cl solution, and further neutralized with HOAc to pH 6. The mixture was extracted with EtOAc (3x50 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The crude product was purified by silica column (80 g) chromatography (eluted with EtOAc / hexanes, 0-100% gradient). The desired fractions were collected and concentrated to yield (S)-tert-butyl 6-((5-amino-3-bromo-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 5 (663.2 mg, 1.050 mmol, 60.3% yield) as an off-white solid.

[0275] LCMS ESI: for C 28 H 40 Calculated value of BrN8O5 = 631.2 (M+H+), found 631.3, 633.3 (M+H + ).

[0276] 1H NMR(400MHz,DMSO-d6)δ8.11(d,J=1.3Hz,1H),7.54(d,J=1.1Hz,1H),6.32(br s,1H),5.91(s,2H),5.75-5.57(m,2H),4.41(br d,J=3.3Hz,2H),4.15-4.03(m,1H),4.02(br s,2H),3.94(s,3H),3.55(br t,J=5.5Hz,2H),3.45(br s,2H),2.50-2.44(m,2H),1.86-1.65(m,2H),1.61-1.49(m,2H),1.43(s,9H),1.33-1.18(m,2H),0.84(t,J=7.3Hz,3H)。

[0277] Preparation of Compound 124: A solution of (S)-tert-butyl 6-((5-amino-3-bromo-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 5 (660 mg, 1.045 mmol) in DCM (5 mL) was treated with TFA (1.5 mL, 19.47 mmol) and stirred at room temperature for 1.5 h, after which LCMS indicated two major products. The reaction mixture was concentrated to dryness. The crude material was suspended in THF (5 mL). NaOH (5.0 N in water, 0.84 mL, 4.18 mmol) was added. The reaction mixture is stirred at room temperature for 1h, neutralized to pH 6-7 with HOAc, and concentrated to dryness. The gained semi-solid residue is suspended in EtOAc and stirred for 5h. Solid is filtered out. The filtrate is concentrated to produce (S)-3-((5-amino-1-((3-methoxyl group-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol, it is suspended in MeOH (20ml) and transferred to the Parr shaker (Parr shaker) containing Pd-C (91mg, 0.852mmol), it is purged with H2 and shaken 16h under H2(45psi). Catalyst is removed by filtering through a syringe filter disk. The filtrate was concentrated to dryness to give (S)-3-((5-amino-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (500 mg, 0.732 mmol, 105% yield). 40 mg of crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 0% B, 0-40% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals.Fractions containing the desired product were combined and dried via centrifugal evaporation to yield 18.4 mg of pure compound 124, which was used in subsequent synthesis without further purification.

[0278] Compound 137 and Compound 152 were similarly prepared by reacting Compound 3 with (5-methylisoxazol-3-yl)methanamine and spiro[2.3]hexan-5-ylmethanamine, respectively, instead of (S)-3-aminohexan-1-ol.

[0279] Example 2-Compound 133

[0280]

[0281] A solution of compound 124 (40 mg, 0.059 mmol) in DMF (1 mL) was treated with molecular sieves, oxetane-3-one (12.67 mg, 0.176 mmol) and 2 drops of HOAc, followed by sodium triacetoxyborohydride (49.7 mg, 0.234 mmol). The reaction mixture was stirred at room temperature for 16 h. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 13% B, 13%-53% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded Compound 133 (4.1 mg, 7.87 μmol, 13.43% yield).

[0282] The following compounds were prepared similarly according to this example using a precursor such as Compound 101, Compound 137, Compound 152, or Compound 186 instead of Compound 124 for reaction with a complementary carbonyl compound, as applicable: Compound 102, Compound 108, Compound 111, Compound 112, Compound 113, Compound 115, Compound 116, Compound 126, Compound 127, Compound 129, Compound 131, Compound 134, Compound 141, Compound 142, Compound 143, Compound 147, Compound 148, Compound 150, Compound 154, Compound 156, Compound 157, Compound 158, Compound 159, Compound 163, Compound 189, Compound 190, and Compound 191.

[0283] Example 3-Compound 125

[0284]

[0285] A solution of compound 124 (60 mg, 0.088 mmol) in DMF (1 mL) was treated with KCO (42.5 mg, 0.308 mmol) and then 2-bromoeth-1-ol (43.9 mg, 0.352 mmol). The reaction mixture was stirred at 50 °C for 1.5 h. The solid was filtered off and the filtrate was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NHOAc); Mobile phase B: 95:5 acetonitrile:water (with NHOAc); Gradient: 0 min at 5% B, 5%-45% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded Compound 125 (16.8 mg, 0.033 mmol, 37.3% yield).

[0286] The following compounds were prepared similarly to this example using a precursor such as Compound 101, Compound 137, Compound 152, or Compound 186 instead of Compound 124 for reaction with a complementary alkyl halide, as applicable: Compound 114, Compound 119, Compound 120, Compound 144, Compound 145, Compound 146, Compound 151, Compound 153, Compound 164, Compound 165, Compound 188, Compound 204, Compound 205, Compound 206, Compound 207, and Compound 209.

[0287] Example 4-Compound 135

[0288]

[0289] A stirred mixture of (S)-3-((5-amino-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol Compound 124 (30 mg, 0.044 mmol) in DMF (1 mL) was treated with dimethylglycine (5.44 mg, 0.053 mmol), Hunin's base (0.023 mL, 0.132 mmol) and BOP (38.9 mg, 0.088 mmol). The reaction mixture was stirred at room temperature for 4 h. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile:water (containing NH4OAc); Gradient: 0 min at 7% B, 7%-47% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded Compound 135 (9.6 mg, 0.017 mmol, 39.1% yield).

[0290] The following compounds were prepared similarly according to this example using a precursor such as Compound 101, Compound 137, Compound 152, Compound 160, or Compound 186 instead of Compound 124 for reaction with a complementary acid, as applicable: Compound 104, Compound 105, Compound 109, Compound 110, Compound 128, Compound 136, Compound 140, Compound 155, Compound 162, Compound 187, and Compound 208.

[0291] Example 5 - Compound 106 and Compound 121

[0292]

[0293] Preparation of 6. To the stirred mixture of (3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)methyl carbamate (1.215g, 3.54mmol) in DMF (20mL), KCO (1.428g, 10.33mmol) was added, followed by 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-tert-butyl formate 2 (1g, 2.95mmol). The reaction mixture was stirred at room temperature for 5h, quenched by adding saturated NHCl solution, and extracted with EtOAc (3x20mL). The combined organic extracts were dried over NaSO and filtered. The filtrate was concentrated. The crude product was purified by silica column (80g) (using EtOAc: hexane, 0-100% gradient elution). The desired fractions were concentrated to give tert-butyl 6-((3-bromo-7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate 6 (1.0 g, 1.549 mmol, 52.5% yield).

[0294] LCMS ESI: for C 28 H 38 Calculated value for BrN8O5 = 645.2 (M+H + ), found values ​​645.3, 647.3 (M+H + ).

[0295] 1 H NMR (400MHz, DMSO-d6) δ9.82(s,1H),8.10(d,J=1.5Hz,1H),7.91(t,J=5.4Hz,1H),7.52(d,J=1.5Hz,1H),6.31(br s,1H),5.79(s,2H),4.01(br d,J=2.0Hz,2H),3.93(s,3H),3.64-3.60(m,3H),3.58-3.48(m,4H),2.54-2.50 (m,2H),1.66-1.53(m,2H),1.42(s,9H),1.34-1.21(m,2H),0.91-0.80(m,3H).

[0296] Preparation of 7. A mixture of compound 6 (100 mg, 0.155 mmol), K2CO3 (74.9 mg, 0.542 mmol) and PdCl2 (dppf)-CH2Cl2 adduct (12.65 mg, 0.015 mmol) in dioxane (0.5 mL) and water (0.1 mL) was bubbled with N2 stream for 2 min. 2,4,6-trimethyl-1,3,5,2,4,6-trioxa triborane (TMB, 0.217 mL, 1.549 mmol) was added, followed by another 2 min of N2 bubble. The reaction mixture was stirred at 110 ° C for 16 h, cooled, and diluted with EtOAc (5 mL). The solid was removed by filtration through a syringe filter disk. The filtrate was concentrated. The crude product was purified by ISCO silica column (24 g) (20% MeOH:DCM in DCM, 0-30% gradient elution). The desired fractions were concentrated to give tert-butyl 6-((5-amino-7-(butylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (35.2 mg, 0.067 mmol, 43.5% yield).

[0297] LCMS ESI: for C 27 H 39 Calculated for N8O3 = 523.3 (M+H + ), found value 523.4 (M+H + ).

[0298] 1 H NMR (400MHz, DMSO-d6) δ8.12(d,J=1.8Hz,1H),7.67(br d,J=4.6Hz,1H),7.51(d,J=1.8Hz,1H),6.31(br d,J=4.4Hz,1H),5.60(s,4H),4.02(br d,J=1.3Hz,2H),3.92(s,3H),3.54(t,J=5.5Hz,2H),3.49-3.39(m,2H),3.18(d,J=5.3Hz,2 H), 2.19 (s, 3H), 1.68-1.54 (m, 2H), 1.43 (s, 9H), 1.39-1.30 (m, 2H), 0.91 (t, J = 7.4Hz, 3H).

[0299] Preparation of compound 106.TFA (0.5ml, 6.49mmol) was added to a mixture of compound 7 (35mg, 0.067mmol) in DCM (1mL). The reaction mixture was stirred at room temperature for 1h and concentrated to dryness. The residue was dissolved in MeOH (5mL) and purged with N2. Pd-C (7.13mg, 0.067mmol) was added. The reaction mixture was allowed to stir at room temperature under H2 balloon for 16h. The catalyst was removed by filtering through a syringe filter disk. The filtrate was concentrated. The crude product was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile:water (containing NH4OAc); Gradient: 2% B for 0 min, 2%-32% B over 30 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded compound 106 (9.7 mg, 0.023 mmol, 33.7% yield).

[0300] Preparation of compound 121. A mixture of compound 106 TFA salt (25 mg, 0.046 mmol) in DMF (1 mL) was treated with tetrahydro-4H-pyran-4-one (46.5 mg, 0.464 mmol), then with sodium triacetoxyborohydride (29.5 mg, 0.139 mmol) and 1 drop of acetic acid. The reaction mixture was stirred at room temperature for 16 h and quenched with a small amount of water. The precipitated solid was filtered off through a syringe filter disk, and the filtrate was purified by preparative LC / MS using the following conditions: column: XBridge C18, 200 mm x 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile: water (containing NH4OAc); mobile phase B: 95:5 acetonitrile: water (containing NH4OAc); gradient: 0 min at 11% B, 11%-51% B over 20 min, then 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded compound 121 (6.5 mg, 0.012 mmol, 25.4% yield).

[0301] Compound 122 and Compound 123 were prepared similarly.

[0302] Example 6-Compound 101

[0303]

[0304] Preparation of 8. A solution of compound 6 (862 mg, 1.335 mmol) in dioxane (5 mL) was treated with NaOH (5.0 N in water; 2.136 mL, 10.68 mmol). The reaction mixture was stirred at 70 ° C for 5 h, cooled, and quenched with saturated NH4Cl, then stirred at room temperature for 1 h. The resulting solid was collected by filtration, washed with water and air-dried to produce 6-((5-amino-3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylic acid tert-butyl ester 8 (690 mg, 1.174 mmol, 88% yield).

[0305] LCMS ESI: for C 26 H 36 Calculated value for BrN8O3 = 587.2 (M+H + ), found values ​​587.2,589.2(M+H + ).

[0306] 1 H NMR (400MHz, DMSO-d6) δ8.12(d,J=1.8Hz,1H),7.68(t,J=5.3Hz,1H),7.52(d,J=1.5Hz,1H),6.31(br d,J=2.2Hz,1H),5.91(s,2H),5.68(s,2H),4.02(br s,2H),3.93(s,3H),3.54(br t,J=5.6Hz,2H),3.45(br d,J=5.5Hz,2H),2.50-2.49(m,2H),1.64-1.53(m,2H),1.43(s,9H),1.37-1.21(m,2H),0.89(t,J=7.4Hz,3H).

[0307] Preparation of Compound 101; Part 1. A mixture of compound 8 (450 mg, 0.766 mmol) in DCM (5 mL) was treated with TFA (3 mL, 38.9 mmol). The reaction mixture was stirred at room temperature for 45 min. The solvent was removed and the residue was triturated twice with Et2O and dried in vacuo to produce 3-bromo-N7-butyl-1-((5-methoxy-1',2',3',6'-tetrahydro-[3,4'-bipyridyl]-6-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine TFA salt (400 mg, 0.665 mmol, 87% yield).

[0308] LCMS ESI: for C 21 H28 Calculated for BrN8O = 487.1 (M+H + ), measured values ​​487.2, 489.2 (M+H + ).

[0309] Part 2. A solution of 3-bromo-N7-butyl-1-((5-methoxy-1',2',3',6'-tetrahydro-[3,4'-bipyridyl]-6-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine TFA salt (300 mg, 0.499 mmol) in MeOH (10 mL) was purged with N2, then Pd-C (10%; 53.1 mg, 0.499 mmol) was added. The reaction mixture was stirred under a balloon of H2 for 16 h. The catalyst was removed by filtration through a syringe disk. The filtrate was concentrated to give 30 mg of crude product, which was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 0% B, 0-40% B over 25 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded Compound 101 (19.7 mg, 0.048 mmol, 9.62% yield).

[0310] The following compounds: Compound 160, Compound 169 and Compound 170 were prepared similarly.

[0311] In the case of compound 160: instead of compound 2, the following compound

[0312]

[0313] (which can be prepared from 4-bromo-2-methoxybenzaldehyde according to Example 1) was used to generate analogs of compound 6.

[0314] This compound (instead of compound 6) was used to prepare compound 169:

[0315]

[0316] This compound can be

[0317]

[0318] Prepare generally according to Examples 1 and 5 above.

[0319] Example 7 - Compound 130 and Compound 132

[0320]

[0321] A mixture of N7-butyl-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (Compound 124) (30 mg, 0.046 mmol) in DMF (1 mL) was treated with 1 drop of HOAc, followed by pentan-3-one (23.65 mg, 0.275 mmol) and Na(OAc)3BH (97 mg, 0.458 mmol). The resulting reaction mixture was stirred at 60 °C for 24 h. The precipitated solid was filtered off. The filtrate was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 12% B, 12%-62% B over 30 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and produced Compound 130 (1.5 mg, 0.003 mmol, 6.45% yield) and Compound 132 (12.2 mg, 0.028 mmol, 60.4% yield).

[0322] Example 8-Compound 103

[0323]

[0324] Compound 101 (25 mg, 0.061 mmol) in DCM (0.5 mL) was treated with Hunin's base (0.011 mL, 0.064 mmol). Ms-Cl (4.75 μl, 0.061 mmol) was added dropwise at 0°C. The reaction mixture was stirred at 0°C for 4 h. The DCM solvent was removed. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 17% B, 17%-57% B over 25 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing compound 103 were combined and dried via centrifugal evaporation (6.0 mg, 0.012 mmol, 20.16% yield).

[0325] Compound 161 was prepared similarly using Compound 160 instead of Compound 101.

[0326] Example 9-Compound 117

[0327]

[0328] Preparation of 9. A mixture of compound 101 TFA salt (150 mg, 0.286 mmol), 2-chloroacetic acid (40.5 mg, 0.429 mmol) in DMF (4 mL) was treated with Hunin's base (0.100 mL, 0.572 mmol), followed by the addition of BOP (190 mg, 0.429 mmol). The reaction mixture was stirred for 4 h, quenched with water, and stirred for 1 h. The resulting solid was collected by filtration and dried in vacuo to yield 1-(4-(6-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidin-1-yl)-2-chloroethan-1-one 9 (220 mg, 0.316 mmol, 111% yield), which was directly carried into the next step without further purification.

[0329] LCMS ESI: for C 23 H 32 Calculated for N8O2 = 487.2 (M+H + ), measured value 487.2 (M+H + ).

[0330] Preparation of compound 117. A mixture of compound 9 (25 mg, 0.051 mmol) in DMA (1 mL) was treated with 2-methyl-2,6-diazaspiro[3.3]heptane HCl salt (38.2 mg, 0.257 mmol) and then with DBU (0.054 mL, 0.359 mmol), and the reaction mixture was stirred at 60 °C for 16 h. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 6% B, 6%-46% B over 30 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded Compound 117 (4.0 mg, 6.03 μmol, 11.74% yield). See Table A for analytical data.

[0331] Compound 118 was prepared similarly.

[0332] Example 10-Compound 139

[0333]

[0334] Preparation of 11. The solution of compound 10 (120mg, 0.197mmol) prepared similarly to the procedure above for compound 133 in DCM (2mL) was treated with TFA (0.5ml, 6.49mmol). The reaction mixture was stirred at room temperature for 1.5h and concentrated to dryness. The crude material was dissolved in THF (2mL) and a few drops of 10NNaOH in water were added to adjust the pH to 10-11. This resulting mixture was stirred at 60°C for 1h and neutralized to pH 6-7 with HOAc. The mixture was concentrated and then ground with 20% DCM (20ml) in MeOH. The solid was filtered out. The filtrate was concentrated to dryness to provide compound 11, which was not further purified and entered the next step.

[0335] LCMS ESI: for C 26 H 40 Calculated for N9O2 = 510.3 (M+H + ), found value 510.2(M+H + ).

[0336] Preparation of compound 139. A solution of compound 11 was treated with molecular sieves, propan-2-one (13.78 mg, 0.237 mmol) and 2 drops of HOAc, followed by Na(OAc)3BH (40.2 mg, 0.190 mmol). The reaction mixture was stirred at 60°C for 16 h. The solid was filtered off. The crude material was purified via preparative LC / MS using the following conditions: column: XBridge C18, 200 mm x19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile: water (containing NH4OAc); mobile phase B: 95:5 acetonitrile: water (containing NH4OAc); gradient: 0 min at 5% B, 5%-45% B over 25 min, then 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation and yielded compound 139 (11.9 mg, 0.021 mmol, 44.6% yield).

[0337] Compound 138 was prepared similarly.

[0338] Example 11-Compound 180

[0339]

[0340]

[0341] Step 1. A purged suspension of 4-bromo-2-methoxybenzyl alcohol (1 g, 4.61 mmol), PdCl2(dppf) (0.270 g, 0.369 mmol), bispinacol diborane (1.228 g, 4.84 mmol) and potassium acetate (0.904 g, 9.21 mmol) in dioxane (10 mL) was heated at 95° C. for 16 h. The cooled suspension was diluted with water (2 mL). Potassium phosphate (2.445 g, 11.52 mmol) and 2-chloropyrazine (0.405 mL, 4.61 mmol) were added. PdCl2(dppf) (0.270 g, 0.369 mmol) was added while purging with nitrogen. After heating at 95° C. for 16 h, the reaction mixture was diluted with ethyl acetate (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in hexanes to provide (2-methoxy-4-(pyrazin-2-yl)phenyl)methanol (812 mg).

[0342] LC-MS m / z 216.9[M+H] + .

[0343] 1 H NMR(400MHz,DMSO-d6)δ9.35-9.25(m,1H),8.77-8.67(m,1H),8.65-8.54(m,1H),7.81-7.72(m,1 H),7.72-7.65(m,1H),7.60-7.47(m,1H),5.17-5.06(m,1H),4.62-4.51(m,2H),3.95-3.85(m,3H)

[0344] Step 2. A suspension of (2-methoxy-4-(pyrazin-2-yl)phenyl)methanol (2.51 g, 11.61 mmol), Pd-C (2.5 g, 1.175 mmol) in ethanol (75 mL) was purged with argon three times and evacuated, and then placed under 50 psi of H2 for 16 h. Pd-C (2.5 g, 1.175 mmol) was added to the reaction mixture. The flask was purged with argon three times and evacuated, and then placed under 50 psi of H2. After 16 h, the reaction mixture was diluted with ethyl acetate (50 mL) and purified by CELITE TM Filtration and evaporation under reduced pressure afforded (2-methoxy-4-(piperazin-2-yl)phenyl)methanol (2.58 g). This product was used without further purification.

[0345] LC-MS m / z 223.0[M+H] + .

[0346] 1 H NMR(400MHz,DMSO-d6)δ7.30-7.22(m,1H),6.96-6.93(m,1H),6.92-6.88(m,1H),4.50-4.42(m,2H ),3.79-3.74(m,3H),3.65-3.55(m,1H),2.95-2.69(m,4H),2.66-2.54(m,2H),2.45-2.34(m,1H).

[0347] Step 3. A solution of (2-methoxy-4-(piperazin-2-yl)phenyl)methanol (513 mg, 2.31 mmol), DIPEA (1.210 mL, 6.93 mmol) and Boc-anhydride (Boc2O, 2.145 mL, 9.24 mmol) in DCM (50 mL) was stirred at room temperature for 80 h. The reaction mixture was evaporated under reduced pressure and dried under high vacuum. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in hexanes to provide di-tert-butyl 2-(4-(hydroxymethyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (664 mg).

[0348] 1 H NMR(400MHz,DMSO-d6)δ7.37-7.29(m,1H),6.90-6.72(m,2H),5.20-5.08(m,1H),5.00-4.90(m,1H),4.50-4.42(m,2H),4.40-4 .30(m,1H),3.91-3.77(m,2H),3.76-3.71(m,3H),3.31-3.20(m,1H),3.11-2.81(m,2H),1.44-1.38(m,9H),1.38-1.25(m,9H).

[0349] Step 4. To a solution of di-tert-butyl 2-(4-(hydroxymethyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (3.24 g, 7.67 mmol) and DIPEA (2.009 mL, 11.50 mmol) in DCM (100 mL) cooled to 0°C was added methanesulfonyl chloride (MsCl, 0.896 mL, 11.50 mmol). The reaction mixture was warmed to room temperature and stirred for 16 h, concentrated, and dried under high vacuum to provide di-tert-butyl 2-(4-(chloromethyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (3.38 g). This product was used without further purification.

[0350] LC-MS m / z 441.1[M+H] + .

[0351] Step 5. A mixture of di-tert-butyl 2-(4-(chloromethyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (3.38 g, 7.67 mmol), methyl (7-hydroxy-3-iodo-2H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.313 g, 6.90 mmol) and CsCO (7.50 g, 23.01 mmol) in DMF (100 mL) was stirred at room temperature. After 16 h, the reaction mixture was partitioned between EtOAc (300 mL) and 10% aqueous LiCl solution (200 mL). The organic layer was dried over NaSO, filtered and concentrated. The crude product was purified on silica gel with a gradient of 0% to 100% EtOAc in DCM to afford di-tert-butyl 2-(4-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (5.26 g).

[0352] LC-MS m / z 740.0[M+H] + .

[0353] Step 6. A solution of di-tert-butyl 2-(4-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (5.26 g, 7.11 mmol), (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (3.03 g, 8.53 mmol), BOP (6.29 g, 14.22 mmol) and DBU (4.29 ml, 28.4 mmol) in DMSO (10 ml) was stirred at room temperature for 16 h. The reaction mixture was evaporated under reduced pressure and dried under high vacuum. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in dichloromethane to afford di-tert-butyl 2-(4-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (1.12 g).

[0354] LC-MS m / z 1077.8[M+H] + .

[0355] Step 7. To a solution of di-tert-butyl 2-(4-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (1.12 g, 1.040 mmol) in MeOH (40 mL) was added TBAF (1 M in THF, 2.080 mL, 2.080 mmol). After 30 min, the reaction mixture was concentrated under reduced pressure and dried under high vacuum. The residue was diluted with MeOH (40 mL). Pd—C (0.221 g, 0.104 mmol) was added. The reaction vessel was purged with vacuum and nitrogen three times, and then with vacuum and hydrogen three times. The mixture was stirred under hydrogen for 70 h and purified by CELITE TM Filter and evaporate under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 20% methanol in dichloromethane to afford di-tert-butyl 2-(4-((7-(((S)-1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate

[0356] LC-MS m / z 713.3[M+H] + .

[0357] The two diastereomers of di-tert-butyl 2-(4-((7-(((S)-1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (239 mg) were separated by SCF using the following conditions: column OX 21X250mm ID, 5μm; mobile phase: 80 / 20 CO2 / MeOH; flow rate: 50mL / min; column temperature 40°C.

[0358] Fractions of the first eluting peak were collected and evaporated under reduced pressure (P1; 73 mg). 1 H NMR(400MHz,DMSO-d6)δ7.05-6.81(m,1H),6.77-6.65(m,1H),6.61-6.42(m,1H),6.39-6.2 4(m,1H),5.86-5.56(m,2H),5.18-5.03(m,1H),4.56-4.43(m,1H),4.39-4.35(m,1H),4.35 -4.25(m,1H),3.82-3.79(m,3H),3.62(s,3H),3.40-3.33(m,2H),1.77-1.43(m,5H),1.42- 1.24(m,19H),1.20-1.01(m,4H),0.97-0.93(m,1H),0.89-0.81(m,2H),0.81-0.74(m,3H).

[0359] Fractions of the second eluting peak were collected and evaporated under reduced pressure (P2; 80 mg). 1 H NMR(400MHz,DMSO-d6)δ7.05-6.78(m,1H),6.77-6.63(m,1H),6.61-6.43(m,1H),6.39- 6.18(m,1H),5.87-5.59(m,2H),5.23-5.01(m,1H),4.57-4.41(m,1H),4.39-4.20(m,2H ),3.82-3.78(m,3H),3.64-3.60(m,3H),3.38-3.32(m,2H),1.75-1.42(m,5H),1.40-1. 21(m,19H),1.20-1.01(m,4H),0.99-0.92(m,1H),0.89-0.82(m,2H),0.82-0.75(m,3H).

[0360] Step 8. A solution of di-tert-butyl 2-(4-((7-(((S)-1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (53 mg, 0.074 mmol) and NaOH (0.149 ml, 1.487 mmol) in dioxane (5 mL) was heated at 60 °C for 16 h. The cooled reaction mixture was evaporated under reduced pressure and dried under high vacuum. The crude mixture was diluted with DCM (5 mL). TFA (1 ml, 12.98 mmol) was added. After 16 h, the reaction mixture was partitioned between ethyl acetate 25 mL and saturated NaHCO (25 mL). The organic layer was dried over NaSO, filtered and concentrated. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 4% B for 0 min, 4%-44% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product, compound 180, were combined and dried via centrifugal evaporation.

[0361] Example 12-Compound 184

[0362]

[0363] Step 1. To a solution of di-tert-butyl 2-(4-((7-(((S)-1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)piperazine-1,4-dicarboxylate (see previous example; 80 mg, 0.112 mmol) in DCM (5 mL) was added TFA (500 μl, 6.49 mmol). After 2 h the reaction mixture was concentrated under reduced pressure and dried under high vacuum. The reaction mixture was diluted with methanol (20 mL). K2CO3 (50 mg, 0.362 mmol) was added. After 2 h the reaction mixture was diluted with ethyl acetate (25 mL) and purified by CELITE TM Filtration and evaporation under reduced pressure afforded methyl (7-(((S)-1-hydroxyhexan-3-yl)amino)-1-(2-methoxy-4-(piperazin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate. This product was used without further purification.

[0364] LC-MS m / z 513.3[M+H] + .

[0365] Step 2. A suspension of methyl (7-(((S)-1-hydroxyhexan-3-yl)amino)-1-(2-methoxy-4-(piperazin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (57.4 mg, 112 mmol), 2-bromopropane (55.1 mg, 0.448 mmol) and KCO (155 mg, 1.120 mmol) in NMP (1 mL) was heated to 50° C. After 16 h, NaOH (0.112 mL, 1.120 mmol) was added and heating was continued for 16 h. The reaction mixture was diluted with methanol (20 mL), filtered and evaporated under reduced pressure. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 0 min at 5% B, 5%-45% B over 25 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing compound 184 were combined and dried via centrifugal evaporation.

[0366] Compound 181 and Compound 182 were prepared similarly.

[0367] Example 13-Compound 175

[0368]

[0369] Step 1. In two identical vials were placed (tert-butoxycarbonyl)-L-proline (793 mg, 3.69 mmol), (4-bromo-2-methoxyphenyl)methanol (400 mg, 1.843 mmol), Ir(dF(CF3)ppy)2(dtbbpy)PF6 (20.67 mg, 0.018 mmol), NiBr2.dttbpy (44.9 mg, 0.092 mmol) and Cs2CO3 (1201 mg, 3.69 mmol) and DMA (20 mL). The suspension was degassed with nitrogen (open lid) for 10 minutes. The lid was sealed with parafilm. The resulting suspension was placed in a block with a Kessil PR160 427 (427 nm) violet lamp with stirring and a cooling fan. After 16 h, the reaction mixture was diluted with DCM (50 mL), combined and filtered through a CELITE TMFilter and evaporate under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in hexanes to afford a 2:3 mixture of tert-butyl 2-(4-(hydroxymethyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate and tert-butyl 2-(4-formyl-3-methoxyphenyl)pyrrolidine-1-carboxylate.

[0370] The mixture was dissolved in EtOH (50 mL) and NaBH (100 mg, 2.64 mmol) was added in batches. After 4 h, the reaction mixture was distributed between ethyl acetate (100 mL) and saturated NaHCO (50 mL). The organic layer was dried over NaSO, filtered and concentrated. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in hexane to provide tert-butyl 2-(4-(hydroxymethyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate LC-MS m / z 252.0 [M+H-tBuOH] + .

[0371] Step 2. To a mixture of tert-butyl 2-(4-(hydroxymethyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (380 mg, 1.236 mmol) and Hunin's base (0.130 mL, 0.742 mmol) in DCM (5 mL) was added Ms-Cl (0.053 mL, 0.680 mmol). After 16 h the reaction mixture was evaporated under reduced pressure and dried under high vacuum to afford tert-butyl 2-(4-(chloromethyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (201 mg). This product was used without further purification.

[0372] LC-MS m / z 326.1[M+H] + .

[0373] Step 3. A mixture of tert-butyl 2-(4-(chloromethyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (401 mg, 1.23 mmol), methyl (7-hydroxy-3-iodo-2H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (412 mg, 1.230 mmol) and CsCO (1202 mg, 3.69 mmol) in DMF (20 mL) was stirred at room temperature for 40 h and concentrated under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in dichloromethane to provide tert-butyl 2-(4-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate

[0374] LC-MS m / z 625.0[M+H] + .

[0375] Step 4. A mixture of tert-butyl 2-(4-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (332 mg, 0.532 mmol), (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine HCl (292 mg, 0.744 mmol), BOP (470 mg, 1.063 mmol) and DBU (0.321 mL, 2.127 mmol) in DMSO (3 mL) was heated at 70° C. for 16 h. The reaction mixture was partitioned between ethyl acetate (100 mL) and water (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in dichloromethane to afford tert-butyl 2-(4-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (146 mg).

[0376] LC-MS m / z 962.5[M+H] + .

[0377] 1 H NMR(400MHz,DMSO-d6)δ7.62-7.53(m,2H),7.51-7.29(m,6H),7.25-7.14(m,2 H),6.78-6.73(m,1H),5.73-5.58(m,2H),4.82-4.52(m,2H),3.77-3.65(m,3H ),3.64-3.46(m,5H),3.44-3.39(m,1H),2.25-2.04(m,1H),1.88-1.77(m,2H) ,1.74-1.29(m,8H),1.29-1.13(m,6H),1.14-0.97(m,6H),0.97-0.72(m,13H)

[0378] Step 5. A suspension of tert-butyl 2-(4-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (146 mg, 0.152 mmol), Pd—C (32.3 mg, 0.015 mmol) and pyridine (0.012 mL, 0.152 mmol) in MeOH (10 mL) was purged with vacuum and nitrogen three times, and then purged with vacuum and hydrogen three times again. The mixture was then stirred under hydrogen for 16 h and purified by CELITE HPLC. TM Filtered and evaporated under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in hexanes to afford tert-butyl 2-(4-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (100 mg).

[0379] LC-MS m / z 836.3[M+H] + .

[0380] Step 6. To a solution of tert-butyl 2-(4-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxyphenyl)pyrrolidine-1-carboxylate (100 mg, 0.120 mmol) in DCM (10 mL) was added TFA (500 μl, 6.49 mmol). After 16 h the solvent was evaporated under reduced pressure and dried under high vacuum to afford methyl (7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-(2-methoxy-4-(pyrrolidin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate trifluoroacetate (102 mg). This product was used without further purification.

[0381] LC-MS m / z 736.3[M+H] + .

[0382] Step 7. A mixture of methyl (7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-(2-methoxy-4-(pyrrolidin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.088 g, 12 mmol) and HCl (0.4 mL, 4.80 mmol) in MeOH (10 mL) was stirred at room temperature for 2 h, then concentrated under reduced pressure and dried under high vacuum to provide methyl (7-(((S)-1-hydroxyhexan-3-yl)amino)-1-(2-methoxy-4-(pyrrolidin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (64 mg). This product was used without further purification.

[0383] LC-MS m / z 498.3[M+H] + .

[0384] Step 8. A mixture of methyl (7-(((S)-1-hydroxyhexan-3-yl)amino)-1-(2-methoxy-4-(pyrrolidin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (59.7 mg, 12 mmol) and NaOH (0.120 mL, 1.200 mmol) in dioxane (7 mL) was heated at 50° C. for 16 h. The reaction mixture was concentrated under reduced pressure, dried under high vacuum and diluted with DMF:acetic acid 1:1 (2 mL). The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 4% B for 0 min, 4%-100% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing compound 175 were combined and dried via centrifugal evaporation.

[0385] Example 14-Compound 179

[0386]

[0387] Step 1. To a 0°C solution of (5-bromo-3-methoxypyridin-2-yl)methanol (Sigma-Aldrich) (2.462 g, 11.29 mmol) in CH2Cl2 (113 ml) was added SOCl2 (1.235 ml, 16.94 mmol) dropwise. The reaction was stirred at room temperature for 1 h and then concentrated in vacuo. This material was mixed with CH2Cl2 and concentrated in vacuo (2x) to provide a crude product, 5-bromo-2-(chloromethyl)-3-methoxypyridine. This material was used without further purification.

[0388] LC-MS m / z 236 / 238[M+H] + .

[0389] Step 2 To a room temperature suspension of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (3.44 g, 10.26 mmol) in DMF (45.6 ml) was added CsCO (13.37 g, 41.0 mmol). The reaction mixture was stirred at 0°C for 10 min; then a solution of the crude material from step 1 in DMF (22.80 ml) was added. The reaction mixture was stirred at 0°C for 1 h, then the cooling bath was removed and stirring was continued at room temperature for 20 h. The reaction mixture was added to H0 (250 mL) and allowed to stand at room temperature. The solid was collected by vacuum filtration and washed with H2O (3x15 mL), MeOH (2x15 mL), CH2Cl2 (15 mL) and hexanes (15 mL) to provide methyl (1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (4.431 g, 81%).

[0390] LC-MS m / z 535 / 537[M+H] + .

[0391] 1 H NMR (400MHz, DMSO-d6) δ13.19-12.96(m,1H),8.95-8.80(m,1H),8.06(s,1H),7.71(s,1H),5.87-5.65(m,2H),3.89(s,3H),3.53(br s,3H).

[0392] Step 3. To a room temperature suspension of methyl (1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.990 g, 1.850 mmol) in DMSO (12.33 ml) was added (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine HCl salt (0.870 g, 2.220 mmol) (US 2020 / 0038403 A1, Figure 8, compound 71a), followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (1.245 ml, 8.33 mmol) and (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (0.982 g, 2.220 mmol). The reaction mixture is stirred at room temperature for 1h, diluted with EtOAc (100mL), and washed with H2O (100mL).Separate each layer, and extract the water layer with EtOAc (100mL).The combined organic layer is washed with saturated NaCl aqueous solution (100mL), dried over Na2SO4, filtered, and concentrated in a vacuum.The crude material is purified by flash chromatography (80g silica gel; linear gradient 0-100% EtOAc-hexanes) to provide (S)-(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidine-5-yl)carbamate (810mg, 50%) in yellow foam.

[0393] LC-MS m / z 872 / 874[M+H] + .

[0394] 1 H NMR(400MHz,DMSO-d6)δ9.69(s,1H),7.92(d,J=1.8Hz,1H),7.79(d,J=1.8Hz,1H),7.57-7 .53(m,2H),7.50-7.46(m,2H),7.42-7.31(m,4H),7.25-7.20(m,2H),7.12(d,J=8.3Hz,1H ),5.78-5.69(m,2H),4.64-4.55(m,1H),3.91(s,3H),3.70-3.64(m,2H),3.58(s,3H),1.9 0-1.82(m,2H),1.57-1.48(m,2H),1.25-1.13(m,2H),0.92(s,9H),0.81(t,J=7.3Hz,3H).

[0395] Step 4. To a 0°C solution of (S)-methyl(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.810 g, 0.928 mmol) in a mixture of MeOH (9.28 ml) and AcOH (9.28 ml) was added zinc (0.607 g, 9.28 mmol). The reaction mixture was stirred at 0°C for 30 min and purified by CELITE TM Filter, and wash with MeOH (10mL) and EtOAc (50mL).Filtrate is diluted with EtOAc (200mL).While stirring, saturated NaHCO3 aqueous solution (250mL) is slowly added to this solution (carefully controlling the speed of gas release).Separate each layer and wash the organic layer with saturated NaCl aqueous solution (250mL), through Na2SO4 drying, filter, and concentrate in a vacuum to provide a crude product, (S)-(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidine-5-yl)methylcarbamate.This material is used without further purification.

[0396] LC-MS m / z 746 / 748[M+H] + .

[0397] Step 5. Add 10M NaOH aqueous solution (928 μl, 9.28 mmol) to the room temperature solution of the crude material from step 4 in 1,4-dioxane (9518 μl) and MeOH (4759 μl). The reaction mixture was stirred at 65 ° C for 16 h, cooled to room temperature, diluted with H2O (100 mL), and extracted with EtOAc (3x100 mL). The combined organic layer was washed with saturated NaCl aqueous solution (100 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography (24 g silica gel; linear gradient 0-10% MeOH-CH2Cl2) to provide (S)-3-((5-amino-1-((5-bromo-3-methoxypyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (368 mg, 88%) in a light yellow foam.

[0398] LC-MS m / z 450 / 452[M+H] + .

[0399] 1H NMR (400MHz, DMSO-d6) δ8.13(d,J=1.9Hz,1H),7.82(d,J=1.9Hz,1H),7.47(s, 1H),6.86(d,J=8.4Hz,1H),5.75-5.68(m,1H),5.66-5.60(m,1H),5.57(s,2H) ,4.43(t,J=5.3Hz,1H),4.41-4.34(m,1H),3.91(s,3H),3.47-3.41(m,2H),1. 78-1.62(m,2H),1.54-1.46(m,2H),1.27-1.16(m,2H),0.83(t,J=7.3Hz,3H).

[0400] Step 6. A mixture of (S)-3-((5-amino-1-((5-bromo-3-methoxypyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (28 mg, 0.062 mmol), 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid (28.5 mg, 0.124 mmol), NiBr2·dtbbpy (1.514 mg, 3.11 μmol) and Ir[dF(CF3)ppy]2(dtbbpy)PF6 (0.698 mg, 0.622 μmol) was evacuated and backfilled with N2. DMA (1244 μl) was added followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (18.60 μl, 0.124 mmol). The reaction mixture is sprayed with N2 for 20min, then sealed and stirred for 18h under irradiation with a purple LED (395-405nm) with a cooling fan. This reaction mixture is merged with the reaction mixture from the repeated operation under similar conditions. The resulting mixture is diluted with H2O (20mL) and extracted with EtOAc (2x20mL). The combined organic layer is washed with a saturated NaCl aqueous solution (20mL), dried over Na2SO4, filtered, and concentrated in a vacuum. The crude material is passed through flash chromatography (12g silica gel; linear gradient 0-10% MeOH-CH2Cl2) purified to provide 2-(6-((5-amino-7-(((S)-1-hydroxyhexyl-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester (mixture of diastereomers) in a mixture with other impurities. This material is used without further purification.

[0401] LC-MS m / z 555[M+H] + .

[0402] Step 7. To a room temperature solution of the material from step 6 in 1,4-dioxane (894 μl) and MeOH (224 μl) was added 4M HCl in 1,4-dioxane (279 μl, 1.118 mmol). The reaction mixture was stirred at room temperature for 3 h and concentrated. The crude material was dissolved in MeOH and concentrated. The crude material was redissolved in DMF (2 mL), filtered (0.45 μm nylon syringe filter), and purified via preparative LC / MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (with 0.05% TFA); Gradient: 0 min at 0% B, 0-40% B over 2 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. The collection of fractions was triggered by the MS signal. The fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile: water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile: water (containing NH4OAc); Gradient: 0 min at 3% B, 3%-43% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. The collection of fractions was triggered by the MS signal. The fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 179 (14.5 mg).

[0403] Compound 178 was prepared similarly.

[0404] Example 15-Compound 183

[0405]

[0406] Step 1. A mixture of (S)-3-((5-amino-1-((5-bromo-3-methoxypyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (40 mg, 0.089 mmol), 1-(tert-butoxycarbonyl)azepane-2-carboxylic acid (32.4 mg, 0.133 mmol), NiBr2·dtbbpy (2.162 mg, 4.44 μmol) and Ir[dF(Me)ppy]2(dtbbpy)PF6 (0.901 mg, 0.888 μmol) was dissolved in DMA (1776 μl) and 1,8-diazabicyclo[5.4.0]undec-7-ene (19.92 μl, 0.133 mmol) was added. The reaction flask is sprayed with N2 for 10min and sealed, and the reaction mixture is stirred for 22h under the irradiation of a purple LED (395-405nm) with a cooling fan. The reaction mixture is diluted with saturated NaHCO3 aqueous solution (20mL) and extracted with EtOAc (3x20mL). The organic layer merged is washed with saturated NaCl aqueous solution (20mL), through Na2SO4 drying, filtered, and concentrated in a vacuum. The crude material is passed through flash chromatography (12g silica gel; Linear gradient 0-10% MeOH-CH2Cl2) purified to provide 2-(6-((5-amino-7-(((S)-1-hydroxyhexyl-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)azepane-1-carboxylic acid tert-butyl ester (mixture of diastereomers) (24.7mg, 49%).

[0407] LC-MS m / z 569[M+H] + .

[0408] Step 2. To a room temperature solution of tert-butyl 2-(6-((5-amino-7-(((S)-1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)azepane-1-carboxylate (mixture of diastereomers) (24.7 mg) in 1,4-dioxane (347 μl) and MeOH (87 μL) was added 4M HCl in dioxane (109 μl, 0.434 mmoL). The reaction mixture was stirred at room temperature for 3 h and concentrated. The crude material was dissolved in MeOH and concentrated. The crude material was redissolved in DMF (2 mL), filtered (0.45 μm nylon syringe filter), and purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (with 0.05% TFA); Gradient: 0% B for 0 min, 0-40% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 183 (13.4 mg).

[0409] Example 16-Compound 185

[0410]

[0411] Step 1. A mixture of (S)-3-((5-amino-1-((5-bromo-3-methoxypyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (40 mg, 0.089 mmol), (2S,4R)-1-(tert-butoxycarbonyl)-4-cyanopyrrolidine-2-carboxylic acid (42.7 mg, 0.178 mmol), NiBr2·dtbbpy (2.162 mg, 4.44 μmol) and Ir[dF(Me)ppy]2(dtbbpy)PF6 (0.901 mg, 0.888 μmol) was dissolved in DMA (1776 μL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (26.6 μl, 0.178 mmol) was added. The reaction mixture is N2 sprayed 10min, then sealed and stirred for 17h under the irradiation of the purple LED (395-405nm) with cooling fan.The reaction is saturated NaHCO3 aqueous solution (20mL) is diluted and extracted with EtOAc (3x20mL).The organic layer merged is washed with saturated NaCl aqueous solution (20mL), through Na2SO4 drying, filtered, and concentrated in a vacuum.The crude material is passed through flash chromatography (12g silica gel; Linear gradient 0-20% MeOH-CH2Cl2) purified, to provide (4R)-2-(6-((5-amino-7-(((S)-1-hydroxyl hexyl-3-yl) amino)-1H-pyrazolo [4,3-d] pyrimidine-1-yl) methyl)-5-methoxypyridine-3-yl)-4-cyano pyrrolidine-1-tert-butyl formate (mixture of diastereomers) (25.4mg, 51%).

[0412] LC-MS m / z 566[M+H] + .

[0413] Step 2. To a room temperature solution of (4R)-tert-butyl 2-(6-((5-amino-7-(((S)-1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)-4-cyanopyrrolidine-1-carboxylate (mixture of diastereomers) (25.4 mg, 0.045 mmol) in CH2Cl2 (808 μl) was added TFA (90 μl). The reaction was stirred at room temperature for 5 h. The reaction was concentrated in vacuo. The crude material was dissolved in CH2Cl2 and concentrated in vacuo (2x).

[0414] The crude material was dissolved in a mixture of CH2Cl2 (225 μL) and MeOH (225 μL), and triethylamine (31.3 μl, 0.225 mmol) was added. The solution was stirred at room temperature for 20 min. The reaction was concentrated. The crude material was dissolved in CH2Cl2 and concentrated. The crude material was dissolved in DMF (2 mL), filtered (0.45 μm nylon syringe filter), and purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% TFA); Gradient: 0 min at 0% B, 0-40% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford compound 185 (mixture of diastereomers) TFA salt (19.3 mg).

[0415] Example 17-Compound 171 and Compound 172

[0416]

[0417]

[0418] Compound A.Solution of (5-bromo-3-methoxypyridine-2-yl)methanol (3.75g, 17.20mmol) in DMF (20mL) is treated with TBDMS-Cl (6.48g, 43.0mmol), then treated with imidazoles (2.58g, 37.8mmol).The resulting reaction mixture is stirred at room temperature for 3h, quenched with water, and extracted with ethyl acetate (3x50mL).The organic extracts merged are dried over Na2SO4 and filtered.The filtrate is concentrated.Residue is purified by silica column (80g) (using ethyl acetate: hexane, 0-30% gradient elution).Desired fraction is concentrated to produce 5-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxypyridine A (5.55g, 16.70mmol, 97% yield).

[0419] LCMS ESI: for C 13 H 23 Calculated values ​​for BrNO2Si = 332.1, 334.1 (M+H + ), measured values ​​332.0, 334.0 (M+H + ).

[0420] 1H NMR (400 MHz, chloroform-d) δ 8.14 (d, J = 2.0 Hz, 1H), 7.19 (d, J = 2.0 Hz, 1H), 4.69 (s, 2H), 3.75 (s, 3H), 0.83-0.75 (m, 9H), 0.02-0.03 (m, 6H).

[0421] Compound B. A stirred solution of 5-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)-3-methoxypyridine A (2.0 g, 6.02 mmol) in toluene (25 mL) was treated with sodium tert-butoxide (1.157 g, 12.04 mmol), tert-butyl piperazine-1-carboxylate (1.681 g, 9.03 mmol), and BINAP (1.874 g, 3.01 mmol). A stream of N2 was bubbled into the reaction mixture for 5 min; then Pd2(dba)3 (0.551 g, 0.602 mmol) was added to the mixture. The reaction mixture was heated at 100°C for 16 h, cooled, diluted with EtOAc, and purified by CELITE HPLC. TM To the 4- (6- (((tert-butyldimethylsilyl) oxygen base) methyl) -5-methoxypyridin-3-yl) piperazine -1- carboxylic acid tert-butyl ester B (1.22g, 2.79mmol, 46.3% yield) .

[0422] LCMS ESI: for C 22 H 40 Calculated value for N3O4Si = 438.3 (M+H + ), found value 438.3 (M+H + ).

[0423] 1 H NMR (400MHz, DMSO-d6) δ7.76(d,J=2.2Hz,1H),6.92(d,J=2.2Hz,1H),4.58(s,2H),3.78(s,3H),3.49-3.38(m,4H),3.17(br s,4H),1.40(s,9H),0.82(s,9H),0.00(s,6H).

[0424] Compound C, part 1.A suspension of tert-butyl 4-(6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methoxypyridin-3-yl)piperazine-1-carboxylate B (550 mg, 1.257 mmol) in THF (5 mL) was treated with TBAF (1.0 M in THF) (1.257 mL, 1.257 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 h and concentrated. The crude residue was purified by silica column (40 g) (eluted with 20% MeOH in DCM: DCM, 0-25% gradient), and the desired fraction was concentrated to produce tert-butyl 4-(6-(hydroxymethyl)-5-methoxypyridin-3-yl)piperazine-1-carboxylate (405 mg, 1.277 mmol, 100% yield) as a brown oil.

[0425] LCMS ESI: for C 16 H 26 Calculated value for N3O4 = 324.2 (M+H + ), found value 324.1(M+H + ).

[0426] 1 H NMR (400 MHz, DMSO-d6) δ 7.84 (d, J = 2.2 Hz, 1H), 6.98 (d, J = 2.2 Hz, 1H), 5.01 (s, 2H), 3.83 (s, 3H), 3.58-3.41 (m, 4H), 3.26-3.17 (m, 4H), 1.43 (s, 9H), one exchangeable proton was not visible.

[0427] Compound C, Part 2. A mixture of tert-butyl 4-(6-(hydroxymethyl)-5-methoxypyridin-3-yl)piperazine-1-carboxylate (230 mg, 0.711 mmol) in anhydrous THF (5 mL) was treated with SOCl2 (0.260 mL, 3.56 mmol) at 0°C for 5 min. The reaction mixture was concentrated. Excess SOCl2 was removed azeotropically with DCM (3x). The resulting crude material tert-butyl 4-(6-(chloromethyl)-5-methoxypyridin-3-yl)piperazine-1-carboxylate C was taken to the next step without purification.

[0428] LCMS ESI: for C 16 H 26 Calculated value for N3O4 = 338.2 (M+H + ), found value 338.2 (M+H + ).

[0429] Compound D. To a stirred mixture of (3-bromo-7-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-5-yl)methylcarbamate (0.219 g, 0.761 mmol) in DMF (5 mL) was added KCO (0.162 g, 1.170 mmol) at 0 °C, followed by tert-butyl 4-(6-(chloromethyl)-5-methoxypyridin-3-yl)piperazine-1-carboxylate (0.2 g, 0.585 mmol). After 5 min, LCMS indicated completion of the reaction with major desired product. The reaction mixture was quenched with saturated NHCl solution and stirred at room temperature for 1 h. The resulting solid was collected by filtration and purified by an ISCO silica column (40 g) (eluted with ethyl acetate: hexane 0-100% gradient). The desired fractions were concentrated to give tert-butyl 4-(6-((3-bromo-7-hydroxy-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperazine-1-carboxylate D (150 mg, 0.253 mmol, 43.2% yield) as a white solid.

[0430] LCMS ESI: for C 23 H 30 Calculated for BrN8O2 = 593.1 595.1 (M+H + ), found values ​​593.1,595.1(M+H + ).

[0431] 1 H NMR (400 MHz, DMSO-d6) δ 8.03-7.83 (m, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 5.68 (s, 2H), 3.83 (s, 3H), 3.75 (s, 3H), 3.44 (br d, J = 5.3 Hz, 4H), 3.18 (br t, J = 5.0 Hz, 4H), 1.42 (s, 9H). One exchangeable proton was not visible.

[0432] Compound 171. (S)-3-((5-amino-1-((3-methoxy-5-(piperazin-1-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (Compound 171) was prepared similarly from Compound D according to the above procedure for Compound 124. See Table A for analytical data.

[0433] Compound 172. A solution of (S)-3-((5-amino-1-((3-methoxy-5-(piperazin-1-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (25 mg, 0.052 mmol) in DMF (1 mL) was treated with 1-chloro-2-methylpropan-2-ol (34.0 mg, 0.313 mmol) and a catalytic amount of NaI. The reaction mixture was stirred at 100 °C for 20 h. After cooling, the solid was filtered off, and the filtrate was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile: water (containing NH4OAc); Mobile phase B: 95:5 acetonitrile: water (containing NH4OAc); Gradient: 0 min at 16% B, 16%-56% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound 172 (6.6 mg, 0.012 mmol, 23.58% yield).

[0434] Example 18-Compound 186

[0435]

[0436] Step 1. A mixture of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1252 mg, 4.05 mmol) in dioxane (4 mL) and water (1 mL) was treated with methyl 6-chloro-3-methoxypicolinate (680 mg, 3.37 mmol), K2CO3 (1.63 g, 11.81 mmol). After bubbling N2 stream into the reaction mixture for 2 min; then PdCl2(dppf)-CH2Cl2 adduct (275 mg, 0.337 mmol) was added. The resulting mixture was stirred at 70 ° C for 2.5 h. After cooling, the reaction mixture was diluted with EtOAc (5 mL). The solid material was purified by centrifugation through CELITE TM The pad was filtered off. The filtrate was dried over Na2SO4, filtered and concentrated. The crude material was purified by silica column (40 g) (eluted with EtOAc / hexane 0-100% gradient). The desired fractions were concentrated to produce 1'-(tert-butyl)6-methyl 5-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1',6(2'H)-dicarboxylate (Compound 1) (700 mg, 2.009 mmol, 59.6% yield).

[0437] LCMS ESI: for C 18 H 25 Calculated value for N2O5 = 349.2 (M+H + ), found value 349.1(M+H + ).

[0438] 1 H NMR(400MHz,DMSO-d6)δ7.74-7.66(m,1H),7.67-7.42(m,1H),6.55(br s,1H),4.03(br d,J=2.2Hz,2H),3.86(s,3H),3.84(s,3H),3.53(t,J=5.7Hz,2H),2.52(br s,2H),1.43(s,9H).

[0439] Step 2, part 1. A solution of 1'-(tert-butyl)6-methyl 5-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1',6(2'H)-dicarboxylate (1.2 g, 3.44 mmol) in THF (30 mL) was treated with LiAlH4 (3.44 mL, 3.44 mmol) in batches at 0°C under N2. The reaction mixture was stirred for 30, carefully quenched with Rochelle salt solution, and stirred at room temperature for 16 h. The two liquid phases were separated. The aqueous phase was back extracted with EtOAc (2x25 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated to give tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.1 g, 3.43 mmol, 100% yield) which was pure enough for the next step.

[0440] LCMS ESI: calcd for C17H25N2O4 = 321.2 (M+H+), found 321.2 (M+H+).

[0441] 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.30-7.25 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.54 (br s, 1H), 4.73 (s, 2H), 4.43 (br s, 1H), 4.14-4.11 (m, 2H), 3.86 (s, 3H), 3.65 (br t, J = 5.7 Hz, 2H), 2.70-2.58 (m, 2H), 1.49 (s, 9H).

[0442] Step 2, Part 2. A mixture of tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.1 g, 3.43 mmol) in DCM (20 mL) was treated with Hunin's base (0.899 mL, 5.15 mmol) followed by Ms-Cl (0.321 mL, 4.12 mmol). The reaction mixture was stirred at room temperature for 16 h, diluted with DCM (10 mL) and washed with water. The two layers were separated. The organic layer was dried over Na2SO4, filtered and concentrated. The crude material was purified by silica column (40 g) eluting with EtOAc:hexane 0-70% gradient. The desired fractions were concentrated to give tert-butyl 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate Compound 2 (724 mg, 2.137 mmol, 62.2% yield).

[0443] LCMS ESI: for C 17 H 25 Calculated value for N2O4 = 321.2 (M+H+), found 321.2 (M+H+).

[0444] 1 H NMR (400MHz, chloroform-d) δ7.31(d,J=8.6Hz,1H),7.18(d,J=8.6Hz,1H),6.54(brs,1H),4.73(s,2H),4.12(br d,J=2.9Hz,2H),3.90(s,3H),3.64(br t,J=5.5Hz,2H),2.62(br dd,J=4.4,2.6Hz,2H),1.49(s,9H)

[0445] tert-Butyl 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate Compound 186 was obtained via steps similar to those for Compound 2.

[0446] Example 19-Compound 192 and Compound 196

[0447]

[0448]

[0449] Step 1, part 1. A mixture of 4,5-difluoro-2-methoxybenzoic acid methyl ester (1.0g, 4.95mmol), piperazine-1-carboxylic acid tert-butyl ester (1.013g, 5.44mmol) and K2CO3 (1.367g, 9.89mmol) in DMF (20mL) was stirred at 90°C for 16h, cooled and quenched with water. The reaction mixture was extracted with EtOAc (3x25mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The resulting crude material was purified by ISCO silica column chromatography (80g) (eluted with EtOAc-hexane 0-80% gradient). The desired fraction was concentrated to produce 4-(2-fluoro-5-methoxy-4-(methoxycarbonyl) phenyl) piperazine-1-carboxylic acid tert-butyl ester (1.31g, 3.56mmol, 71.9% yield).

[0450] LCMS ESI: for C 18 H 26 Calculated value for FN2O5 = 369.2 (M+H+), found 369.1 (M+H+).

[0451] 1 H NMR (400MHz, chloroform-d) δ7.57 (d, J = 13.4Hz, 1H), 6.48 (d, J = 7.0Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.65-3.58 (m, 4H), 3.22-3.11 (m, 4H), 1.49 (s, 9H).

[0452] Step 1, part 2. A solution of tert-butyl 4-(2-fluoro-5-methoxy-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (1.3 g, 3.53 mmol) in THF (30 mL) was treated in batches with LiAlH (2.0 M in THF) (1.764 mL, 3.53 mmol) at room temperature under N. After 10 min, the reaction was carefully quenched with Rochelle salt solution. After stirring at room temperature for 16 h, the two layers were separated. The organic layer was dried over NaSO, filtered and concentrated to produce tert-butyl 4-(2-fluoro-4-(hydroxymethyl)-5-methoxyphenyl)piperazine-1-carboxylate (1.20 g, 3.53 mmol, 100% yield), which was pure enough for the next step.

[0453] LCMS ESI: for C 17 H 26 Calculated for FN2O4 = 341.2 (M+H + ), found value 341.2 (M+H + ).

[0454] 1H NMR (400 MHz, CHLOROFORM-d) δ 7.00 (d, J = 12.3 Hz, 1H), 6.46 (d, J = 6.8 Hz, 1H), 4.59 (br s, 2H), 3.88-3.82 (m, 3H), 3.69-3.40 (m, 4H), 3.17-2.85 (m, 4H), 1.48 (s, 9H).

[0455] Step 1, part c. A solution of tert-butyl 4-(2-fluoro-4-(hydroxymethyl)-5-methoxyphenyl)piperazine-1-carboxylate (1.2 g, 3.53 mmol) in THF (20 mL) was treated with SOCl2 (0.334 mL, 4.58 mmol) at 0°C. After 10 min, LCMS showed only starting material. However, NMR indicated that the crude product was the desired tert-butyl 4-(4-(chloromethyl)-2-fluoro-5-methoxyphenyl)piperazine-1-carboxylate (Compound 21-1), which was taken directly to the next step.

[0456] 1 H NMR (400MHz, chloroform-d) δ8.30(d,J=6.4Hz,1H),7.33(d,J=12.5Hz,1H),4.59(s,2H),4.11(br t,J=4.8Hz,4H),3.93(s,3H),3.61(br t,J=5.1Hz,4H),1.50(s,9H).

[0457] Compound 192 was prepared from methyl (3-bromo-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate and tert-butyl 4-(4-(chloromethyl)-2-fluoro-5-methoxyphenyl)piperazine-1-carboxylate (compound 21-1) by reactions analogous to those used to prepare compound 101 (Examples 5 and 6 above).

[0458] LCMS ESI: for C 21 H 30 Calculated for FN8O = 429.2 (M+H+), found 429.1 (M+H+).

[0459] 1H NMR (500 MHz, DMSO-d6) δ 9.54-9.23 (m, 1H), 7.97 (s, 1H), 7.87 (br s, 2H), 7.01 (br d, J = 12.5 Hz, 1H), 6.69 (br d, J = 7.0 Hz, 1H), 5.41 (s, 2H), 3.82 (s, 3H), 3.26 (s, 4H), 1.68-1.51 (m, 2H), 1.41-1.23 (m, 2H), 0.91 (br t, J = 7.3 Hz, 3H). Seven protons are not visible, most likely due to water suppression and overlap with the DMSO-d6 peak.

[0460] Step 2. A mixture of N7-butyl-1-(5-fluoro-2-methoxy-4-(piperazin-1-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine and TFA (150 mg, 0.276 mmol) in THF (5 mL) was treated with Hunin's base (0.145 mL, 0.829 mmol) at room temperature, followed by 2-bromoacetyl chloride (43.5 mg, 0.276 mmol) dropwise. After 5 min, the reaction was quenched with water and extracted with EtOAc (3x15 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The crude product was purified by ISCO silica column (12 g) eluting with 20% MeOH:DCM 0-60% gradient in DCM. The desired fractions were concentrated to give 153 mg of a mixture of 1-(4-(4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-2-fluoro-5-methoxyphenyl)piperazin-1-yl)-2-chloroethan-1-one (compound 21-2) and 1-(4-(4-((5-amino-7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-2-fluoro-5-methoxyphenyl)piperazin-1-yl)-2-bromoethan-1-one (compound 21-3).

[0461] LCMS ESI (Compound 21-2): for C 23 H 31 Calculated value for ClFN8O2 = 505.2 (M+H+), found 505.2 (M+H+).

[0462] LCMS ESI (Compound 22-3): for C 23 H 31 Calculated value of BrFN8O2 = 548.2, 550.2 (M+H+), found value 548.2, 550.2 (M+H+).

[0463] Step 3. A mixture of compound 21-2 and compound 21-3 (25 mg,) in N,N-dimethylacetamide (0.5 mL) was treated with 1-amino-2-methylpropan-2-ol (44.1 mg, 0.495 mmol). After stirring at 60°C for 16 h, LCMS indicated that the reaction was complete. The mixture was purified via preparative LC / MS using the following conditions: column: XBridge C18, 200 mm x 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile: water (containing NH4OAc); mobile phase B: 95:5 acetonitrile: water (containing NH4OAc); gradient: 0 min at 8% B, 8%-48% B over 20 min, then 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound 196 (22 mg).

[0464] The following compounds: Compound 194, Compound 195, Compound 197, Compound 198 and Compound 199 were prepared similarly.

[0465] Compound 193 was prepared from Compound 192 using a procedure analogous to that used to prepare Compound 103 in Example 8 above.

[0466] Example 20-Compound 149

[0467]

[0468] Step 1. A suspension of (7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)methyl carbamate (500 mg, 1.892 mmol) in DMF (9.5 ml) was treated once with N-chlorosuccinimide (NCS, 303 mg, 2.270 mmol) at room temperature. After stirring for 10 min, the reaction mixture was diluted with DCM (100 mL), washed with water (3x75 mL), dried over Na2SO4, and filtered. The filtrate was concentrated. The crude material was purified by silica column chromatography (24 g) (eluted with DCM: 10% MeOH 0-10% gradient in DCM). The desired fractions were concentrated to give methyl (7-(butylamino)-3-chloro-2H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (Compound A) (536.8 mg, 1.80 mmol, 95% yield).

[0469] LCMS ESI: for C 11 H 16 Calculated value for ClN6O2 = 299.7 (M+H+), found 299.1 (M+H+).

[0470] 1 H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1H), 3.62 (s, 3H), 3.54 (br d, J = 5.7 Hz, 2H), 1.71-1.54 (m, 2H), 1.40 (br dd, J = 15.0, 7.5 Hz, 2H), 0.94 (br t, J = 7.4 Hz, 3H). Two exchangeable protons were not visible.

[0471] Step 2. Tert-butyl 6-((5-amino-7-(butylamino)-3-chloro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (Compound B) was prepared from Compound A by procedures analogous to those for Compound 6.

[0472] LCMS ESI: for C 26 H 36 Calculated value for ClN8O3 = 543.3 (M+H + ), measured value 543.2 (M+H+)

[0473] Step 3. N7-butyl-3-chloro-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (Compound C) was prepared from Compound B analogously to the procedure above for Compound B.

[0474] LCMS ESI: for C 26 H 30 Calculated for ClN8O = 445.2 (M+H + ), found value 445.2(M+H + )

[0475] Step 4. Compound 149 was prepared from Compound C using procedures similar to those used for Compound 121.

[0476] Example 21-Compound 107

[0477]

[0478] Step 1. A mixture of compound 6 (100 mg, 0.155 mmol), K2CO3 (74.9 mg, 0.542 mmol) and PdCl2(dppf)-CH2Cl2 adduct (12.65 mg, 0.015 mmol) in dioxane (0.5 mL) and water (0.1 mL) was bubbled with N2 stream for 3 min. Cyclopropylboronic acid (133 mg, 1.549 mmol) was added. N2 stream was bubbled for another 1 min. The reaction vessel was sealed and the reaction mixture was stirred at 110°C for 24. The reaction mixture was diluted with EtOAc (15 ml). The resulting solid was purified by filtration through CELITE TM The pad was filtered off. The filtrate was concentrated. The crude product was purified by ISCO silica column (12 g) chromatography (eluted with 20% MeOH:DCM in DCM, 0-30% gradient). The desired fraction was concentrated to produce 6-((5-amino-7-(butylamino)-3-cyclopropyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-tert-butyl carboxylate (Compound D) (20 mg, 0.036 mmol, 23.53% yield).

[0479] LCMS ESI: for C 29 H 41 Calculated value for N8O3 = 549.3 (M+H+), found 549.4 (M+H+).

[0480] Step 2. Compound 107 was prepared from compound D in analogy to the synthetic procedure employed above for compound 121.

[0481] Example 22 - Compound 166 and Compound 167

[0482]

[0483]

[0484] Step 1. To a stirred solution of methyl 6-chloro-4-methoxynicotinate (4.0 g, 19.84 mmol) in 1,4-dioxane (40.0 mL) was added water (10.0 mL), Cs2CO3 (19.39 g, 59.5 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (9.20 g, 29.8 mmol) and PdCl2(dppf)-CH2Cl2 adduct (1.620 g, 1.984 mmol) while purging with N2. The reaction mixture was stirred at 100°C for 4 h and purified by CELITE TMTo 4-(tert-butyl)-5-methyl-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1',5(2'H)-diformate (5.19 g, 14.15 mmol, 71.3% yield) was added in 4-(tert-butyl)-5-methyl-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1',5(2'H)-diformate (5.19 g, 14.15 mmol, 71.3% yield) to provide 1'-(tert-butyl)-5-methyl-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1',5(2'H)-diformate (5.19 g, 14.15 mmol, 71.3% yield) in a light brown oil.

[0485] LC-MS m / z 349.3[M+H] + .

[0486] 1 H NMR (300MHz, DMSO-d6)d=8.72-8.66(m,1H),7.27-7.18(m,1H),6.94-6.81(m,1H),5.78-5.7 3(m,1H),4.12-4.05(m,2H),3.95(d,J=3.0Hz,6H),3.80(s,3H),3.57-3.49(m,2H),2.58(br d,J=1.5Hz,2H),1.45-1.41(m,9H),1.09-1.05(m,15H).

[0487] Step 2. To a stirred solution of 1'-(tert-butyl)5-methyl 4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1',5(2'H)-dicarboxylate (1.5 g, 4.31 mmol) in THF (12.0 mL) was added MeOH (3.0 mL), LiBH4 (in THF; 5.38 mL, 10.76 mmol). After 16 h, the reaction mixture was quenched with 10% NaOH solution and partitioned between EtOAc and water. The organic layer was washed with brine and dried over Na2SO4, filtered and concentrated under reduced pressure to provide tert-butyl 5-(hydroxymethyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.1 g, 3.36 mmol, 78% yield) as a brown thick oil. The product was used as is.

[0488] LC-MS m / z 321.2[M+H] + .

[0489] 1H NMR (300MHz, DMSO-d6)d=8.32(s,1H),7.10(s,1H),6.67(br s,1H),5.77-5.76(m,1H),5.77(s,1H),5.09(t,J=5.5Hz,1H),4.48(d,J=5.7Hz,2H),4.07-4.02(m,2H),3.95( s,1H),3.88(s,3H),3.57-3.49(m,2H),2.62-2.54(m,2H),2.01-1.98(m,1H),1.43(s,9H),1.09-1.05(m,3H).

[0490] Step 3. TEA (1.044 mL, 7.49 mmol), Ms-Cl (0.584 mL, 7.49 mmol) and lithium chloride (0.318 g, 7.49 mmol) were added to a stirred solution of 5-(hydroxymethyl)-4-methoxy-3', 6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylic acid tert-butyl ester (1.2 g, 3.75 mmol) in DCM (15.0 mL) at 0°C. The reaction mixture was stirred at the same temperature for 30 min and then at room temperature for 4 h and partitioned between DCM and water. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to provide 5-(chloromethyl)-4-methoxy-3', 6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylic acid tert-butyl ester (1.3 g, 3.68 mmol, 98% yield) as a brown oil. The product was used without further purification.

[0491] LC-MS m / z 339.2[M+H] +

[0492] 1 H NMR (300MHz, DMSO-d6)d=8.74-8.65(m,1H),7.58-7.48(m,1H),6.98-6.86(m,1H),5.77-5.74(m,1H),4.82(s,2H),4.19-4.12(m,5H),3.62 -3.54(m,2H),2.67-2.58(m,2H),2.36-2.32(m,2H),1.50-1.48(m,1H),1.44(s,9H),1.31(s,1H).

[0493] Step 4. To a stirred solution of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.0 g, 2.98 mmol) in DMF (10.0 mL) was added CsCO (1.945 g, 5.97 mmol). To this mixture was added tert-butyl 5-(chloromethyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.011 g, 2.98 mmol) in DMF (5.0 mL) at 0°C. The reaction mixture was stirred at 0°C for 1 h and at room temperature for 1 h and partitioned between EtOAc and water. The organic layer was washed with brine, dried over NaSO, filtered and concentrated under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in petroleum ether to afford tert-butyl 5-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (718 mg, 0.946 mmol, 31.7% yield) as a light brown solid.

[0494] LC-MS m / z 638.0[M+H] +

[0495] 1 H NMR (300MHz, DMSO-d6)d=11.74-11.66(m,1H),11.44-11.36(m,1H),8.06-7.98(m,1H),7.19-7.09(m, 1H),6.75-6.63(m,1H),5.74-5.67(m,2H),4.07-4.01(m,2H),3.85(s,3H),3.78-3.71(m,5H),3.52(br t,J=5.3Hz,2H),2.59-2.53(m,2H),1.42(s,13H),1.07(s,1H).

[0496] Step 5. To a stirred solution of tert-butyl 5-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (0.5 g, 0.784 mmol) in DMSO (5.0 mL) was added DBU (0.355 mL, 2.353 mmol), BOP (0.520 g, 1.177 mmol) and (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (0.335 g, 0.941 mmol). The reaction mixture was stirred at 45 °C for 16 h and partitioned between EtOAc and water. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified on silica gel with a gradient of 0% to 100% ethyl acetate in petroleum ether to afford (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (0.16 g, 0.100 mmol, 12.76% yield) as a brown solid.

[0497] LC-MS m / z 975.3[M+H] + .

[0498] 1 H NMR (300MHz, DMSO-d6)d=9.77(s,1H),7.83-7.80(m,1H),7.59-7.52(m,3H),7.51-7.44(m,3H),7.42-7 .30(m,6H),7.28-7.18(m,3H),7.11-7.08(m,1H),6.70-6.61(m,2H),5.75-5.64(m,2H),4.69-4.60(m, 1H),4.05-3.97(m,2H),3.74(s,3H),3.70-3.59(m,4H),3.57(s,3H),3.50-3.40(m,2H),2.02-1.97(m, 1H),1.91-1.78(m,3H),1.46-1.40(m,11H),1.26-1.16(m,4H),0.95-0.88(m,12H),0.84-0.75(m,5H).

[0499] Step 6. To a stirred solution of (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (0.35 g, 0.359 mmol) in MeOH (5.0 mL) was added Pd—C (0.191 g, 0.179 mmol). The reaction mixture was stirred at 50° C. under 100 psi hydrogen for 16 h and purified by CELITE TM The mixture was filtered through a pad of 4-nitropropene and washed with methanol. The filtrate was concentrated under reduced pressure to provide (S)-tert-butyl 4-(5-((7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxypyridin-2-yl)piperidine-1-carboxylate (0.23 g, 0.208 mmol, 58.0% yield) as a light brown solid. The product was used without further purification.

[0500] LC-MS m / z 851.5[M+H] + .

[0501] Step 7. To a stirred solution of (S)-tert-butyl 4-(5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxypyridin-2-yl)piperidine-1-carboxylate (0.1 g, 0.117 mmol) in MeOH (2.0 mL) was added HCl (0.2 mL, 2.304 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 4 h, concentrated under reduced pressure, and co-distilled with DCM and diethyl ether to afford (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate HCl (103 mg, 0.116 mmol, 99% yield) as a light brown solid. The product was used without further purification.

[0502] LC-MS m / z 513.3[M+H] + .

[0503] Step 8. To a stirred solution of (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester HCl (0.1 g, 0.182 mmol) in dioxane (1.5 mL) was added water (1.5 mL), NaOH (0.073 g, 1.821 mmol). The reaction mixture was stirred at 70 °C for 4 h. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified via preparative LC / MS using the following conditions: Column: Waters XBridge C18, 150 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile: water (containing 10 mM NH4OAc); Mobile phase B: 95:5 acetonitrile: water (containing 10 mM NH4OAc); Gradient: 0 min at 7% B, 7%-25% B over 20 min, then 5 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide (16.3 mg, 0.035 mmol, 19.49% yield).

[0504] Step 9. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (50.0 mg, 0.098 mmol) in DMF (2.0 mL) was added KCO (40.4 mg, 0.293 mmol) and 2-bromopropane (0.027 mL, 0.293 mmol). The reaction mixture was stirred at 50° C. for 6 h and partitioned between EtOAc and water. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to provide (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(1-isopropylpiperidin-4-yl)-4-methoxypyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (60 mg, 0.089 mmol, 91% yield) as a light brown semisolid. The product was used without further purification.

[0505] LC-MS m / z 555.2[M+H] + .

[0506] Step 10. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(1-isopropylpiperidin-4-yl)-4-methoxypyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (80.0 mg, 0.144 mmol) in 1,4-dioxane (1.0 mL), water (1.0 mL) was added NaOH (28.8 mg, 0.721 mmol). The reaction mixture was stirred at 70° C. for 6 h. The organic layer was separated and concentrated under reduced pressure. The crude material was purified via preparative LC / MS using the following conditions: Column: Waters XBridge C18, 19x150 mm, 5 μm particles; Mobile phase A: 10 mM NH4OAc; Mobile phase B: acetonitrile; Gradient: 9%-27% B over 22 minutes, then held at 100% B for 5 minutes; Flow rate: 20 mL / min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 167 (14.4 mg, 0.028 mmol, 19.70% yield).

[0507] The following compounds: Compound 168, Compound 173, Compound 174 and Compound 176 were prepared similarly.

[0508] Example 23-Compound 177

[0509]

[0510] Step 1. 25% NaOMe (2.009 g, 37.2 mmol) in methanol was added dropwise to a stirred solution of 4,6-dichloropyridazine-3-methyl formate (7 g, 33.8 mmol) in anhydrous THF (70 mL) at 0 ° C. The ice bath was removed. The reaction mixture was stirred at room temperature for 16 h, diluted with 1.5 N HCl (40 mL), and added to saturated NaHCO solution. The mixture was extracted with DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified on silica gel with 15% ethyl acetate in petroleum ether to provide 6-chloro-4-methoxypyridazine-3-methyl formate (3.8 g, 17.82 mmol, 52.7% yield) as an off-white solid.

[0511] LCMS (ES): m / z = 205.1 [M+H] + .

[0512] Step 2. Lithium borohydride (29.0 mL, 58.0 mmol) was added dropwise to a stirred solution of 6-chloro-4-methoxypyridazine-3-methyl carboxylate (4.7 g, 23.20 mmol) in a mixture of THF (40 mL) and methanol (8 mL) at 0 ° C. The ice bath was removed. The reaction mixture was stirred at room temperature for 2 h and cooled to 0 ° C. Ice-cold water was added dropwise. The reaction mixture was distributed with ethyl acetate, and the organic layer was washed with H2O, saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide (6-chloro-4-methoxypyridazine-3-yl) methanol (3.5 g, 18.04 mmol, 78% yield) as a brown solid. The product was used without further purification.

[0513] LCMS (ES): m / z = 175.0 [M+H] + .

[0514] Step 3. To a stirred solution of (6-chloro-4-methoxypyridazin-3-yl)methanol (1 g, 5.73 mmol) in anhydrous DCM (15 mL) was added PBr (0.810 mL, 8.59 mmol) at 0°C. The ice bath was removed. The reaction mixture was stirred at room temperature for 1 h and partitioned between saturated NaHCO and DCM. The organic layer was washed with H2O, saturated NaCl, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide 3-(bromomethyl)-6-chloro-4-methoxypyridazine (1 g, 3.37 mmol, 58.8% yield) as a brown solid.

[0515] LCMS (ES): m / z = 238.9 [M+H] + .

[0516] Step 4. To a stirred solution of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.25 g, 3.73 mmol) in anhydrous DMF (25 mL) was added CsCO (2.431 g, 7.46 mmol) and 3-(bromomethyl)-6-chloro-4-methoxypyridazine (0.886 g, 3.73 mmol) at 0°C. After stirring for 1 h at 0°C, the reaction mixture was partitioned between water and DCM. The organic layer was washed with H2O, saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified on silica gel with 5% methanol in chloroform to afford methyl (1-((6-chloro-4-methoxypyridazin-3-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.1 g, 2.014 mmol, 54.0 % yield) as a brown solid.

[0517] LC-MS (ES): m / z = 492.0 [M + H] + .

[0518] Step 5. To a stirred solution of methyl (1-((6-chloro-4-methoxypyridazin-3-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.1 g, 2.237 mmol) in anhydrous DMSO (8 mL) was added DBU (0.675 mL, 4.47 mmol), BOP (1.979 g, 4.47 mmol) and finally (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (0.875 g, 2.461 mmol) at room temperature. The reaction mixture was heated to 45° C. for 1 h and partitioned between water and ethyl acetate. The organic layer was washed with H2O, saturated NaCl, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified on silica gel with 55% ethyl acetate in petroleum ether to afford (S)-methyl(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((6-chloro-4-methoxypyridazin-3-yl)methyl)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.1 g, 1.327 mmol, 59.3% yield) as a light yellow semisolid.

[0519] LCMS (ES): m / z = 829.1 [M+H] + .

[0520] Step 6. To a stirred solution of (S)-methyl(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((6-chloro-4-methoxypyridazin-3-yl)methyl)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (900 mg, 1.085 mmol) in a mixture of anhydrous ethyl acetate (25 mL) and EtOH (5 mL) was added Pd / C (866 mg, 0.814 mmol) at room temperature. The reaction mixture was stirred under hydrogen for 16 h. The suspension was filtered through CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to provide (S)-(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((6-chloro-4-methoxypyridazin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (650 mg, 0.739 mmol, 68.1% yield) as a light yellow semisolid. The product was used without further purification.

[0521] LCMS (ES): m / z = 703.3 [M+H] + .

[0522] Step 7. To a stirred solution of (S)-methyl(7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1-((6-chloro-4-methoxypyridazin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (650 mg, 0.924 mmol) in anhydrous dioxane (15 mL) and water (0.2 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (572 mg, 1.848 mmol), Cs2CO3 (903 mg, 2.77 mmol) and PdCl2(dppf)-CH2Cl2 adduct (75 mg, 0.092 mmol) at room temperature. The reaction mixture was purged with nitrogen and heated to 100° C. After 16 h, the suspension was passed through a CELITE TM The mixture was stirred for 2 hours at 4 ℃ for 10 minutes.Filter and wash with ethyl acetate.The filtrate is concentrated under reduced pressure.The crude product is purified on silica gel with 35% ethyl acetate in petroleum ether to provide (S)-4-(6-((7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridazine-3-yl)-3,6-dihydropyridine-1(2H)-tert-butyl carboxylate (380mg, 0.358mmol, 38.7% yield) as a pale yellow solid.

[0523] LCMS (ES): m / z = 850.4 [M+H] + .

[0524] Step 8. To a stirred solution of (S)-tert-butyl 4-(6-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridazin-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate (370 mg, 0.435 mmol) in anhydrous methanol (15 mL) was added Pd / C (232 mg, 0.218 mmol) at room temperature. The reaction mixture was heated to 50° C. under 5 kPa of hydrogen in an autoclave. After 24 h, the suspension was passed through a CELITE TMThe mixture was filtered through a pad of 4-nitropropene and the pad was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to provide (S)-tert-butyl 4-(6-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridazin-3-yl)piperidine-1-carboxylate (350 mg, 0.370 mmol, 85% yield) as a light yellow semisolid. The product was used without further purification.

[0525] LCMS (ES): m / z = 552.3 [M+H] + .

[0526] Step 9. To a stirred solution of (S)-tert-butyl 4-(6-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridazin-3-yl)piperidine-1-carboxylate (70 mg, 0.082 mmol) in methanol (2 mL) was added HCl (0.5 mL, 16.46 mmol) at room temperature. After 4 h, the reaction mixture was concentrated to dryness under high vacuum to afford methyl (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridazin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate HCl (crude 60 mg) as a brown semisolid. The product was used without further purification.

[0527] LCMS (ES): m / z = 514.3 [M+H] +

[0528] Step 10. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridazin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (60 mg, 0.117 mmol) in anhydrous DMF (1 mL) was added KCO (81 mg, 0.584 mmol) and 2-bromopropane (0.055 mL, 0.584 mmol) at room temperature. The reaction mixture was heated to 50°C. After 16 h, the reaction mixture was concentrated to dryness under high vacuum to provide (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(1-isopropylpiperidin-4-yl)-4-methoxypyridazin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (60 mg). The product was used without further purification.

[0529] LCMS (ES): m / z = 556.3 [M+H] + .

[0530] Step 11. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(1-isopropylpiperidin-4-yl)-4-methoxypyridazin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (60 mg, 0.108 mmol) in a mixture of dioxane (1.5 mL) and water was added NaOH (43.2 mg, 1.080 mmol). The reaction mixture was heated to 75°C. After 3 h, the dioxane layer was separated from the reaction mixture and concentrated to dryness to give the crude product. The crude material was purified via preparative LC / MS using the following conditions: Column: Waters XBridge C18, 19x150 mm, 5 μm particles; Mobile phase A: 10 mM NH4OAc; Mobile phase B: acetonitrile; Gradient: 7%-22% B over 20 minutes, then hold at 100% B for 5 minutes; Flow rate: 20 mL / min. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide Compound 177 (12.7 mg, 0.025 mmol, 24%).

[0531] Example 24-Compound 200

[0532]

[0533]

[0534] Step 1. A mixture of (5-bromo-3-methoxypyridin-2-yl)methanol (1 g, 4.59 mmol) in DCM (10 mL) was treated with SOCl2 (0.669 mL, 9.17 mmol) at 0°C. After stirring for 2 h, the reaction mixture was concentrated. Excess SOCl2 was removed by azeotropy with DCM three times. The resulting compound A was directly taken to the next step.

[0535] LCMS ESI: Calculated for C7H8BrClNO = 235.9, 237.9 (M+H + ), measured values ​​235.9, 237.9 (M+H + ).

[0536] 1 H NMR (400MHz, DMSO-d6) δ8.27 (d, J = 1.8 Hz, 1H), 7.82 (d, J = 1.8 Hz, 1H), 4.70 (s, 2H), 3.93 (s, 3H).

[0537] Step 2. Compound B was prepared using a procedure similar to that in Example 1 from Compound A and methyl (3-bromo-7-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate.

[0538] LCMS ESI: for C 12 H 13 Calculated value for Br2N6O4 = 488.0 (M+H + ), found value 488.9(M+H + ).

[0539] 1 H NMR (400MHz, DMSO-d6) δ8.10 (d, J = 1.8 Hz, 1H), 7.78 (d, J = 1.8 Hz, 1H), 5.75 (s, 2H), 3.91 (s, 3H), 3.75 (s, 3H).

[0540] Step 3. A suspension of compound B (750 mg, 1.537 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (713 mg, 2.305 mmol) and K2CO3 (849 mg, 6.15 mmol) in DMF (10 mL) was bubbled with N2 stream for 2 min. PdCl2(dppf)-CH2Cl2 adduct (125 mg, 0.154 mmol) was added. The reaction mixture was bubbled with N2 stream for another 1 min and then stirred at 100°C under N2 for 16 h. After cooling, the reaction mixture was diluted with DCM. The catalyst was removed by filtration through CELITE TM The mixture was stirred for 1 h at room temperature for 2 h. The mixture was stirred for 2 h at room temperature for 30 min. The mixture was stirred for 30 min. The mixture was stirred for 2 h at room temperature ...

[0541] LCMS ESI: for C 22 H 27 Calculated value of BrN7O4 = 532., 534.1 (M+H + ), found values ​​532.1,534.1(M+H + ).

[0542] 1H NMR (400MHz, DMSO-d6) δ11.23-10.87(m,1H),8.04(d,J=1.5Hz,1H),7.45(d,J=1.5Hz,1H),6.33(br s,2H),6.28(br s,1H),4.01(br d,J=2.0Hz,2H),3.90(s,3H),3.52-3.50(m,2H),2.48(br d,J=1.8Hz,2H),1.43(s,9H).

[0543] Step 4. A Parr shake flask containing a mixture of compound C (70 mg, 0.131 mmol) in MeOH (10 mL) was purged with N2. Pd-C 10% (13.99 mg, 0.131 mmol) was added. The flask was purged with H2 and then shaken under H2 (20 psi) for 3 days. The catalyst was removed by filtering through a syringe filter disk. The filtrate was concentrated to produce compound D (46.4 mg, 0.102 mmol, 77% yield).

[0544] LCMS ESI: for C 22 H 30 Calculated for N7O4 = 456.2 (M+H + ), found value 456.2(M+H + ).

[0545] 1 H NMR (400MHz, DMSO-d6) δ10.98-10.76(m,1H),7.84(d,J=1.5Hz,1H),7.48(s,1H),7.33(d,J=1.5Hz,1H),5.68( s,2H),3.86(s,3H),3.37-3.32(m,4H),2.74-2.66(m,1H),1.81-1.70(m,2H),1.63-1.53(m,2H),1.42(s,9H).

[0546] Step 5, Part 1. To a solution of compound D (45 mg, 0.099 mmol) and (5-methyl-1,2,4-oxadiazol-3-yl)methylamine hydrochloride (29.6 mg, 0.198 mmol) in DMSO (2 mL) was added DBU (0.074 mL, 0.494 mmol) followed by BOP (87 mg, 0.198 mmol). The reaction mixture was stirred at 50 °C for 45 min. After cooling, the reaction mixture was poured onto saturated NH4Cl solution and stirred at room temperature for 30 min. The solid was collected by filtration and purified by silica column (12 g) chromatography (eluted with 5% MeOH:DCM in DCM = 0-25%). The desired fractions were concentrated to give tert-butyl 4-(6-((5-amino-7-(((5-methyl-1,2,4-oxadiazol-3-yl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (20 mg, 0.036 mmol, 36.8 % yield) as an off-white solid.

[0547] LCMS ESI: for C 26 H 35 N 10 Calculated for O2 = 551.3 (M+H + ), found value 551.3 (M+H + ).

[0548] Step 5, Part 2. The above solid was dissolved in DCM (0.5 mL). TFA (0.5 mL, 6.49 mmol) was added. After stirring at room temperature for 1 h, the reaction was complete. The mixture was concentrated to dryness to give Compound E (18 mg, 0.032 mmol, 32.3% yield) as a TFA salt, which was directly carried into the next step.

[0549] LCMS ESI: for C 21 H 27 N 10 Calculated for O4 = 451.2 (M+H + ), found value 451.3 (M+H + ).

[0550] Step 6. Compound 200 was prepared from Compound E and tetrahydro-4H-pyran-4-one similarly to the procedure of Example 2 using sodium triacetoxyborohydride.

[0551] Example 25-Compound 201

[0552]

[0553] Step 1. Prepare a biphasic mixture of (S)-methyl(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (130 mg, 0.174 mmol), tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (108 mg, 0.348 mmol), PdCl2(dppf) (25.5 mg, 0.035 mmol) and K2CO3 (96 mg, 0.696 mmol) in dioxane (4 mL) and water (300 μL). The reaction mixture is purged with vacuum and nitrogen 3 times, then heated to 80 ° C for 3h. The reaction mixture is diluted with ethyl acetate (50mL). The organic layer is dried with Na2SO4, filtered and concentrated. The crude product is purified on silica gel with 0% to 100% ethyl acetate in petroleum ether to provide (S) -6 '- ((7- ((1- ((tert-butyldiphenylsilyl) oxy) hex-3-yl) amino) -5- ((methoxycarbonyl) amino) -1H- pyrazolo [4,3-d] pyrimidine -1- yl) methyl) -5 '- methoxy -5,6- dihydro - [3,3 '- bipyridine] -1 (2H) - tert-butyl formate (100mg, 67.7% yield) in light brown solid.

[0554] LC-MS m / z 849.6[M+H] + .

[0555] 1 H NMR (400MHz, DMSO-d6) δ9.49-9.41(m,1H),7.96-7.88(m,1H),7.82-7.79(m,1H),7.78-7.72(m,1H),7.63-7.53(m, 4H),7.50-7.43(m,4H),7.41-7.35(m,1H),7.35-7.26(m,3H),7.23-7.16(m,2H),6.37-6.28(m,1H),5.79-5.57(m,2 H),4.67-4.53(m,1H),4.18-4.11(m,2H),3.95-3.88(m,3H),3.79-3.68(m,2H),3.63-3.56(m,3H),3.45-3.38(m,2H ),2.26-2.16(m,2H),2.00-1.84(m,2H),1.67-1.54(m,2H),1.47-1.38(m,9H),1.35-1.27(m,2H),0.94-0.89(m,9H)

[0556] Step 2. A suspension of (S)-tert-butyl 6'-((7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5'-methoxy-5,6-dihydro-[3,3'-bipyridine]-1(2H)-carboxylate (100 mg, 0.118 mmol) and Pd / C (50.1 mg, 0.024 mmol) in MeOH (10 mL) was purged with vacuum and nitrogen three times and then with vacuum and hydrogen three times. It was then stirred under hydrogen for 16 h. After purging with nitrogen, the reaction mixture was passed through CELITE TM The mixture was filtered through a pad of Cetyl acetate and evaporated under reduced pressure and dried under high vacuum to give tert-butyl 3-(6-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate which was used as is without further purification.

[0557] LC-MS m / z 851.7[M+H] +

[0558] Step 3. A solution of tert-butyl 3-(6-((7-(((S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (100 mg, .118 mmol) and NaOH (.15 mL, 1.500 mmol) in MeOH (1.000 mL) and dioxane (2 mL) was heated at 50° C. for 16 h. The reaction mixture was partitioned between ethyl acetate (50 mL) and saturated NH4Cl (10 mL). The organic layer was dried over Na2SO4, filtered and concentrated. The crude product was purified on silica gel with a gradient of 0% to 20% methanol in dichloromethane to afford tert-butyl 3-(6-((5-amino-7-(((S)-1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (50 mg, 76% yield) as a light brown solid.

[0559] LC-MS m / z 555.4[M+H] + .

[0560] Step 4. A solution of tert-butyl 3-(6-((5-amino-7-(((S)-1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (50 mg, 0.090 mmol) and TFA (0.069 mL, 0.901 mmol) in DCM (1 mL) was stirred at room temperature for 16 h. The reaction mixture was diluted with methanol 2 mL and K2CO3 (276 mg, 2 mmol) was added. After 2 h, the reaction mixture was diluted with methanol (10 mL), filtered and evaporated under reduced pressure. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (with 0.05% TFA); Gradient: 0 min at 1% B, 1%-41% B over 20 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (with 0.05% TFA); Gradient: 0% B for 0 min, 0-40% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation. The second eluting diastereomer of compound 201 (4.9 mg, 23% yield) was separated via SCF using the following conditions: column OD 30X250 mm ID, 5 μm; mobile phase: 85 / 15 CO2 / MeOH w / 0.1% DEA; flow rate: 100 mL / min; column temperature 40°C.

[0561] Example 26-Compound 202

[0562]

[0563] To a solution of (3S)-3-((5-amino-1-(2-methoxy-4-(piperazin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (0.107 g, 0.236 mmol), 3-(dimethylamino)propanoic acid (0.028 g, 0.236 mmol) and TEA (0.164 mL, 1.180 mmol) in NMP (1 mL) was added BOP (0.157 g, 0.354 mmol). After 3 h, the reaction mixture was filtered. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (with 0.05% TFA); Gradient: 1% B for 0 min, 1%-41% B over 20 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25° C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford 1-(3-{4-[(5-amino-7-{[(3S)-1-hydroxyhexan-3-yl]amino}-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl]-3-methoxyphenyl}piperazin-1-yl)-3-(dimethylamino)propan-1-one (2.2 mg, 3.6% yield). See Table A for analytical data.

[0564] Example 27-Compound 203

[0565]

[0566] To a solution of (3S)-3-((5-amino-1-(2-methoxy-4-(piperazin-2-yl)benzyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (0.107 g, 0.236 mmol) and tetrahydro-4H-pyran-4-one (40 mg, 0.400 mmol) in NMP (1 mL) was added 15 mg of molecular sieve powder and sodium triacetoxyborohydride (0.250 g, 1.180 mmol). After 16 h at room temperature the reaction mixture was diluted with DMF:acetic acid 1:1 1 mL. The crude material was purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (with NH4OAc); Mobile phase B: 95:5 acetonitrile:water (with NH4OAc); Gradient: 8% B for 0 min, 8%-48% B over 30 min, then 100% B for 0 min; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC / MS using the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water (containing 0.05% TFA); Mobile phase B: 95:5 acetonitrile:water (containing 0.05% TFA); Gradient: 0 min at 0% B, 0-40% B over 30 min, then 0 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25°C. Collection of fractions was triggered by MS signal. Fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 203 (10.1 mg, 7.8% yield).

[0567] Example 28-Compound 210

[0568]

[0569]

[0570] Step 1. Add Cs to a stirred solution of 5-bromo-2-methylpyridine-3-ol (5g, 26.6mmol) in anhydrous acetonitrile (100mL) at room temperature CO (8.66g, 26.6mmol) and methyl iodide (4.16mL, 66.5mmol). The reaction mixture is stirred at room temperature for 2h. The reaction mixture is distributed between water and ethyl acetate. The organic layer is washed with H o and saturated NaCl solution, dried over anhydrous Na sO , filtered and concentrated under reduced pressure to provide a crude product. The residue is purified using CombiFlash (silica gel 60-120 mesh; 25% ethyl acetate in petroleum ether as eluent) to provide 5-bromo-3-methoxy-2-methylpyridine (3.5g, 15.59mmol, 58.6% yield) as an off-white solid.

[0571] 1 H NMR (400 MHz, methanol-d4) δ = 8.07 (d, J = 2.0 Hz, 1H), 7.55-7.54 (m, 1H), 3.90 (s, 3H), 2.39 (s, 3H).

[0572] LCMS (ES): m / z = 204.1 [M+H] +

[0573] Step 2. NBS (6.47 g, 36.4 mmol) and AIBN (1.138 g, 6.93 mmol) were added to a stirred solution of 5-bromo-3-methoxy-2-methylpyridine (7 g, 34.6 mmol) in anhydrous CCl4 (70 mL) at room temperature. The reaction mixture was heated to 65 ° C and stirred for 16 h. The reaction mixture was concentrated to dryness under high vacuum to provide a crude product. The residue was purified using CombiFlash (silica gel 60-120 mesh; 25% ethyl acetate in petroleum ether as eluent) to provide 5-bromo-2-(bromomethyl)-3-methoxypyridine (7.2 g, 21.78 mmol, 62.9% yield) as a light yellow solid.

[0574] 1 H NMR (400 MHz, chloroform-d) δ = 8.26 (d, J = 2.0 Hz, 1H), 7.36 (d, J = 1.5 Hz, 1H), 4.60 (s, 2H), 3.95 (s, 3H).

[0575] LCMS (ES): m / z = 281.9 [M+H] +

[0576] Step 3. To a stirred solution of (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (1.1 g, 3.28 mmol) in anhydrous DMF (10 mL) was added CsCO (2.139 g, 6.57 mmol) and 5-bromo-2-(bromomethyl)-3-methoxypyridine (0.922 g, 3.28 mmol) at 0°C. The reaction mixture was stirred at 0°C for 1 h. The reaction mixture was partitioned between water and DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a crude product. The residue was purified using CombiFlash (silica gel 60-120 mesh; 5% methanol in chloroform as eluent) to afford methyl (1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (450 mg, 0.757 mmol, 23.05% yield) as a brown solid.

[0577] 1 H NMR (400MHz, DMSO-d6) δ = 11.65 (br s, 1H), 11.33 (br s,1H),8.08(d,J=1.5Hz,1H),7.76(d,J=2.0Hz,1H),5.77-5.73(m,2H),3.90(s,3H),3.74(s,3H).

[0578] LCMS (ES): m / z = 537.0 [M+H] + .

[0579] Step 4. To a stirred solution of methyl (1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (3 g, 5.61 mmol) in anhydrous DMSO (40 mL) was added BOP (4.96 g, 11.21 mmol), DBU (1.268 mL, 8.41 mmol) and (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (2.193 g, 6.17 mmol) at room temperature. The reaction mixture was heated to 40° C. and stirred for 4 h. The reaction mixture was cooled to 0° C. Ice-cold water was added dropwise. The mixture was extracted with DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide the crude product. The residue was purified using CombiFlash (silica gel 60-120 mesh; 25% ethyl acetate in petroleum ether as eluent) to afford (S)-methyl(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.7 g, 2.63 mmol, 46.9% yield) as a light yellow semisolid.

[0580] 1 H NMR (400 MHz, methanol-d4) δ = 8.02 (d, J = 1.5 Hz, 1H), 7.73-7.71 (m, 1H), 7.58-7.53 (m, 2H), 7.47-7.43 (m, 2H), 7.37-7.30 (m, 1H), 7.29-7.20 (m, 3H), 7.13-7.06 (m, 2H), 5.64-5.46 ( m,2H),3.99(s,3H),3.88(d,J=7.5Hz,1H),3.76(s,3H),2.17-2.04(m,1H),1.98-1.82 (m,1H),1.75-1.62(m,2H),1.50-1.35(m,3H),1.33-1.27(m,1H),1.00-0.91(m,13H).

[0581] LCMS (ES): m / z = 872.5 [M+H] + .

[0582] Step 5. To a stirred solution of (S)-methyl(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (5.5 g, 6.30 mmol) in a mixture of methanol (40 mL) and acetic acid (10 mL) at 0° C. was added zinc powder (4.12 g, 63.0 mmol). After stirring at 0° C. for 2 h, the reaction mixture was allowed to cool to room temperature, diluted with water and extracted with DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford methyl (S)-(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (4.7 g, 5.03 mmol, 80% yield) as a brown solid.

[0583] 1 H NMR (400MHz, methanol-d4) δ = 8.02 (d, J = 2.0Hz, 1H), 7.85 (s, 1H), 7.59-7.55 (m ,2H),7.48-7.43(m,6H),7.30-7.26(m,2H),7.11-7.10(m,1H),5.70-5.4 9(m,2H),4.76-4.72(m,1H),3.96(s,3H),3.79(s,3H),2.14-2.05(m,1H) ,,1.75-1.62(m,3H),1.46-1.39(m,3H),1.05-1.03(m,5H),0.98(s,9H).

[0584] LCMS (ES): m / z = 748.5 [M+H] + .

[0585] Step 6. To a stirred solution of (S)-methyl(1-((5-bromo-3-methoxypyridin-2-yl)methyl)-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (4.6 g, 6.16 mmol) in a mixture of dioxane (50 mL) and water (1 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (3.05 g, 9.86 mmol), PdCl2(dppf)-CH2Cl2 adduct (0.503 g, 0.616 mmol) and Cs2CO3 (6.02 g, 18.48 mmol) at room temperature. The reaction mixture was purged with nitrogen, heated to 100°C and stirred for 16 h. The residue was purified using CombiFlash (silica gel 60-120 mesh; 4% methanol in chloroform as eluent) to afford (S)-tert-butyl 6-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (4.6 g, 4.60 mmol, 74.8% yield) as a light yellow semisolid.

[0586] LCMS (ES): m / z = 849.7 [M+H] +

[0587] Step 7. To a stirred solution of (S)-tert-butyl 6-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (4.6 g, 5.42 mmol) in anhydrous methanol (100 mL) was added Pd / C (2.88 g, 2.71 mmol) at room temperature. The reaction mixture was heated to 50°C under 5 Kg hydrogen pressure in an autoclave for 24 h. The black suspension was purified by CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to afford (S)-tert-butyl 4-(6-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (4.1 g, 3.85 mmol, 71.1% yield) as a brown semisolid.

[0588] LCMS (ES): m / z = 851.4 [M+H] +

[0589] Step 8. To a stirred solution of (S)-tert-butyl 4-(6-((7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (1 g, 1.175 mmol) in methanol (10 mL) was added concentrated HCl (0.357 mL, 11.75 mmol) at room temperature. After stirring for 4 h, the reaction mixture was concentrated to dryness under high vacuum to give the crude product. The crude product was triturated with diethyl ether and then the ether was decanted. The resulting residue was dried to afford (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (550 mg, 0.858 mmol, 73.1% yield) as a brown solid.

[0590] LCMS (ES): m / z = 513.4 [M+H] +

[0591] Step 9. To a stirred solution of (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (250 mg, 0.488 mmol) in anhydrous DCE (5 mL) was added dihydrofuran-3(2H)-one (126 mg, 1.463 mmol) at room temperature. After stirring for 30 min, sodium triacetoxyborohydride (517 mg, 2.438 mmol) was added at room temperature and stirred for 16 h. The reaction mixture was partitioned between saturated NaHCO solution and DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide crude methyl (7-(((S)-1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (350 mg), which was used as is in the next reaction.

[0592] LCMS (ES): m / z = 583.4 [M+H] + .

[0593] Step 10 To a stirred solution of methyl (7-(((S)-1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (350 mg, 0.601 mmol) in a mixture of dioxane (5 mL) and water (2 mL) was added NaOH (240 mg, 6.01 mmol) at room temperature. The reaction mixture was heated to 75 °C and stirred for 3 h. The organic layer was separated from the reaction mixture and concentrated to dryness to give a residue. The crude compound was purified via preparative LC / MS with the following conditions: Column: Waters XBridge Phenyl C18, 19x250mm, 5μm particles; Mobile phase A: 10mM ammonium bicarbonate pH 9.5 in water; Mobile phase B: acetonitrile; Gradient: 20%-59% B over 15 minutes; Flow rate: 19mL / min. The reaction mixture was purified in RP HPLC (using NH4OAc as buffer). The preparative fractions were concentrated at 30°C under high vacuum. The residue was dissolved in a mixture of MeCN and water, frozen and lyophilized for 12h to provide diastereomeric compound 210 (65mg, 0.124mmol, 20.63% yield) as a white solid.

[0594] Using a chiral SFC method (column: Chiralpak IG (250x4.6) mm, 5 μm, mobile phase: 0.2% DEA + isopropanol (1:1) in CH3CN, temperature: 30°C), diastereomeric compound 210 was subjected to chiral separation to obtain individual diastereomers. The first isomer (eluted at 7.51 min) was compound 211. The second isomer (eluted at 13.37 min) was compound 212. Compounds 211 and 212 are therefore enantiomers that differ in stereochemistry at the asterisk (*) carbon.

[0595]

[0596] Example 29-Compound 213

[0597]

[0598] Step 1. To a stirred solution of (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (100 mg, 0.195 mmol) in DCE (2.5 mL) was added 1-methylpiperidin-4-one (44.2 mg, 0.390 mmol) and sodium triacetoxyborohydride (124 mg, 0.585 mmol) at room temperature. The reaction mixture was stirred at ambient temperature for 16 h. The suspension was filtered through CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to afford crude (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(1'-methyl-[1,4'-bipiperidinyl]-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (130 mg) as a brown semisolid, which was used as is in the next reaction.

[0599] LCMS (ES) m / z = 611.3 [M+H] +

[0600] Step 2. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(1'-methyl-[1,4'-bipiperidinyl]-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (130 mg, 0.213 mmol) in a mixture of dioxane (2 mL) and water (1 mL) was added NaOH (85 mg, 2.132 mmol) at room temperature. The reaction mixture was heated to 75°C and stirred for 3 h. The dioxane layer was separated from the reaction mixture and then concentrated to dryness to provide the crude product. The crude material was purified via preparative LC / MS using the following conditions: column: Waters XBridge C18, 19x150mm, 5μm particles; mobile phase A: 10mM NH4OAc; mobile phase B: acetonitrile; gradient: 10%-35% B over 20 minutes, then held at 100% B for 5 minutes; flow rate: 15mL / min. Collection of fractions was triggered by MS and UV signals. The fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 213 (6.9mg, 0.013mmol, 5.87% yield).

[0601] Example 30-Compound 214

[0602]

[0603] Step 1. To a stirred solution of (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (100 mg, 0.195 mmol) in DCE (2.5 mL) was added tert-butyl 4-oxopiperidine-1-carboxylate (78 mg, 0.390 mmol) and sodium triacetoxyborohydride (124 mg, 0.585 mmol) at room temperature. The reaction mixture was stirred for 16 h. The suspension was filtered through CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to provide crude (S)-tert-butyl 4-(6-((7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)-[1,4'-bipiperidine]-1'-carboxylate (150 mg) as a brown semisolid, which was used as is in the next reaction.

[0604] LCMS (ES) m / z = 696.4 [M+H] +

[0605] Step 2. To a stirred solution of (S)-tert-butyl 4-(6-((7-((1-hydroxyhexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)-[1,4'-bipiperidine]-1'-carboxylate (150 mg, 0.216 mmol) in anhydrous DCM (2 mL) was added 4 M HCl in dioxane (2.5 mL, 10.00 mmol) dropwise at room temperature. After stirring for 1 h, the reaction mixture was concentrated to dryness under high vacuum to afford crude (S)-methyl(1-((5-([1,4'-bipiperidinyl]-4-yl)-3-methoxypyridin-2-yl)methyl)-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (130 mg) which was used as is in the next reaction.

[0606] LCMS (ES) m / z = 596.4 [M+H] + .

[0607] Step 3. To a stirred solution of (S)-methyl(1-((5-([1,4'-bipiperidinyl]-4-yl)-3-methoxypyridin-2-yl)methyl)-7-((1-hydroxyhexan-3-yl)amino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (130 mg, 0.218 mmol) in a mixture of dioxane (2 mL) and water (1 mL) was added NaOH (87 mg, 2.182 mmol) at room temperature. The reaction mixture was heated to 75°C and stirred for 4 h. The dioxane layer was separated from the reaction mixture and concentrated to dryness to afford the crude product. The crude material was purified via preparative LC / MS using the following conditions: column: Waters XBridge C18, 19x150 mm, 5 μm particles; mobile phase A: 10 mM NH4OAc; mobile phase B: acetonitrile; gradient: 10%-40% B over 20 minutes, then held at 100% B for 5 minutes; flow rate: 15 mL / min. Collection of fractions was triggered by MS and UV signals. The fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 214 (5.6 mg, 9.89 μmol, 4.53% yield).

[0608] Example 31-Compound 216

[0609]

[0610]

[0611] Step 1. To a stirred solution of methyl 6-bromonicotinate (5 g, 23.14 mmol) in 1,4-dioxane (100 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (10.73 g, 34.7 mmol), CsCO (15.08 g, 46.3 mmol) and PdCl(dppf)-CHCl adduct (1.890 g, 2.314 mmol). The mixture was purged with N gas. After stirring at 100 ° C for 5 h, the reaction mixture was partitioned between ethyl acetate and ice-cold water. The organic layer was washed with water and brine, dried over anhydrous NaSO and concentrated in vacuo at 45 ° C. The crude product was purified by CombiFlash chromatography (60-120 silica gel; 20%-60% ethyl acetate in petroleum ether as eluent) to afford 1'-(tert-butyl) 5-methyl 3',6'-dihydro-[2,4'-bipyridyl]-1',5(2'H)-dicarboxylate (4.6 g, 14.45 mmol, 62.4% yield) as a light yellow oil.

[0612] 1H NMR (400MHz, chloroform-d) δ = 9.16 (s, 1H), 8.25 (d, J = 8.6Hz, 1H), 7.45 (d, J = 8.5Hz, 1H), 6.81-6.78 (m, 1H), 4.18 (br d,J=3.0Hz,2H),3.96(s,3H),3.69-3.65(m,2H),2.67(br d,J=2.0Hz,2H),1.50(s,9H).

[0613] LCMS (ES) m / z = 319.2 [M+H] +

[0614] Step 2. To a solution of 1'-(tert-butyl)5-methyl 3',6'-dihydro-[2,4'-bipyridine]-1',5(2'H)-dicarboxylate (4 g, 12.56 mmol) in a mixture of THF (50 mL) and MeOH (10 mL) was added LiBH4 (31.4 mL, 62.8 mmol) under nitrogen atmosphere and then partitioned between ammonium chloride solution and EtOAc. The organic layer was washed with water and brine, dried over anhydrous Na2SO4 and concentrated to give the crude product as a brown oil, which was purified by CombiFlash chromatography (60-120 silica gel; 10%-100% ethyl acetate in petroleum ether) to provide tert-butyl 5-(hydroxymethyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (3.6 g, 12.40 mmol, 99% yield) as a light yellow oil.

[0615] 1 H NMR (400MHz, DMSO-d6) δ = 8.47 (d, J = 2.0Hz, 1H), 7.70 (dd, J = 2.0, 8.0Hz, 1H), 7.53 (d, J = 8.5Hz, 1H), 6.66 (br s,1H),5.30(t,J=5.5Hz,1H),4.52(d,J=5.5Hz,2H),4.10-3.99(m,2H),3.54(t,J=5.8Hz,2H),2.58-2.52(m,2H),1.43(s,9H).

[0616] LCMS (ES) m / z = 291.3 [M+H] +

[0617] Step 3. To a stirred solution of tert-butyl 5-(hydroxymethyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (3.5 g, 12.05 mmol) in dry DCM (30 mL) was added TEA (3.36 mL, 24.11 mmol), MsCl (1.878 mL, 24.11 mmol) and lithium chloride (1.022 g, 24.11 mmol) at 0°C. The reaction mixture was allowed to cool to room temperature and stirred for 16 h. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo to give the crude product, which was purified by CombiFlash chromatography (60-120 silica gel; 10%-30% ethyl acetate in petroleum ether) to provide tert-butyl 5-(chloromethyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (3.7 g, 11.98 mmol, 99% yield) as a white solid.

[0618] 1 H NMR (400MHz, chloroform-d) δ = 8.58 (d, J = 2.0Hz, 1H), 7.72 (dd, J = 2.3, 8.3Hz, 1H), 7.41 (d, J = 8.0Hz, 1H), 6.66 (td, J = 1.6, 3.4Hz, 1H), 4.61 (s, 2H), 4.16 (br d,J=3.0Hz,2H),3.67(br t,J=5.5Hz,2H),2.70-2.63(m,2H),1.58(s,9H).

[0619] LCMS (ES) m / z = 309.2 [M+H] + .

[0620] Step 4. To a stirred solution of (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (3.8 g, 11.34 mmol) in dry DMF (20 mL) was added CsCO (7.39 g, 22.68 mmol) and tert-butyl 5-(chloromethyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (3.50 g, 11.34 mmol) at room temperature. After stirring for 12 h, the reaction mixture was partitioned between ethyl acetate and ice-cold water. The organic layer was washed with water and brine, dried over anhydrous NaSO and concentrated in vacuo. The crude product was purified by CombiFlash chromatography (60-120 silica gel; 20%-60% ethyl acetate in CHCl3 as eluent) to afford tert-butyl 5-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.5 g, 2.470 mmol, 21.77% yield) as an off-white solid.

[0621] 1 H NMR (400MHz, DMSO-d6) δ = 11.72 (br s, 1H), 11.36 (br s,1H),8.50(d,J=1.5Hz,1H),7.65(d,J=7.9Hz,1H),7.53(d,J=8.0Hz,1H),6.70-6.62(m,1H),5.79-5.70( m,2H),4.07-3.98(m,2H),3.75(s,3H),3.52(t,J=5.8Hz,2H),2.56-2.53(m,2H),1.48(s,1H),1.42(s,9H).

[0622] LCMS (ES): m / z = 608.2 [M+H] + .

[0623] Step 5. To a stirred solution of tert-butyl 5-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.50 g, 2.470 mmol) in anhydrous DMSO (15 mL) was added DBU (1.117 mL, 7.41 mmol), BOP (1.638 g, 3.70 mmol) and (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (0.878 g, 2.470 mmol) at room temperature. The reaction mixture was heated to 45°C, stirred for 4 h, and partitioned between water and ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give the crude product as a light yellow oil. The crude product was purified using CombiFlash (silica gel 60-120 mesh; 25% ethyl acetate in chloroform as eluent). Fractions were concentrated at 50 °C using high vacuum to afford (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin1yl)methyl)3',6'dihydro[2,4'-bipyridine]-1'(2'H)-carboxylate (0.900 g, 0.867 mmol, 35.1% yield) as a yellow solid.

[0624] 1 H NMR (400MHz, DMSO-d6) δ = 8.24 (d, J = 2.0Hz, 1H), 7.62-7.58 (m, 3H), 7.51-7.48 (m, 2H), 7.34 (br d, J = 7.0Hz, 4H), 7.15-7.08 (m, 3H), 6.42 (br s,1H),5.93-5.78(m,2H),4.65(br dd,J=4.0,8.0Hz,1H),4.01(q,J=7.0Hz,1H),3.89(br s,2H),3.55(s,3H),3.46-3.39(m,1H),3.35(t,J=5.8Hz,2H),2.30(br s,2H),1.77(br d,J=4.5Hz,2H),1.62-1.52(m,2H),1.39(s,9H),1.16(t,J=7.0Hz,3H).

[0625] LCMS (ES) m / z = 945.2 [M+H] +

[0626] Step 6. To a stirred solution of (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (930 mg, 0.984 mmol) in anhydrous methanol (25 mL) was added Pd / C (524 mg, 0.492 mmol) at room temperature. The reaction mixture was heated to 50°C under 5 Kg hydrogen pressure in an autoclave for 24 h. The black suspension was purified by CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to afford (S)-tert-butyl 4-(5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)pyridin-2-yl)piperidine-1-carboxylate (800 mg, 0.779 mmol, 79% yield) as a light yellow semisolid.

[0627] LCMS (ES): m / z = 821.5 [M+H] +

[0628] Step 7. To a stirred solution of (S)-tert-butyl 4-(5-((7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)pyridin-2-yl)piperidine-1-carboxylate (200 mg, 0.244 mmol) in methanol (2 mL) was added concentrated HCl (4 mL, 132 mmol) at room temperature. After stirring for 3 h, the reaction mixture was concentrated to dryness under high vacuum to afford the crude product. The crude product was triturated with diethyl ether and the ether layer was decanted. The residue was dried to provide (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate as a brown solid (170 mg, assumed 100% yield).

[0629] LCMS (ES) m / z = 483.3 [M+H] +

[0630] Step 8. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (130 mg, 0.269 mmol) in anhydrous DMF (2 mL) was added K2CO3 (112 mg, 0.808 mmol) and 4-iodotetrahydro-2H-pyran (86 mg, 0.404 mmol) at room temperature. The reaction mixture was heated to 55 °C, stirred for 24 h, and concentrated to dryness under high vacuum to provide crude (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (160 mg) which was used as is in the next reaction.

[0631] LC-MS (ES) m / z = 567.3 [M + H] +

[0632] Step 9. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((6-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (160 mg, 0.282 mmol) in a mixture of dioxane (2 mL) and water (1 mL) was added NaOH (113 mg, 2.82 mmol) at room temperature. The reaction mixture was heated to 70° C. and stirred for 3 h. The organic layer was separated from the reaction mixture and concentrated to dryness to afford the crude product. The residue was purified by reverse phase preparative LC / MS (column: Waters XBridge C18, 19x150mm, 5μm particles; mobile phase A: 10mM NH4OAc; mobile phase B: acetonitrile; gradient: 10%-45% B over 20 minutes, then hold at 100% B for 5 minutes; flow rate: 15mL / min). Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation using Genevac to provide compound 216 (20.7mg, 0.040mmol, 14.05% yield).

[0633] Example 32-Compound 215

[0634]

[0635]

[0636] Step 1. Add H2SO4 (2.297 mL, 43.1 mmol) to a stirred solution of 5-bromo-3-methoxypicolinic acid (10 g, 43.1 mmol) in anhydrous methanol (100 mL) at room temperature. The reaction mixture is heated to 70 ° C, stirred for 16 h, and concentrated to dryness under high vacuum to provide a crude product. The residue is distributed between saturated NaHCO3 solution and DCM. The organic layer is washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide 5-bromo-3-methoxypicolinic acid methyl ester (10.1 g, 41.0 mmol, 95% yield) as a light yellow oil.

[0637] 1 H NMR (400 MHz, CHLOROFORM-d) δ = 8.35 (d, J = 1.8 Hz, 1H), 7.53 (d, J = 1.8 Hz, 1H), 3.98 (s, 3H), 3.95 (s, 3H).

[0638] LCMS (ES): m / z = 246.0 [M+H] + .

[0639] Step 2. To a stirred solution of 5-bromo-3-methoxypicolinic acid methyl ester (5 g, 20.32 mmol) in a mixture of dioxane (75 mL) and water (1 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (10.05 g, 32.5 mmol), Cs2CO3 (19.86 g, 61.0 mmol) and PdCl2(dppf)-CH2Cl2 adduct (1.659 g, 2.032 mmol) at room temperature. The reaction mixture was purged with nitrogen, heated to 100°C and stirred for 16 h. The black suspension was purified by CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to provide a crude product in a brown semi-solid. The residue was purified using CombiFlash (silica gel 60-120 mesh; 35% ethyl acetate in petroleum ether as eluent) to provide 1'-(tert-butyl) 6-methyl 5-methoxy-3', 6'-dihydro-[3,4'-bipyridine]-1', 6 (2'H)-diformate (4.4 g, 12.63 mmol, 62.2% yield) in a brown semi-solid.

[0640] 1H NMR (400 MHz, CHLOROFORM-d) δ = 8.33 (s, 1H), 6.23 (br s, 1H), 4.17-4.14 (m, 2H), 4.00 (s, 3H), 3.97 (s, 3H), 3.70 (t, J = 5.5 Hz, 2H), 2.59-2.55 (m, 2H), 1.52-1.52 (m, 9H).

[0641] LCMS (ES): m / z = 349.3 [M+H] + .

[0642] Step 3. To a stirred solution of 1'-(tert-butyl)6-methyl 5-methoxy-3',6'-dihydro-[3,4'-bipyridyl]-1',6(2'H)-dicarboxylate (3.7 g, 10.62 mmol) in a mixture of THF (40 mL) and methanol (5 mL) was added 2M LiBH4 (21.24 mL, 42.5 mmol) in THF at 0°C. The ice bath was removed and the reaction mixture was stirred at room temperature for 6 h and then cooled to 0°C. Ice-cold water was added dropwise. The mixture was extracted with DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (3.1 g, 8.22 mmol, 77% yield) as a brown solid.

[0643] 1 H NMR (400MHz, DMSO-d6) δ = 8.18 (d, J = 1.0Hz, 1H), 7.40 (d, J = 1.0Hz, 1H), 6.32-6.25 (m, 1H), 4.80 (t, J = 5.8Hz, 1H), 4.52 (d, J = 6.0Hz, 2H), 4.03 (br s, 2H), 3.86 (s, 3H), 3.56 (t, J = 5.5Hz, 2H), 1.46-1.42 (m, 11H).

[0644] LCMS (ES): m / z = 321.0 [M+H] + .

[0645] Step 4. To a stirred solution of tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (2.8 g, 8.74 mmol) in anhydrous DCM (40 mL) was added TEA (3.65 mL, 26.2 mmol) and methanesulfonyl chloride (1.362 mL, 17.48 mmol) at room temperature. After stirring at room temperature for 5 min, lithium chloride (0.741 g, 17.48 mmol) was added. After stirring for 16 h, the reaction mixture was partitioned between saturated NaHCO3 solution and DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (3.2 g, 8.03 mmol, 92% yield) as a brown semisolid.

[0646] 1 H NMR (400 MHz, methanol-d4) δ = 8.23-8.21 (m, 1H), 7.64 (s, 1H), 6.38-6.33 (m, 1H), 4.77-4.75 (m, 2H), 4.20 (s, 2H), 4.02 (s, 3H), 3.71-3.67 (m, 2H), 2.64-2.58 (m, 2H), 2.60 (brs, 2H), 1.51 (s, 9H).

[0647] LCMS (ES): m / z = 339.2 [M+H] +

[0648] Step 5. To a stirred solution of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.7 g, 8.06 mmol) in a mixture of DMF (30 mL) at 0°C was added CsCO (5.25 g, 16.12 mmol) and tert-butyl 6-(bromomethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (3.09 g, 8.06 mmol). The ice bath was removed and the reaction mixture was stirred at room temperature for 16 h and then partitioned between water and DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the crude product. The residue was purified using CombiFlash (silica gel 60-120 mesh; 5% methanol in chloroform as eluent) to afford tert-butyl 6-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (1.95 g, 2.294 mmol, 28.5% yield) as a brown solid.

[0649] 1 H NMR (400 MHz, methanol-d4) δ = 8.03 (s, 1H), 7.44 (s, 1H), 6.27-6.20 (m, 1H), 5.91-5.88 (m, 2H), 4.20 (s, 2H), 4.10 (br s, 3H), 3.93 (s, 3H), 3.69-3.64 (m, 2H), 2.58-2.52 (m, 2H), 1.31 (s, 9H).

[0650] LCMS (ES): m / z = 638.2 [M+H] + .

[0651] Step 6. To a stirred solution of tert-butyl 6-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (1.8 g, 2.82 mmol) in a mixture of dioxane (50 mL) and water (0.1 mL) was added K2CO3 (1.171 g, 8.47 mmol), PdCl2(dppf)-CH2Cl2 adduct (0.231 g, 0.282 mmol) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (1.974 mL, 14.12 mmol) at room temperature. The reaction mixture was purged with nitrogen, heated to 100°C, and stirred for 16 h. The black suspension was passed through CELITE TM The bed is filtered and the bed is washed with ethyl acetate. The filtrate is concentrated under reduced pressure to provide a crude product in a semisolid. The residue is purified using CombiFlash (silica gel 60-120 mesh; 3% methanol in chloroform as eluent) to provide 6-((5-amino-7-hydroxy-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-tert-butyl formate (550mg, 0.765mmol, 27.1% yield) in a light yellow semisolid.

[0652] 1 H NMR (400MHz, DMSO-d6)δ=10.85-10.76(m,1H),8.02(s,1H),7.42(br s,1H),6.26(br s,1H),6.03-5.98(m,2H),4.01(br s,2H),3.89(s,3H),3.54(br t,J=5.5Hz,2H),2.18(s,3H),1.43(s,9H),1.28-1.21(m,2H).

[0653] LCMS (ES): m / z = 468.2 [M+H] +

[0654] Step 7. To a stirred solution of tert-butyl 6-((5-amino-7-hydroxy-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (450 mg, 0.963 mmol) in anhydrous DMSO (3 mL) was added BOP (851 mg, 1.925 mmol), DBU (0.290 mL, 1.925 mmol) and (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (376 mg, 1.059 mmol) at room temperature. The reaction mixture was heated to 40°C and stirred for 3 h. The reaction mixture was allowed to cool to room temperature and diluted with water and extracted with DCM. The organic layer was washed with H2O and saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide the crude product. The residue was purified using CombiFlash (silica gel 60-120 mesh; 3% methanol in chloroform as eluent) to afford (S)-tert-butyl 6-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (800 mg, 0.894 mmol, 93% yield) as a light yellow semisolid.

[0655] 1 H NMR (400MHz, methanol-d4) δ = 7.96 (s, 1H), 7.59 (d, J = 7.0Hz, 2H), 7.48-7.40 (m, 7H), 7.32-7.26 (m, 2H), 6.10 (br d,J=2.5Hz,1H),5.47(s,2H),4.73-4.65(m,1H),4.18-4.09(m,2H),4.01(br s,2H),3.97(s,3H),3.86-3.78(m,2H),1.72-1.67(m,2H),1.51(s,9H),1.33(br d,J=7.5Hz,5H),1.07-1.01(m,4H),0.99(s,9H).

[0656] LCMS (ES): m / z = 805.4 [M+H] + .

[0657] Step 8. To a stirred solution of (S)-tert-butyl 6-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (800 mg, 0.994 mmol) in anhydrous methanol (20 mL) was added Pd / C (529 mg, 0.497 mmol). The reaction mixture was stirred at 50° C. under 5 kg hydrogen pressure for 16 h. The black suspension was purified by CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to provide (S)-tert-butyl 4-(6-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (700 mg, 0.867 mmol, 87% yield) as a light yellow semisolid, which was used as is in the next reaction.

[0658] LCMS (ES): m / z = 807.4 [M+H] +

[0659] Step 9. To a stirred solution of (S)-tert-butyl 4-(6-((5-amino-7-((1-((tert-butyldiphenylsilyl)oxy)hex-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (700 mg, 0.867 mmol) in methanol (2 mL) was added concentrated HCl (5 mL, 165 mmol) at room temperature. After stirring for 4 h, the reaction mixture was concentrated to dryness under high vacuum to afford the crude product. The crude product was triturated with diethyl ether and the ether was then decanted. The residue was dried to afford (S)-3-((5-amino-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (500 mg) as a brown semisolid.

[0660] LCMS (ES): m / z = 469.4 [M+H] +

[0661] Step 10. To a stirred solution of (S)-3-((5-amino-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (80 mg, 0.171 mmol) in anhydrous DMF (1 mL) was added KCO (70.8 mg, 0.512 mmol) and 4-iodotetrahydro-2H-pyran (181 mg, 0.854 mmol) at room temperature. The reaction mixture was heated to 50° C. and stirred for 16 h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was washed with H0 and saturated NaCl solution, dried over anhydrous NaSO, filtered and concentrated under reduced pressure to provide the crude product. The residue was purified by reverse phase preparative LC / MS (column: Waters XBridge C18, 19x150mm, 5μm particles; mobile phase A: 10mM NH4OAc; mobile phase B: acetonitrile; gradient: 10%-45% B over 20 minutes, then hold at 100% B for 5 minutes; flow rate: 15mL / min). Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation using Genevac to provide compound 215 (8.1 mg, 0.014 mmol, 8.17% yield).

[0662] Example 33-Compound 217

[0663]

[0664]

[0665] Step 1: Slowly add sulfuric acid (18.38mL, 345mmol) to the solution of 5-bromo-3-methoxypicolinic acid (10g, 43.1mmol) in dry methanol (180mL). The reaction mixture is stirred for 16h under reflux. Stop heating and allow the reaction mixture to be cooled to room temperature. Methanol is evaporated into residue, and the residue is dissolved in DCM (200mL) and washed with saturated NaHCO3 aqueous solution (2x100mL). The organic layer is dried over Na2SO4, filtered and evaporated to dryness, to provide the crude 5-bromo-3-methoxypicolinic acid methyl ester (9.8g, 39.8mmol, 92% yield) as colorless oil, which is not further purified into the next step.

[0666] 1 H NMR (400MHz, CDCl3) δ = 8.36 (d, J = 2.0 Hz, 1H), 7.54 (d, J = 1.5 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 3H).

[0667] LC-MS m / z 247.9[M+H] + .

[0668] Step 2. To a stirred solution of 5-bromo-3-methoxypicolinic acid methyl ester (4 g, 16.26 mmol) in 1,4-dioxane (90 mL) and H2O (10 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (10.05 g, 32.5 mmol) and Cs2CO3 (13.24 g, 40.6 mmol), followed by tetrakis(triphenylphosphine)palladium(0) (1.879 g, 1.626 mmol). The reaction mixture was purged with argon for about 5 minutes and then stirred at 100°C for 6 h. The reaction mixture was allowed to cool slowly to room temperature and then filtered through CELITE TM The filtrate was evaporated to give the crude product, which was purified by flash column chromatography (SiO2, 0-2% methanol in chloroform) to afford 1'-(tert-butyl)6-methyl 5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1',6(2'H)-dicarboxylate (4.5 g, 12.92 mmol, 79% yield) as a light yellow oil.

[0669] 1 H NMR(400MHz, DMSO-d6)δ=8.30-8.25(m,1H),7.60-7.58(m,1H),6.50-6.34(m,1H),4.09-4 .00(m,2H),3.89(s,3H),3.83(s,3H),3.61-3.53(m,2H),2.58-2.53(m,2H),1.44(s,9H).

[0670] LC-MS m / z 348.2[M+H] + .

[0671] Step 3. To a stirred solution of 1'-(tert-butyl)6-methyl 5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1',6(2'H)-dicarboxylate (5 g, 14.35 mmol) in THF (90 mL) and methanol (10 mL) at 0°C, a 2M solution of lithium borohydride in THF (35.9 mL, 71.8 mmol) was carefully added dropwise. Once the addition was complete, the reaction mixture was allowed to reach room temperature and stirred at 45°C for 6 h. Crushed ice was added to the reaction mixture, followed by ethyl acetate. A white precipitate appeared. The clear liquid was decanted and evaporated to produce tert-butyl 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (4.3 g, 13.43 mmol, 94% yield) as a light yellow oil.

[0672] 1 H NMR (400MHz, DMSO-d6) δ = 8.18 (d, J = 1.0Hz, 1H), 7.40 (d, J = 1.0Hz, 1H), 6.32-6.25 (m, 1H), 4.80 (t, J = 5.8Hz, 1H), 4.52 (d, J = 6.0Hz, 2H), 4.03 (br s, 2H), 3.86 (s, 3H), 3.56 (t, J = 5.5Hz, 2H), 1.46-1.42 (m, 11H).

[0673] LC-MS m / z 321.4[M+H] + .

[0674] Step 4. To a solution of 6-(hydroxymethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-tert-butyl carboxylate (4.3 g, 13.42 mmol) in DCM (30 mL) was added methanesulfonyl chloride (2.092 mL, 26.8 mmol), triethylamine (3.74 mL, 26.8 mmol) and lithium chloride (1.138 g, 26.8 mmol) at 0°C. The reaction mixture was stirred for 4 h and allowed to slowly reach room temperature. Crushed ice was added. The reaction mixture was extracted with DCM (2x150 mL). The combined organic layers were dried over Na2SO4 and evaporated on a rotary evaporator, keeping the water bath temperature below 35°C, to afford tert-butyl 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (3.3 g, 9.74 mmol, 72.6% yield) as a yellow oil.

[0675] 1H NMR (400 MHz, methanol-d4) δ = 8.23-8.21 (m, 1H), 7.64 (s, 1H), 6.38-6.33 (m, 1H), 4.20 (s, 2H), 4.02 (s, 3H), 3.71-3.67 (m, 2H), 2.64-2.58 (m, 2H), 2.60 (br s, 2H), 1.51 (s, 9H).

[0676] LC-MS m / z 339.4[M+H] + .

[0677] Step 5. To a stirred solution of (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamic acid methyl ester (3.2 g, 9.55 mmol) in DMF (20 mL) at 0°C was added 6-(chloromethyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-tert-butyl carboxylate (3.24 g, 9.55 mmol) followed by CsCO (6.22 g, 19.10 mmol). The reaction mixture was allowed to slowly reach 25°C and was stirred at the same temperature for 6 h. After adding crushed ice, the reaction mixture was extracted with DCM (2x100 mL). The combined organic layers were dried over Na2SO4 and evaporated to give the crude product, which was purified by flash column chromatography (SiO2, 0-5% methanol in chloroform) to afford tert-butyl 6-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (3.5 g, 5.49 mmol, 57.5% yield) as a light brown semisolid.

[0678] 1 H NMR (400 MHz, methanol-d4) δ = 8.03 (s, 1H), 7.44 (s, 1H), 6.27-6.20 (m, 1H), 5.91-5.88 (m, 2H), 4.20 (s, 2H), 4.10 (br s, 3H), 3.93 (s, 3H), 3.69-3.64 (m, 2H), 2.58-2.52 (m, 2H), 1.31 (s, 9H).

[0679] LC-MS m / z 638.2[M+H] + .

[0680] Step 6. To a mixture of tert-butyl 6-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (2 g, 3.14 mmol) and butan-1-amine (1.639 mL, 15.69 mmol) in THF (5 mL) at 25°C was added BOP (2.082 g, 4.71 mmol) and DBU (1.419 mL, 9.41 mmol). The reaction mixture was stirred at the same temperature for 12 h. Crushed ice was added. The reaction mixture was then extracted with DCM (2x50 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated to give a residue, which was purified by flash column chromatography (SiO2, 0-5% methanol in chloroform) to produce tert-butyl 6-((5-amino-7-(butylamino)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (1.5 g, 2.166 mmol, 69.0% yield) as a yellow oil.

[0681] LC-MS m / z 693.4[M+H] + .

[0682] Step 7. To a suspension of tert-butyl 6-((7-(butylamino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxy-3',6'-dihydro-[3,4'-bipyridine]-1'(2'H)-carboxylate (2.5 g, 3.61 mmol) in methanol (100 mL) was added dry palladium on carbon (0.384 g, 3.61 mmol) under inert atmosphere. The reaction mixture was stirred in an autoclave at 50°C under a hydrogen atmosphere at a pressure of 10 bar for 18 h. The reaction mixture was purified by CELITE TM The bed was filtered and the filtrate was evaporated to give a residue, which was purified by flash column chromatography (SiO2, 0-5% methanol in chloroform) to produce tert-butyl 4-(6-((7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (1.5 g, 2.64 mmol, 73.1% yield) as a colorless oil.

[0683] 1H NMR (400MHz, DMSO-d6) δ = 11.63 (s, 1H), 9.49 (s, 1H), 8.00 (s, 1H), 7.97-7.95 (m, 1 H),7.52-7.42(m,1H),5.84(s,2H),4.14-4.03(m,2H),3.91(s,3H),3.82(s,3H),3 .68-3.61(m,2H),2.74-2.65(m,2H),2.39-2.30(m,2H),1.73-1.70(m,1H),1.67-1 .61(m,2H),1.61-1.54(m,2H),1.41(s,9H),1.37-1.30(m,2H),0.94-0.89(m,3H).

[0684] LC-MS m / z 569.5[M+H] + .

[0685] Step 8. To a stirred solution of tert-butyl 4-(6-((7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-5-methoxypyridin-3-yl)piperidine-1-carboxylate (1.5 g, 2.64 mmol) in THF (15 mL) was added 4N hydrochloric acid (6.59 mL, 26.4 mmol) in 1,4-dioxane. The reaction mixture was stirred at room temperature for 6 h. The solvent was evaporated to give a residue, which was washed with ether (2x30 mL). The residue was dissolved in methanol and solid Na2CO3 (1 g) was added. After stirring for 30 minutes, the suspension was filtered through CELITE TM The filtrate was evaporated to give methyl (7-(butylamino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (400 mg, 0.854 mmol, 32.4% yield) as a light brown solid.

[0686] LC-MS m / z 469.4[M+H] + .

[0687] Step 9. To a stirred solution of methyl (7-(butylamino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (100 mg, 0.213 mmol) and 1-methyl-1H-1,2,4-triazole-3-carbaldehyde (47.4 mg, 0.427 mmol) in DMF (1 mL) and THF (1 mL) was added acetic acid (2.444 μL, 0.043 mmol). The reaction mixture was stirred at room temperature for 12 h after which NaCNBH3 (40.2 mg, 0.64 mmol) was added. After the reaction mixture was stirred for 1.5 h, crushed ice was added. The reaction mixture was extracted with DCM (2x15 mL). The combined organic layers were dried over Na2SO4 and evaporated to give methyl (7-(butylamino)-1-((3-methoxy-5-(1-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (100 mg, 0.177 mmol, 83% yield) as an off-white solid.

[0688] LC-MS m / z 564.4[M+H] + .

[0689] Step 10. To a stirred solution of methyl (7-(butylamino)-1-((3-methoxy-5-(1-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (100 mg, 0.177 mmol) in 1,4-dioxane (2 mL) was added a solution of NaOH (0.355 mL, 0.887 mmol) in water and the reaction mixture was stirred at 75° C. for 4 h. The reaction mixture was slowly cooled to room temperature. The separated upper layer was removed and evaporated to give a residue, which was purified via preparative LC / MS using the following conditions: column: Waters XBridge C18, 19x150 mm, 5 μm particles; mobile phase A: 10 mM NH4OAc; mobile phase B: acetonitrile; gradient: 12%-37% B over 22 minutes, then held at 100% B for 5 minutes; flow rate: 20 mL / min. Collection of fractions was triggered by MS and UV signals. The fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound 217 (26.1 mg, 5.16 mmol, 28%).

[0690] Example 34-Compound 218

[0691]

[0692] Step 1. To a stirred solution of methyl (7-(butylamino)-1-((3-methoxy-5-(piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (100 mg, 0.213 mmol) and tetrahydro-2H-pyran-4-carbaldehyde (48.7 mg, 0.427 mmol) in DMF (1 mL) and THF (1 mL) was added acetic acid (2.444 μl, 0.043 mmol). The reaction mixture was stirred at room temperature for 12 h, after which NaCNBH3 (40.2 mg, 0.64 mmol) was added. After stirring for 1.5 h, crushed ice was added. The reaction mixture was extracted with DCM (15x2 mL). The combined organic layers were dried over Na2SO4 and evaporated to give methyl (7-(butylamino)-1-((3-methoxy-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (100 mg, 0.176 mmol, 83% yield).

[0693] LC-MS m / z 567.5[M+H] + .

[0694] Step 2. To a stirred solution of methyl (7-(butylamino)-1-((3-methoxy-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)pyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (100 mg, 0.176 mmol) in 1,4-dioxane (2 mL) was added NaOH (0.353 mL, 0.882 mmol) and the reaction mixture was stirred at 75° C. for 4 h. The reaction mixture was slowly cooled to room temperature. The separated upper layer was taken and evaporated to give a residue, which was purified via preparative LC / MS (column: Waters XBridge C18, 19x150mm, 5μm particles; mobile phase A: 10mM NH4OAc; mobile phase B: acetonitrile; gradient: 10%-35% B over 20 minutes, then held at 100% B for 5 minutes; flow rate: 20mL / min). The fractions containing the desired product were combined and dried via centrifugal evaporation to provide compound 218 (7.4mg, 1.4mmol, 8.2%).

[0695] Example 35-Compound 219

[0696]

[0697] Step 1. Methanol (3.25mL, 80mmol) was added to a stirred solution of sodium hydride (2.96g, 74.1mmol) in DMF (30.0mL) and ether (30.0mL) at 0°C. The reaction mixture was stirred at 0°C for 20 minutes. 2,4-dichloro-5-methylpyridine (7.58mL, 61.7mmol) in ether (30.0mL) was added to this mixture at the same temperature. The reaction mixture was stirred for 1h at 0°C to room temperature and then stirred for 16h at room temperature. The reaction mixture was quenched with ice-cold water and distributed between ethyl acetate and water. The organic layer was washed with saline solution, dried over Na2SO4, filtered and concentrated under reduced pressure to provide a residue, which was ground with ether and petroleum ether. The solid was dried under vacuum to provide 2-chloro-4-methoxy-5-methylpyridine (10.4g, 60.7mmol, 98% yield) as a light brown solid.

[0698] 1 H NMR (300MHz, DMSO-d6) δ = 8.10-7.95 (m, 1H), 7.12-7.02 (m, 1H), 3.90 (s, 3H), 2.12-2.03 (m, 3H).

[0699] LC-MS m / z 158.0[M+H] + .

[0700] Step 2. To a stirred solution of 2-chloro-4-methoxy-5-methylpyridine (5.0 g, 31.7 mmol) in CCl4 (50.0 mL) was added NBS (6.78 g, 38.1 mmol) and AIBN (1.042 g, 6.35 mmol). The reaction mixture was stirred at 60 °C for 18 h. The reaction mixture was purified by CELITE TM The bed was filtered and washed with CCl4. The filtrate was concentrated to dryness under reduced pressure to provide a residue. The crude product was purified by ISCO combiflash chromatography (eluted with 0-100% ethyl acetate in petroleum ether) to provide 5-(bromomethyl)-2-chloro-4-methoxypyridine (4.8 g, 16.85 mmol, 53.1% yield) as a light brown solid.

[0701] 1 H NMR (300MHz, DMSO-d6) δ = 8.34-8.30 (m, 1H), 7.26-7.22 (m, 1H), 4.61 (s, 2H), 4.00-3.96 (m, 3H).

[0702] LC-MS m / z 236.0[M+H] + .

[0703] Step 3. To a stirred solution of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (9.0 g, 26.9 mmol) in DMF (100.0 mL) was added CsCO (17.50 g, 53.7 mmol). To this mixture was added 5-(bromomethyl)-2-chloro-4-methoxypyridine (6.35 g, 26.9 mmol) at 0°C. The reaction mixture was stirred at 0°C for 1 h and water was added. The precipitated solid was filtered and washed with excess water and then with petroleum ether. The solid was dried under vacuum to provide the crude compound, which was purified by ISCO combiflash chromatography (eluting with 0-100% ethyl acetate in petroleum ether) to afford methyl (1-((6-chloro-4-methoxypyridin-3-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (5.8 g, 10.28 mmol, 38.3% yield) as an off-white solid.

[0704] 1 H NMR (300MHz, DMSO-d6) δ = 11.81-11.30 (m, 2H), 7.99-7.92 (m, 2H), 7.23-7.18 (m, 1H), 5.68 (s, 2H), 3.85 (s, 3H), 3.75 (s, 3H).

[0705] LC-MS m / z 491.0[M+H] + .

[0706] Step 4. To a stirred solution of methyl (1-((6-chloro-4-methoxypyridin-3-yl)methyl)-7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (2.5 g, 5.10 mmol) in DMSO (10.0 mL) was added BOP (3.38 g, 7.64 mmol) and butan-1-amine (0.755 mL, 7.64 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with brine solution, dried over Na2SO4, filtered and concentrated under reduced pressure to provide a residue. The residue was purified by ISCO combiflash chromatography (eluting with 0-100% ethyl acetate in chloroform) to afford methyl (7-(butylamino)-1-((6-chloro-4-methoxypyridin-3-yl)methyl)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.02 g, 1.813 mmol, 35.6% yield) as a light brown solid.

[0707] 1 H NMR (300MHz, DMSO-d6) δ = 9.84 (s, 1H), 7.85 (s, 1H), 7.44 (br t,J=5.1Hz,1H),7.21(s,1H),5.70(s,2H),3.81(s,3H),3.62(s,3H),3.59-3.50(m,2H),3.33(s,2H) ,1.67-1.55(m,2H),1.40-1.26(m,1H),1.35-1.23(m,1H),1.36-1.15(m,1H),0.89(t,J=7.4Hz,3H).

[0708] LC-MS m / z 546.0[M+H] + .

[0709] Step 5. To a stirred solution of methyl (7-(butylamino)-1-((6-chloro-4-methoxypyridin-3-yl)methyl)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.0 g, 1.832 mmol) in ethyl acetate (10.0 mL) and ethanol (10.0 mL) was added Pd—C (0.975 g, 0.916 mmol). The reaction mixture was stirred at room temperature under hydrogen atmosphere for 16 h. The reaction mixture was purified by CELITE TM The bed was filtered and washed with excess methanol. The filtrate was concentrated under reduced pressure to afford methyl (7-(butylamino)-1-((6-chloro-4-methoxypyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.8 g, 1.810 mmol, 99% yield) as a light brown solid.

[0710] LC-MS m / z 420.2[M+H] + .

[0711] Step 6. To a stirred solution of methyl (7-(butylamino)-1-((6-chloro-4-methoxypyridin-3-yl)methyl)-1H pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (730 mg, 1.739 mmol) in anhydrous dioxane (15 mL) and water (0.4 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1075 mg, 3.48 mmol), Cs2CO3 (1699 mg, 5.22 mmol) and PdCl2(dppf).CH2Cl2 adduct (142 mg, 0.174 mmol) at room temperature. The reaction mixture was purged with nitrogen, heated to 100°C and stirred for 16 h. The black suspension was purified by CELITE TM The bed was filtered and the bed was washed with ethyl acetate. The filtrate was concentrated under reduced pressure to provide a crude product. The residue was purified using combiflash (silica gel 60-120 mesh; 35% ethyl acetate in petroleum ether as eluent) to provide 5-((7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-tert-butyl formate (650 mg, 1.147 mmol, 66.0% yield) as a pale yellow solid.

[0712] LC-MS m / z 567.3[M+H] + .

[0713] Step 7. To a stirred solution of tert-butyl 5-((7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (0.770 g, 1.359 mmol) in tetrahydrofuran (10 mL):methanol (10 mL) was added 10% palladium on carbon (0.723 g, 0.679 mmol). The reaction mixture was stirred under H2 (5 kg pressure) at 50°C for 14 h. The reaction mixture was purified by CELITE TM The bed was filtered and the bed was washed with methanol and DCM (200 mL). The filtrate was concentrated below 50 °C under vacuum to give tert-butyl 4-(5-((7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxypyridin-2-yl)piperidine-1-carboxylate (0.600 g, 0.591 mmol, 43.5% yield) as a brown solid.

[0714] LC-MS m / z 569.4[M+H] + .

[0715] Step 8. To a stirred solution of tert-butyl 4-(5-((7-(butylamino)-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxypyridin-2-yl)piperidine-1-carboxylate (0.700 g, 1.231 mmol) in dichloromethane (3 mL) was added HCl in dioxane (6.15 mL, 24.62 mmol). The reaction mixture was stirred at room temperature for 2 h and concentrated under reduced temperature to afford methyl (7-(butylamino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.400 g, 0.666 mmol, 54.1% yield) as a brown solid.

[0716] LC-MS m / z 469.2[M+H] + .

[0717] Step 9. To a stirred solution of methyl (7-(butylamino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate hydrochloride (0.100 g, 0.198 mmol) in DMF (2 mL) was added 4-iodotetrahydro-2H-pyran (0.084 g, 0.396 mmol) and K2CO3 (0.082 g, 0.594 mmol). The reaction mixture was stirred at 50°C for 14 h. The reaction mixture was concentrated under high vacuum to give methyl (7-(butylamino)-1-((4-methoxy-6-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.100 g, 0.181 mmol) as a yellow oil.

[0718] LC-MS m / z 553.5[M+H] + .

[0719] Step 10. To a stirred solution of methyl (7-(butylamino)-1-((4-methoxy-6-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)pyridin-3-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.100 g, 0.181 mmol) in 1,4-dioxane (1 mL) was added an aqueous solution (1 mL) of NaOH (0.036 g, 0.905 mmol). The reaction mixture was stirred at 70 °C for 3 h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous Na2SO4, filtered and concentrated under vacuum to give the crude compound. It was purified by reverse phase preparative LC / MS (column: Waters XBridge C18, 150 mm x 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water (containing 10 mM NH4OAc); mobile phase B: 95:5 acetonitrile:water (containing 10 mM NH4OAc); gradient: 10% B for 0 min, 10%-45% B over 25 min, then 100% B for 5 min; flow rate: 15 mL / min). LC-MS m / z 158.0 [M+H] + The collection of fractions was triggered by MS and UV signals. The fractions containing the desired product were combined and dried via centrifugal evaporation using Genevac to afford compound 219 (0.008 g, 0.016 mmol, 8.58% yield).

[0720] Example 36-Compound 220

[0721]

[0722] Step 1. SOCl2(2.63mL, 36.0mmol) is added to a stirred solution of 6-chloro-4-methoxynicotinic acid (4.5g, 23.99mmol) in MeOH (45.0mL). The reaction mixture is stirred at 75°C for 16h. The reaction mixture is concentrated under reduced pressure to provide a residue, which is quenched with saturated NaHCO3 solution and then the reaction mixture is distributed between DCM and water. The organic layer is washed with saline solution and dried over Na2SO4, filtered and concentrated under reduced pressure to provide a crude compound. It is purified by ISCO combiflash chromatography (eluted with 0-100% ethyl acetate in petroleum ether) to provide 6-chloro-4-methoxynicotinic acid methyl esters (3.86g, 18.95mmol, 79% yield) as an off-white solid.

[0723] 1H NMR (300MHz, DMSO-d6) δ = 8.57 (s, 1H), 7.38 (s, 1H), 3.96 (s, 3H), 3.83-3.79 (m, 3H).

[0724] LC-MS m / z 202.0[M+H] + .

[0725] Step 2. To a stirred solution of methyl 6-chloro-4-methoxynicotinate (3.8 g, 18.85 mmol) in 1,4-dioxane (40.0 mL): water (10.0 mL) was added Cs2CO3 (18.42 g, 56.5 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (8.74 g, 28.3 mmol) and PdCl2(dppf).CH2Cl2 adduct (1.539 g, 1.885 mmol) under nitrogen purge. The reaction mixture was stirred at 100°C for 4 h. The reaction mixture was filtered through CELITE TM The bed was filtered and washed with excess EtOAc. The filtrate was concentrated under reduced pressure to provide a residue. The crude compound was purified by ISCO combiflash chromatography (washed with 0-100% ethyl acetate in petroleum ether) to provide 1'-(tert-butyl) 5-methyl 4-methoxy-3', 6'-dihydro-[2,4'-bipyridine]-1', 5 (2'H)-dicarboxylate (4.06 g, 10.72 mmol, 56.9% yield) as a light brown oil.

[0726] 1 H NMR(300MHz, DMSO-d6)δ=8.73-8.66(m,1H),7.27-7.19(m,1H),6.92-6.84(m,1H),4.13-4.03(m,2 H),3.97-3.93(m,4H),3.82-3.77(m,3H),3.59-3.48(m,2H),2.63-2.53(m,2H),1.47-1.39(m,9H).

[0727] LC-MS m / z 349.2[M+H] + .

[0728] Step 3. To a stirred solution of 1'-(tert-butyl)5-methyl 4-methoxy-3',6'-dihydro-[2,4'-bipyridyl]-1',5(2'H)-dicarboxylate (4.0 g, 11.48 mmol) in THF (40.0 mL):MeOH (10.0 mL) was added LiBH4 (2M in THF) (14.35 mL, 28.7 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was treated with 10% NaOH solution, diluted with EtOAc, and purified by CELITE TM The filtrate was filtered through a bed of 4-nitropropene. The filtrate was partitioned between EtOAc and water. The organic layer was washed with brine solution, dried over Na2SO4, filtered and concentrated under reduced pressure to provide tert-butyl 5-(hydroxymethyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (2.69 g, 8.14 mmol, 70.9% yield) as a brown oil.

[0729] 1 H NMR (300MHz, DMSO-d6)δ=8.32(s,1H),7.10(s,1H),6.67(br s,1H),5.11-5.05(m,1H),4.50-4.45(m,2H),4.04(br s,2H),3.95(s,1H),3.88(s,3H),3.57-3.48(m,2H),2.61-2.54(m,2H),1.43(s,9H).

[0730] LC-MS m / z 321.2[M+H] + .

[0731] Step 4. To a stirred solution of tert-butyl 5-(hydroxymethyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (2.6 g, 8.12 mmol) in DCM (25.0 mL) was added TEA (2.262 mL, 16.23 mmol), MsCl (1.265 mL, 16.23 mmol) and lithium chloride (0.688 g, 16.23 mmol) at 0°C. The reaction mixture was stirred at the same temperature for 30 minutes and then at room temperature for 5 h. The reaction mixture was partitioned between DCM and water. The organic layer was washed with brine solution, dried over Na2SO4, filtered and concentrated under reduced pressure to provide tert-butyl 5-(chloromethyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (2.68 g, 7.59 mmol, 94% yield) as a brown oil. The crude product was used as is.

[0732] 1 H NMR(300MHz, DMSO-d6)δ=8.75-8.68(m,1H),7.59-7.53(m,1H),6.98-6.88(m,1H),4.85-4.7 9(m,2H),4.18(s,3H),4.16-4.10(m,2H),3.61-3.52(m,2H),2.68-2.58(m,2H),1.43(s,9H).

[0733] LC-MS m / z 339.2[M+H] + .

[0734] Step 5. To a stirred solution of methyl (7-hydroxy-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (1.0 g, 2.98 mmol) in DMF (10.0 mL) was added CsCO (1.945 g, 5.97 mmol). To this mixture was added tert-butyl 5-(chloromethyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.011 g, 2.98 mmol) in DMF (5.0 mL) at 0°C. The reaction mixture was stirred at 0°C for 1 h and at room temperature for 1 h. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with brine solution, dried over NaSO, filtered and concentrated under reduced pressure to provide a residue. The crude compound was purified by ISCO combiflash chromatography (eluting with 0-100% ethyl acetate in petroleum ether) to afford tert-butyl 5-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (718 mg, 0.946 mmol, 31.7% yield) as a light brown solid.

[0735] 1 H NMR(300MHz, DMSO-d6)δ=11.74-11.66(m,1H),11.44-11.36(m,1H),8.06-7.98(m,1H),7.19-7.09(m, 1H),6.75-6.63(m,1H),5.74-5.67(m,2H),4.07-4.01(m,2H),3.85(s,3H),3.78-3.71(m,5H),3.52(br t,J=5.3Hz,2H),2.59-2.53(m,2H),1.42(s,9H).

[0736] LC-MS m / z 638.0[M+H] + .

[0737] Step 6. To a stirred solution of tert-butyl 5-((7-hydroxy-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (0.5 g, 0.784 mmol) in DMSO (5.0 mL) was added DBU (0.355 mL, 2.353 mmol), BOP (0.520 g, 1.177 mmol) and (S)-1-((tert-butyldiphenylsilyl)oxy)hexan-3-amine (0.335 g, 0.941 mmol). The reaction mixture was stirred at 45 °C for 4 h. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with brine solution, dried over Na2SO4, filtered and concentrated under reduced pressure to provide a residue, which was purified by ISCO combiflash chromatography (eluting with 0-100% ethyl acetate in petroleum ether) to afford (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (0.16 g, 0.100 mmol, 12.76% yield) as a brown solid.

[0738] LC-MS m / z 975.3[M+H] + .

[0739] Step 7. To a stirred solution of (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-3-iodo-5-((methoxycarbonyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (2.1 g, 2.154 mmol) in 1,4-dioxane (20.0 mL) was added K2CO3 (0.595 g, 4.31 mmol), trimethylboroxine (0.541 g, 4.31 mmol) and PdCl2(dppf).CH2Cl2 adduct (0.176 g, 0.215 mmol) under nitrogen purge. The reaction mixture was stirred at 100°C for 6 h. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with brine solution, dried over Na2SO4, filtered and concentrated under reduced pressure to provide the crude compound, which was purified by ISCO combiflash chromatography (eluting with 0-100% ethyl acetate in petroleum ether) to provide (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.29 g, 1.495 mmol, 69.4% yield) as a light brown solid.

[0740] LC-MS m / z:861.5[MH] + .

[0741] Step 8. To a stirred solution of (S)-tert-butyl 5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxy-3',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate (1.2 g, 1.390 mmol) in THF (15.0 mL):MeOH (15.0 mL) was added Pd—C (0.740 g, 0.695 mmol). The reaction mixture was stirred in an autoclave under a hydrogen atmosphere at 100 psi pressure at 50° C. for 16 h. The reaction mixture was purified by CELITE TMThe bed was filtered and washed with excess methanol. The filtrate was concentrated under reduced pressure to afford (S)-tert-butyl 4-(5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxypyridin-2-yl)piperidine-1-carboxylate (1.0 g, 1.156 mmol, 83% yield) as a light brown solid.

[0742] LC-MS m / z 865.4[M+H] + .

[0743] Step 9. To a stirred solution of (S)-tert-butyl 4-(5-((7-((1-((tert-butyldiphenylsilyl)oxy)hexan-3-yl)amino)-5-((methoxycarbonyl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-4-methoxypyridin-2-yl)piperidine-1-carboxylate (0.9 g, 1.040 mmol) in MeOH (10.0 mL) was added concentrated HCl (3.0 mL, 35.1 mmol) at 0°C. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated completely under reduced pressure to afford the crude compound, which was triturated with diethyl ether and petroleum ether. The solvent was decanted and the residue was dried under vacuum to afford (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.88 g, 0.969 mmol, 93% yield) as a brown solid.

[0744] LC-MS m / z 527.2[M+H] + .

[0745] Step 10. To a stirred solution of (S)-methyl(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.15 g, 0.285 mmol) in DMF (2.5 mL) was added KCO (0.079 g, 0.570 mmol) and 2-bromoacetonitrile (0.051 g, 0.427 mmol). The reaction mixture was stirred at 50° C. for 1 h. The reaction mixture was purified by CELITE TMThe bed was filtered and washed with excess ethyl acetate, and the filtrate was then concentrated under reduced pressure to afford methyl (S)-(1-((6-(1-(cyanomethyl)piperidin-4-yl)-4-methoxypyridin-3-yl)methyl)-7-((1-hydroxyhexan-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (212 mg, 0.154 mmol, 53.9% yield) as a brown semisolid.

[0746] LC-MS m / z 566.5[M+H] + .

[0747] Step 11. To a stirred solution of (S)-(1-((6-(1-(cyanomethyl)piperidin-4-yl)-4-methoxypyridin-3-yl)methyl)-7-((1-hydroxyhexan-3-yl)amino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.15 g, 0.265 mmol) in 1,4-dioxane (2.0 mL):water (2.0 mL) was added NaOH (0.053 g, 1.326 mmol). The reaction mixture was stirred at 70 °C for 16 h. The layers of the reaction mixture were observed to separate. The organic layer was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to provide the crude compound. It was purified by reverse phase preparative LC / MS (column: Waters XBridge C18, 150 mm x 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water (containing 10 mM NH4OAc); mobile phase B: 95:5 acetonitrile:water (containing 10 mM NH4OAc); gradient: 5% B for 0 min, 5%-20% B over 20 min, then 100% B for 5 min; flow rate: 20 mL / min; column temperature: 25°C). Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation using Genevac to provide compound 220 (10.7 mg, 0.020 mmol, 7.58% yield).

[0748] Example 37-Compound 221

[0749]

[0750] To a stirred solution of (S)-(7-((1-hydroxyhexan-3-yl)amino)-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (0.1 g, 0.190 mmol) in 1,4-dioxane (2.0 mL) was added NaOH (1.0 mL, 0.190 mmol). The reaction mixture was stirred at 70 °C for 4 h. The layers of the reaction mixture were observed to separate. The organic layer was separated, dried over Na2SO4, filtered and concentrated under reduced pressure to provide the crude compound. It was purified by reverse phase preparative LC / MS (column: Waters XBridge C18, 19x150mm, 5μm particles; mobile phase A: 10mM NH4OAc; mobile phase B: acetonitrile; gradient: 15%-55% B over 20 minutes, then hold at 100% B for 5 minutes; flow rate: 15mL / min). Collection of fractions was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation using Genevac to provide compound 221 (50.9mg, 0.105mmol, 55.5% yield).

[0751] Example 38-Compound 222

[0752]

[0753] To a stirred solution of (S)-3-((5-amino-1-((4-methoxy-6-(piperidin-4-yl)pyridin-3-yl)methyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)hexan-1-ol (90.0 mg, 0.192 mmol) in DMF (1.5 mL) was added K2CO3 (80 mg, 0.576 mmol) and 4-iodotetrahydro-2H-pyran (0.034 mL, 0.288 mmol). The reaction mixture was stirred at 50 °C for 4 h. The reaction mixture was purified by CELITE TMThe 1-hydroxy-2-nitropropene was added to 4-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 4-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 4-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (2-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (3-nitropropene) and 4-nitropropene (3-nitropropene) was added to 5-nitropropene (4-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (3-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (4-nitropropene) and 4-nitropropene (2-nitropropene) was added to 5-nitropropene (

[0754] Example 39 - Starting Materials and Intermediates

[0755] Scheme 5 below shows a scheme for preparing compounds that can be used as starting materials or intermediates for preparing TLR7 agonists disclosed herein. The scheme can be applied to prepare other similar compounds that can be used as starting materials or intermediates. The reagents used are well known in the art, and in many cases, their use has been demonstrated in the preceding examples.

[0756] Solution 5

[0757]

[0758] Biological activity

[0759] The biological activity of the compounds disclosed herein as TLR7 agonists can be determined by the following procedure.

[0760] Human TLR7 agonist activity assay

[0761] This procedure describes a method for determining the human TLR7 (hTLR7) agonist activity of compounds disclosed in this specification.

[0762] Human embryonic kidney blue cells (HEK-Blue) with a human TLR7 secretory embryonic alkaline phosphatase (SEAP) reporter transgene were engineered to express TM HEK-Blue TLR cells (Invivogen) were suspended in non-selective medium (DMEM high glucose (Invitrogen) supplemented with 10% fetal bovine serum (Sigma). TM TLR7 cells were added to each well of a 384-well tissue culture plate (15,000 cells / well) and incubated at 37°C, 5% CO2 for 16-18 h. Compounds (100 nl) were dispensed into the HEK-Blue TMTLR cells were added to the wells and the treated wells were incubated at 37°C, 5% CO2. After 18 h of treatment, ten microliters of freshly prepared Quanti-Blue TM The reagent (Invivogen) was added to each well, incubated for 30 min (37°C, 5% CO2), and the SEAP level was measured using an Envision plate reader (OD = 620 nm). The half-maximal effective concentration (EC 50 ; the concentration of compound that elicits a response halfway between the assay baseline and maximum).

[0763] Induction of type I interferon gene (MX-1) and CD69 in human blood

[0764] Induction of the type I interferon (IFN) MX-1 gene and the B cell activation marker CD69 are downstream events that occur following activation of the TLR7 pathway. The following is a human whole blood assay that measures induction in response to a TLR7 agonist.

[0765] Heparinized human whole blood was harvested from human subjects and treated with 1mM of the test TLR7 agonist compound. Blood was diluted with RPMI 1640 culture medium and 10nL / well was pre-dotted using Echo to obtain a final concentration of 1uM (10nL in 10uL blood). After mixing on a shaker for 30 seconds, the plate was covered and placed in a 37°C chamber overnight = 17h. Fixation / lysis buffer (5x->1x in H2O, heated at 37°C; Catalog No. BD 558049) was prepared and perm buffer (on ice) was kept for later use.

[0766] For surface marker (CD69) staining: Prepare surface Ab: 0.045ul hCD14-FITC (ThermoFisher catalog number MHCD1401) + 0.6ul hCD19-ef450 (ThermoFisher catalog number 48-0198-42) + 1.5ul hCD69-PE (catalog number BD555531) + 0.855ul FACS buffer. Add 3ul / well, rotate 1000rpm for 1min, and mix on a shaker for 30 seconds, place on ice for 30min. Stop stimulation after 30 minutes with 70uL pre-warmed 1x fixation / lysis buffer, and resuspend using Feliex partner (15 times, change the tip for each plate) and incubate at 37C for 10 minutes.

[0767] Centrifuge at 2000rpm for 5 minutes, draw off with HCS plate washer, mix on shaker for 30 seconds, and then wash and pellet 2 times with 70uL in dPBS (2000rpm for 5min), and wash and pellet 1 time with 50ul in FACS buffer (2000rpm for 5min). Mix on shaker for 30 seconds. For intracellular marker (MX-1) staining: add 50ul BD Perm buffer III, and mix on shaker for 30 seconds. Incubate on ice for 30 minutes (in the dark). Wash 2 times with 50uFACS buffer (spin at 2300rpm for 5min after perm), then mix on shaker for 30 seconds. Resuspend in 20ul FACS buffer containing MX1 antibody ((4812)-Alexa 647: Novus Biologicals #NBP2-43704AF647) 20ul FACS buffer + 0.8ul hIgG + 0.04ul MX-1. Spin at 1000rpm for 1min, mix on a shaker for 30 seconds, and incubate the samples in the dark at room temperature for 45 minutes, then wash twice with FACS buffer (after perm, spin at 2300rpm for 5min). Resuspend in 20ul (35uL total per well) FACS buffer, and cover with foil and place at 4°C to read the next day. Read the plate on iQuePlus. Load the results into the tool set and generate an IC50 curve in curvemaster. Set the y-axis 100% to 1uM resiquimod.

[0768] Induction of TNF-α and type I IFN-responsive genes in mouse blood

[0769] Induction of TNF-α and type I IFN response genes are downstream events that occur following activation of the TLR7 pathway. The following is an assay to measure induction in response to TLR7 agonists in mouse whole blood.

[0770] Heparinized mouse whole blood was diluted with RPMI 1640 culture medium containing penicillin-streptomycin at a ratio of 5:4 (50uL whole blood and 40uL culture medium). 90uL volume of diluted blood was transferred to the wells of Falcon flat-bottom 96-well tissue culture plates, and the plate was incubated for 1h at 4°C. The test compound in 100% DMSO stock solution was diluted 20 times in the same culture medium for concentration response determination, and then 10uL diluted test compound was added to the wells so that the final DMSO concentration was 0.5%. Control wells received 10uL culture medium containing 5% DMSO. The plate was then incubated for 17h at 37°C in a 5% CO2 incubator. After incubation, 100uL culture medium was added to each well. The plate was centrifuged, and 130uL supernatant was taken out for measuring the generation of TNFa by ELISA (Invitrogen, catalog number 88-7324, Thermo-Fisher Scientific). 70uL volume of mRNA capture lysis buffer (1x) containing DTT from Invitrogen mRNA Catcher Plus kit (Catalog No. K1570-02) was added to the remaining 70uL sample in the well and mixed by pipetting up and down 5 times. The plate was then shaken at room temperature for 5-10min, and then 2uL proteinase K (20mg / mL) was added to each well. The plate was then shaken at room temperature for 15-20min. The plate was then stored at -80°C until further processing.

[0771] Frozen samples were thawed and mRNA was extracted using the Invitrogen mRNA CatcherPlus kit (Cat. No. K1570-02) according to the manufacturer's instructions. Half of the mRNA yield from RNA extraction was used to synthesize cDNA in a 20 μL reverse transcriptase reaction using Invitrogen SuperScript IV VILO MasterMix (Cat. No. 11756500). QuantStudio Real-Time PCR System from ThermoFisher (Applied Biosystems) was used for Real-time PCR. All real-time PCR reactions were run in duplicate using commercial pre-designed TaqMan assays and TaqMan Master Mix for mouse IFIT1, IFIT3, MX1 and PPIA gene expression. PPIA was used as a housekeeping gene. The advice from the manufacturer was followed. All raw data (Ct) were normalized by the average housekeeping gene (Ct), and then the relative gene expression (RQ) was quantified using the comparative Ct (ΔΔCt) method for experimental analysis.

[0772] definition

[0773] "Aliphatic" means a straight or branched chain, saturated or unsaturated, non-aromatic hydrocarbon moiety having a specified number of carbon atoms (e.g., as in "C3 aliphatic," "C 1-5 In the phrases "aliphatic", "C1-C5 aliphatic" or "C1 to C5 aliphatic", the latter three phrases are synonymous with aliphatic moieties having from 1 to 5 carbon atoms) or, if the number of carbon atoms is not explicitly specified, from 1 to 4 carbon atoms (2 to 4 carbons in the case of unsaturated aliphatic moieties). A similar understanding applies to the number of carbons in the other types, such as in C 2-4 olefins, C4-C7 alicyclics, etc. In a similar manner, such as "(CH2) 1-3 " are to be understood as shorthand for subscripts 1, 2, or 3, such that such terms represent CH2, CH2CH2, and CH2CH2CH2.

[0774] "Alkyl" means a saturated aliphatic moiety in which the same conventions for specifying the number of carbon atoms are applicable. By way of illustration, C1-C4 alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, 1-butyl, 2-butyl, and the like. "Alkanediyl" (sometimes also referred to as "alkylene") means the divalent counterpart of an alkyl group, such as

[0775]

[0776] "Alkenyl" means an aliphatic moiety having at least one carbon-carbon double bond, wherein the same convention for specifying the number of carbon atoms is applicable. By way of illustration, C2-C4 alkenyl moieties include, but are not limited to, ethenyl / vinyl, 2-propenyl (allyl or prop-2-enyl), cis-1-propenyl, trans-1-propenyl, E- (or Z-) 2-butenyl, 3-butenyl, 1,3-butadienyl (buta-1,3-dienyl), and the like.

[0777] "Alkynyl" means an aliphatic moiety having at least one carbon-carbon triple bond, wherein the same convention for specifying the number of carbon atoms is applicable. By way of illustration, C2-C4 alkynyl includes ethynyl (ethynyl / acetylenyl), propargyl (prop-2-ynyl), 1-propynyl, but-2-ynyl, etc.

[0778] "Alicyclic" means a saturated or unsaturated non-aromatic hydrocarbon moiety having from 1 to 3 rings, each ring having from 3 to 8 (preferably from 3 to 6) carbon atoms. "Cycloalkyl" means an alicyclic moiety in which each ring is saturated. "Cycloalkenyl" means an alicyclic moiety in which at least one ring has at least one carbon-carbon double bond. "Cycloalkynyl" means an alicyclic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, alicyclic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl and adamantyl. Preferred alicyclic moieties are cycloalkyl moieties, especially cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. "Cycloalkanediyl" (sometimes also referred to as "cycloalkylene") means the divalent counterpart of cycloalkyl. Similarly, "bicycloalkanediyl" (or "bicycloalkylene") and "spiroalkanediyl" (or "spiroalkylene") refer to the divalent counterparts of bicycloalkyl and spiroalkyl (or "spirocycloalkyl").

[0779] "Heteroalicyclic" means an alicyclic moiety in which, in at least one of its rings, up to three (preferably 1 to 2) carbons have been replaced by heteroatoms independently selected from N, O or S, wherein N and S may optionally be oxidized and N may optionally be quaternized. Preferred alicyclic moieties consist of a ring size of 5 to 6 members. Similarly, "heterocycloalkyl", "heterocycloalkenyl" and "heterocycloalkynyl" mean a cycloalkyl, cycloalkenyl or cycloalkynyl moiety, respectively, in which at least one ring has been so modified. Exemplary heteroalicyclic moieties include aziridine, azetidinyl, 1,3-dioxanyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothiphenyl, 1,4-dioxanyl, thietanyl, and the like. "Heterocycloalkylene" means the divalent counterpart of heterocycloalkyl.

[0780] "Alkoxy", "aryloxy", "alkylthio" and "arylthio" mean -O(alkyl), -O(aryl), -S(alkyl) and -S(aryl), respectively. Examples are methoxy, phenoxy, methylthio and phenylthio, respectively.

[0781] Unless a narrower meaning is indicated, "halogen" or "halo" means fluorine, chlorine, bromine or iodine.

[0782] "Aryl" means a hydrocarbon moiety having a mono-, bi- or tricyclic ring system (preferably monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is aromatic. The rings in the ring system may be fused to each other (as in naphthyl) or bonded to each other (as in biphenyl), and may be fused to or bonded to a non-aromatic ring (as in indanyl or cyclohexylphenyl). By way of further illustration, aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthrenyl, anthracenyl, and acenaphthenyl. "Arylene" means the divalent counterpart of aryl, such as 1,2-phenylene, 1,3-phenylene or 1,4-phenylene.

[0783] "Heteroaryl" means a moiety having a mono-, bi- or tricyclic ring system (preferably a 5- to 7-membered monocyclic ring), wherein each ring has from 3 to 7 carbon atoms, and at least one ring is an aromatic ring containing from 1 to 4 heteroatoms independently selected from N, O or S, wherein N and S may optionally be oxidized and N may optionally be quaternized. Such at least one aromatic ring containing heteroatoms may be fused to other types of rings (such as in benzofuranyl or tetrahydroisoquinolinyl), or directly bonded to other types of rings (such as in phenylpyridinyl or 2-cyclopentylpyridinyl). By way of further illustration, heteroaryl moieties include pyrrolyl, furanyl, thiophenyl / thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridinyl, N-oxopyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolynyl, quinazolinyl, cinnolinyl, quinozalinyl, naphthyridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, carbazolyl, dibenzothiophenyl, acridinyl, and the like. "Heteroarylene" means the divalent counterpart of a heteroaryl.

[0784] Where a moiety is indicated to be substituted (such as by using the phrase "unsubstituted or substituted" or "optionally substituted" as in "unsubstituted or substituted C1-C5 alkyl" or "optionally substituted heteroaryl"), such a moiety may have one or more independently selected substituents, preferably in an amount of 1 to 5, more preferably in an amount of 1 or 2. Substituents and substitution patterns can be selected by one of ordinary skill in the art, taking into account the moiety to which the substituents are attached, to provide a compound that is chemically stable and that can be synthesized by techniques known in the art and the methods outlined herein. Where a moiety is identified as "unsubstituted or substituted" or "optionally substituted", in a preferred embodiment, such a moiety is unsubstituted.

[0785] "Arylalkyl", "(heteroalicyclic)alkyl", "arylalkenyl", "arylalkynyl", "biarylalkyl" and the like mean alkyl, alkenyl or alkynyl moieties (as the case may be) substituted with aryl, heteroalicyclic, biaryl, etc. moieties (as the case may be) with the open (unsatisfied) valences being at the alkyl, alkenyl or alkynyl moiety, e.g., as in benzyl, phenethyl, N-imidazolylethyl, N-morpholinoethyl, etc. Conversely, "alkylaryl", "alkenylcycloalkyl" and the like mean aryl, cycloalkyl, etc. moieties (as the case may be) substituted with alkyl, alkenyl, etc. moieties (as the case may be) such as in methylphenyl (tolyl) or allylcyclohexyl. "Hydroxyalkyl", "haloalkyl", "alkylaryl", "cyanoaryl" and the like mean alkyl, aryl, etc. moieties (as the case may be) substituted with one or more identified substituents (hydroxy, halo, etc., as the case may be).

[0786] For example, permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, alicyclic, heteroalicyclic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxy, hydroxyalkyl (especially hydroxyethyl), cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl) (especially -OCF3), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -C(=O)(alkyl), -C(=O)H, -C02H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl), -OCF3, -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -NH(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)2, azido, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2, -NHC(=NH)NH2, -OSO2(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl), -S(=O)alkyl, -SO2(alkyl), -SO2NH2, -SO2NH(alkyl), -SO2N(alkyl)2, etc.

[0787] In the case where the substituted moiety is an aliphatic moiety, preferred substituents are aryl, heteroaryl, alicyclic, heteroalicyclic, halo, hydroxy, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -CO2H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl), -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC( -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2, -NHC(=NH)NH2, -OSO2(alkyl), -SH, -S(alkyl), -S(aryl), -S(=O)alkyl, -S(cycloalkyl), -SO2(alkyl), -SO2NH2, -SO2NH(alkyl), and -SO2N(alkyl)2. More preferred substituents are halo, hydroxy, cyano, nitro, alkoxy, -O(aryl), =O, =NOH, =NO(alkyl), -OC(=O)(alkyl), -OC(=O)O(alkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl), azido, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl), and -NHC(=NH)NH2. Particularly preferred are phenyl, cyano, halo, hydroxy, nitro, C1-C4 alkoxy, O(C2-C4 alkanediyl)OH, and O(C2-C4 alkanediyl)halo.

[0788] In the case where the substituted moiety is an alicyclic, heteroalicyclic, aryl or heteroaryl moiety, preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(aryl), -O(cycloalkyl), -O(heterocycloalkyl), alkylthio, arylthio, -C(=O)(alkyl), -C(=O)H, -CO2H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl)2, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)2, azido, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2, -NHC(=NH)NH2, -OSO2(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl), -S(=O)alkyl, -SO2(alkyl), -SO2NH2, -SO2NH(alkyl), and -SO2N(alkyl)2. More preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxy, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -C(=O)(alkyl), -C(=O)H, -CO2H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl)2, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH2, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)2, -NH2, -NH(alkyl), -N(alkyl), -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH2, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)2 and -NHC(=NH)NH2. Particularly preferred are C1-C4 alkyl, cyano, nitro, halo and C1-C4 alkoxy.

[0789] Where a range is stated, such as in "C1-C5 alkyl" or "5% to 10%", such a range includes the endpoints of the range, such as C1 and C5 in the first example and 5% and 10% in the second example.

[0790] Unless a particular stereoisomer is specifically indicated (e.g., by bolding or dashing bonds at the relevant stereocenter in a structural formula, by depicting double bonds in a structural formula as having the E or Z configuration, or by using stereochemically designated nomenclature or symbols), all stereoisomers as pure compounds and mixtures thereof are included within the scope of the present invention. Unless otherwise indicated, racemates, individual enantiomers (whether optically pure or partially resolved), diastereomers, geometric isomers, and combinations and mixtures thereof are all encompassed by the present invention.

[0791] It will be understood by those skilled in the art that compounds may have tautomeric forms (e.g., keto and enol forms), resonance forms, and zwitterionic forms that are equivalent to those depicted in the structural formulas used herein, and that the structural formulas encompass such tautomeric forms, resonance forms, or zwitterionic forms.

[0792] "Pharmaceutically acceptable ester" means an ester that hydrolyzes in vivo (e.g., in the human body) to produce the parent compound or its salt or that itself has an activity similar to that of the parent compound. Suitable esters include C1-C5 alkyl, C2-C5 alkenyl or C2-C5 alkynyl esters, especially methyl, ethyl or n-propyl esters.

[0793] "Pharmaceutically acceptable salt" means a salt of a compound suitable for use in a pharmaceutical formulation. In the case where the compound has one or more basic groups, the salt may be an acid addition salt, such as sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methylsulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, toluenesulfonate, etc. In the case where the compound has one or more acidic groups, the salt may be a salt such as calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzyl salt, sodium salt, tetramethylammonium salt, etc. Polymorphic crystalline forms and solvates are also encompassed within the scope of the present invention.

[0794] "Subject" refers to an animal, including but not limited to a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" with respect to, for example, a mammalian subject (such as a human) are used interchangeably herein.

[0795] In the context of treating a disease or disorder, the terms "treat," "treating," and "treatment" are intended to include alleviating or eliminating the disorder, disease or condition, or one or more symptoms associated with the disorder, disease or condition; or slowing the progression, spread, or worsening of the disorder, disease or condition, or one or more symptoms thereof. "Treatment of cancer" refers to one or more of the following effects: (1) inhibiting tumor growth to some extent, including (i) slowing and (ii) completely stopping growth; (2) reducing the number of tumor cells; (3) maintaining tumor size; (4) reducing tumor size; (5) inhibiting, including (i) reducing, (ii) slowing, or (iii) completely preventing tumor cell infiltration into peripheral organs; (6) inhibiting, including (i) reducing, (ii) slowing, or (iii) completely preventing metastasis; (7) enhancing anti-tumor immune responses, which can result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing tumor growth, (iv) reducing, slowing, or preventing invasion, and / or (8) alleviating to some extent the severity or number of one or more symptoms associated with the disorder.

[0796] In the formulae of this specification, the wavy line transverse to the bond or an asterisk (*) at the end of a bond indicates a covalent attachment site. For example,

[0797] In-style R is or R is The statement means

[0798] In the formulae of this specification, a bond across an aromatic ring between its two carbons means that the group attached to the bond may be located at any position of the aromatic ring that is made available by removing a hydrogen that is implicitly there (or explicitly there, if written). By way of illustration:

[0799] represent

[0800] represent

[0801] and

[0802] represent

[0803] The present disclosure includes all isotopes of atoms occurring in the compounds described herein. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and14 C. Isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described herein using an appropriate isotopically labeled reagent in place of the unlabeled reagent originally employed. By way of example, C1-C3 alkyl can be undeuterated, partially deuterated, or fully deuterated, and "CH3" includes CH3, 13 CH3, 14 CH3, CH2T, CH2D, CHD2, CD3, etc. In one embodiment, the various elements in the compound are present in their natural isotopic abundance.

[0804] It will be understood by those skilled in the art that certain structures may be drawn in one tautomeric form or the other, such as keto and enol, and that both forms are equivalent.

[0805] Acronyms and abbreviations

[0806] Table C provides a list of acronyms and abbreviations used in this specification and their meanings.

[0807]

[0808]

[0809] References

[0810] Full citations for the following references cited earlier in this specification in an abbreviated manner by first author (or inventor) and date are provided below. Each of these references is incorporated herein by reference for all purposes.

[0811] Akinbobuyi et al., Tetrahedron Lett. 2015, 56, 458, "Facile syntheses of functionalized toll-like receptor 7agonists".

[0812] Akinbobuyi et al., Bioorg.Med.Chem.Lett.2016,26,4246, “Synthesis and immunostimulatory activity of substituted TLR7 agonists.”

[0813] Barberis et al., US 2012 / 0003298 A1(2012).

[0814] Beesu et al.,J.Med.Chem.2017,60,2084,“Identification of High-PotencyHuman TLR8 and Dual TLR7 / TLR8 Agonists in Pyrimidine-2,4-diamines.”

[0815] et al.,J.Immunol.2007,178,4072,“Natural and Synthetic TLR7Ligands Inhibit CpG-A-and CpG-C-Oligodeoxynucleotide-Induced IFN-αProduction.”

[0816] Bonfanti et al.,US 2014 / 0323441 A1(2015)[2015a].

[0817] Bonfanti et al.,US 2015 / 0299221 A1(2015)[2015b].

[0818] Bonfanti et al.,US 2016 / 0304531 A1(2016).

[0819] Carson et al.,US 2013 / 0202629 A1(2013).

[0820] Carson et al.,US 8,729,088 B2(2014).

[0821] Carson et al.,US 9,050,376 B2(2015).

[0822] Carson et al.,US 2016 / 0199499 A1(2016).

[0823] Chan et al.,Bioconjugate Chem.2009,20,1194,“Synthesis andImmunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates.”

[0824] Chan et al.,Bioconjugate Chem.2011,22,445,“Synthesis andCharacterization of PEGylated Toll Like Receptor 7 Ligands.”

[0825] Chen et al.,US 7,919,498 B2(2011).

[0826] Coe et al.,US 9,662,336 B2(2017).

[0827] Cortez and Va,Medicinal Chem.Rev.2018,53,481,“Recent Advances inSmall-Molecule TLR7 Agonists for Drug Discovery”.

[0828] Cortez et al.,US 2017 / 0121421 A1(2017).

[0829] Cortez et al.,US 9,944,649 B2(2018).

[0830] Dellaria et al.,WO 2007 / 028129 A1(2007).

[0831] Desai et al.,US 9,127,006 B2(2015).

[0832] Ding et al.,WO 2016 / 107536 A1(2016).

[0833] Ding et al.,US 2017 / 0273983 A1(2017)[2017a].

[0834] Ding et al.,WO 2017 / 076346 A1(2017)[2017b].

[0835] Gadd et al.,Bioconjugate Chem.2015,26,1743,“Targeted Activation ofToll-Like Receptors:Conjugation of a Toll-Like Receptor 7 Agonist to aMonoclonal Antibody Maintains Antigen Binding and Specificity.”

[0836] Graupe et al.,US 8,993,755 B2(2015).

[0837] Embrechts et al.,J.Med.Chem.2018,61,6236,“2,4-Diaminoquinazolines asDual Toll Like Receptor(TLR)7 / 8 Modulators for the Treatment of Hepatitis BVirus.”

[0838] Halcomb et al.,US 9,161,934 B2(2015).

[0839] Hashimoto et al.,US 2009 / 0118263 A1(2009).

[0840] He et al.,US 10,487,084 B2(2019)[2019a].

[0841] He et al.,US 10,508,115 B2(2019)[2019b].

[0842] Hirota et al.,US 6,028,076(2000).

[0843] Holldack et al.,US 2012 / 0083473 A1(2012).

[0844] Isobe et al.,US 6,376,501 B1(2002).

[0845] Isobe et al.,JP 2004137157(2004).

[0846] Isobe et al.,J.Med.Chem.2006,49(6),2088,“Synthesis and BiologicalEvaluation of Novel 9-Substituted-8-Hydroxyadenine Derivatives as PotentInterferon Inducers.”

[0847] Isobe et al.,US 7,521,454 B2(2009)[2009a].

[0848] Isobe et al.,US 2009 / 0105212 A1(2009)[2009b].

[0849] Isobe et al.,US 2011 / 0028715 A1(2011).

[0850] Isobe et al.,US 8,148,371 B2(2012).

[0851] Jensen et al.,WO 2015 / 036044 A1(2015).

[0852] Jones et al.,US 7,691,877 B2(2010).

[0853] Jones et al.,US 2012 / 0302598 A1(2012).

[0854] Kasibhatla et al.,US 7,241,890 B2(2007).

[0855] Koga-Yamakawa et al.,Int.J.Cancer 2013,132(3),580,“Intratracheal andoral administration of SM-276001:A selective TLR7 agonist,leads to antitumorefficacy in primary and metastatic models of cancer.”

[0856] Li et al.,US 9,902,730 B2(2018).

[0857] Lioux et al.,US 9,295,732 B2(2016).

[0858] Lund et al.,Proc.Nat’l Acad.Sci(USA)2004,101(15),5598,“Recognition ofsingle-stranded RNA viruses by Toll-like receptor 7.”

[0859] Maj et al.,US 9,173,935 B2(2015).

[0860] McGowan et al.,US 2016 / 0168150 A1(2016)[2016a].

[0861] McGowan et al.,US 9,499,549 B2(2016)[2016b].

[0862] McGowan et al.,J.Med.Chem.2017,60,6137,“Identification andOptimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7(TLR7)SelectiveAgonists for the Treatment of Hepatitis B.”

[0863] Musmuca et al.,J.Chem.Information&Modeling 2009,49(7),1777,“Small-Molecule Interferon Inducers.Toward the Comprehension of the MolecularDeterminants through Ligand-Based Approaches.”

[0864] Nakamura et al.,Bioorg.Med.Chem.Lett.2013,13,669,“Synthesis andevaluation of 8-oxoadenine derivatives as potent Toll-like receptor agonistswith high water solubility.”

[0865] Ogita et al.,US 2007 / 0225303 A1(2007).

[0866] Ota et al.,WO 2019 / 124500 A1(2019).

[0867] Pilatte et al.,WO 2017 / 216293 A1(2017).

[0868] Poudel et al.,US 10,472,361 B2(2019)[2019a].

[0869] Poudel et al.,US 10,494,370 B2(2019)[2019b].

[0870] Poudel et al.,US 2020 / 0038403 A1(2020)[2020a]..

[0871] Poudel et al.,US 2020 / 0039986 A1(2020)[2020b].

[0872] Purandare et al.,WO 2019 / 209811 A1(2019).

[0873] Pryde,US 7,642,350 B2(2010).

[0874] Sato-Kaneko et al.,JCI Insight 2017,2,e93397,“CombinationImmunotherapy with TLR Agonists and Checkpoint Inhibitors Suppresses Head andNeck Cancer”.

[0875] Smits et al.,The Oncologist 2008,13,859,“The Use of TLR7 and TLR8Ligands for the Enhancement of Cancer Immunotherapy”.

[0876] Vasilakos and Tomai,Expert Rev.Vaccines 2013,12,809,"The Use of Toll-like Receptor 7 / 8 Agonists as Vaccine Adjuvants".

[0877] Vernejoul et al., US 2014 / 0141033 A1(2014).

[0878] Young et al., US 10,457,681B2(2019).

[0879] Yu et al.,PLoS One 2013,8(3),e56514, "Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular DockingStudies."

[0880] Zhang et al., Immunity 2016, 45, 737, “Structural Analysis Reveals that Toll-like Receptor 7Is a Dual Receptor for Guanosine and Single-StrandedRNA.”

[0881] Zhang et al.,WO 2018 / 095426 A1(2018)>

[0882] Zurawski et al., US 2012 / 0231023 A1(2012).

[0883] The foregoing detailed description includes paragraphs that are primarily or exclusively related to a particular part or aspect of the present invention. It should be understood that this is for clarity and convenience, that a particular feature may be relevant in more than just the paragraphs that disclose it, and that the disclosure herein includes all appropriate combinations of information found in different paragraphs. Similarly, although the description herein relates to a specific embodiment of the present invention, it should be understood that where a specific feature is disclosed in the context of a specific embodiment, such a feature may also be used in the context of another embodiment, in combination with another feature, or in the present invention as a whole to an appropriate degree.

[0884] Furthermore, while the invention has been specifically described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.

Claims

1. A compound having a structure according to formula (I) or formula (II) in yes yes yes R 1 yes R 3 It is H, Me, R 5 It's H.

2. The compound according to claim 1, which has a structure represented by formula (Ic):

3. The compound according to claim 1, which has a structure represented by formula (IIa):

4. A compound having a structure represented by formula (Ia) in R 1 yes R 3 It is H, Me, and R 5 It's H.

5. A compound having a structure represented by formula (Ib) in R 1 yes and R 3 It is H.

6. A compound selected from:

7. Use of a compound according to any one of claims 1 to 6 in the preparation of a medicament for use in a method of treating cancer, the method comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapeutic agent and a compound according to any one of claims 1 to 6.

8. The use according to claim 7, wherein the anti-cancer immunotherapeutic agent is an antagonistic anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibody.

9. The use according to claim 8, wherein the cancer is lung cancer, pancreatic cancer, kidney cancer, head and neck cancer, lymphoma, skin cancer, urothelial carcinoma, gastric cancer, hepatocellular carcinoma or colorectal cancer.

10. The use according to claim 8, wherein the cancer is non-small cell lung cancer, Hodgkin's lymphoma, melanoma, Merkel skin cancer or bladder cancer.

11. The use according to claim 9 or 10, wherein the anti-cancer immunotherapeutic agent is ipilimumab, nivolumab or pembrolizumab.